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i 
ABSTRACT 
 Small molecules have proven to be very important tools for exploration of 
biological systems including diagnosis and treatment of lethal diseases like cancer. 
Fluorescent probes have been extensively used to further amplify the utilization of small 
molecules. The manipulation of naturally occurring biological targets with the help of 
synthetic compounds is the focus of the work described in this thesis.  
 Bleomycins (BLMs) are a class of water soluble, glycopeptide-derived antitumor 
antibiotics consisting of a structurally complicated unnatural hexapeptide and a 
disaccharide, clinically used as an anticancer chemotherapeutic agent at an exceptionally 
low therapeutic dose. The efficiency of BLM is likely achieved both by selective 
localization within tumor cells and selective binding to DNA followed by efficient 
double-strand cleavage. The disaccharide moiety is responsible for the tumor cell 
targeting properties of BLM. A recent study showed that both BLM and its disaccharide, 
conjugated to the cyanine dye Cy5**, bound selectively to cancer cells. Thus, the 
disaccharide moiety alone recapitulates the tumor cell targeting properties of BLM. Work 
presented here describes the synthesis of the fluorescent carbohydrate conjugates. A 
number of dye-labeled modified disaccharides and monosaccharides were synthesized to 
study the nature of the participation of the carbamoyl moiety in the mechanism of tumor 
cell recognition and uptake by BLM saccharides. It was demonstrated that the 
carbamoylmannose moiety of BLM is the smallest structural entity capable for the 
cellular targeting and internalization, and the carbamoyl functionality is indispensible for 
tumor cell targeting. It was also confirmed that BLM is a modular molecule, composed of 
 
 
ii 
a tumor cell targeting moiety (the saccharide) attached to a cytotoxic DNA cleaving 
domain (the BLM aglycone). These finding encouraged us to further synthesize 
carbohydrate probes for PET imaging and to conjugate the saccharide moiety with 
cytotoxins for targeted delivery to tumor cells.  
 The misacylated suppressor tRNA technique has enabled the site-specific 
incorporation of noncanonical amino acids into proteins. The focus of the present work 
was the synthesis of unnatural lysine analogues with nucleophilic properties for 
incorporation at position 72 of the lyase domain of human DNA polymerase beta, a 
multifunctional enzyme with dRP lyase and polymerase activity. 
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CHAPTER 1 
INTRODUCTION 
1.1. Cancer 
The term "cancer" was derived from the Greek word carcinos, which means crab. 
It was used by Hippocrates to describe the ulcerous diseases causing finger-spreading 
projections.1 The disruption of the balance between cell division and cell death results in 
the transition of a normal cell to a cancerous cell. This results in faster multiplication of 
the cells leading to augmented uncontrolled proliferation and loss of cellular 
differentiation, producing a growing mass of tissue called a ‘tumor’ or ‘malignancy’ 
(Figure 1.1). Biologically, cancer is a disease which involves a cycle of dynamic genetic 
and epigenetic changes in a normal cell.2 For several decades, studies have been ongoing 
to discover the specific alterations that result in a malignancy. 
 
Figure 1.1. Overview of Oncogenesis. 
 
 
2 
There are more than 100 clinically different types of cancer, which are recognized 
by their unique properties and symptoms, and require specific treatment strategies.3 
However, they still can be categorized into four major subdivisions: leukemias, 
lymphomas, sarcomas and carcinomas. A leukemia involves an abnormality in white 
blood cells or leukocytes, which are produced by the bone marrow. A lymphoma results 
from an abnormality in lymphocytes, which are produced by spleen and lymph nodes; 
these are considered similar to a leukemia. A sarcoma is solid tumor of mesodermal 
origin such as connective tissues, bone, and muscles. Finally, a carcinoma is a solid 
tumor of epithelial origin and constitutes the major form of cancer, accounting for about 
of all malignant neoplasms.3 The hallmarks of cancer mainly involves six biological traits 
acquired during the various stages of cancer development.4 They include hyperplasia 
(uncontrolled proliferation), growth factor abnormalities, suppression of programmed cell 
death or apoptosis, replication of immortality in the cells, angiogenesis (expansion of 
blood vessels), and metastasis (the ability of cells to dissociate from a tumor mass and 
create a new tumor at an anatomically distant site).4 
 
1.2. Bleomycins 
Bleomycins (BLMs) are a class of water soluble, glycopeptide-derived antitumor 
antibiotics consisting of a structurally complicated unnatural hexapeptide and a 
disaccharide (Figure 1.2).5 It was first isolated from a culture broth of a bacterium, 
Streptomyces verticillus, as a Cu(II) chelate by Umezawa and co-workers in 1966.6 
Clinically, bleomycin is used for the treatment of various kinds of tumors of soft tissues, 
 
 
3 
especially squamous cell carcinomas and malignant lymphomas.7 In the United States, it 
is sold under the tradename Blenoxane as a mixture consisting mainly bleomycin A2 and 
B2, whereas bleomycin A5 is used clinically in Japan, Russia and China.8 Bleomycin 
mediates oxidative cleavage of DNA selectively at 5ʹ-GPy-3ʹ sequences in the presence 
of a metal co-factor and oxygen.5 The exceptionally low therapeutic dose of BLM (~5 
µmol) implies extremely high therapeutic efficiency in comparison to other drugs. Such 
efficiency of BLM is likely achieved both by selective localization within tumor cells9,10 
and selective binding to DNA followed by efficient double-strand cleavage.11  
  
Figure 1.2. Core Structure of BLM, Illustrating its Various Domains. 
 
The efficiency of DNA cleavage by BLM depends on its complex structure which 
can be dissected into different structural domains: the C-terminal DNA binding domain 
comprising of a bithiazole attached to a positively charged alkyl substituent, the linker 
domain with threonine and methylvalerate constituents, the metal binding domain 
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4 
containing the pyrimidoblamic acid and β-hydroxyhistidine moieties, and the 
disaccharide moiety. The metal binding domain is the primary determinant of the 
sequence selectivity of DNA, which is responsible for chelation to metal and oxygen 
required for the activation of BLM.12-15 The DNA binding domain binds to DNA through 
specific interactions. The linker domain maintains the essential compact folded structure 
required for the cleavage.16,17 The disaccharide sugar moiety is essential for cancer cell 
targeting.10,18 The first total synthesis of bleomycin was accomplished by the Umezawa19 
and Hecht20 laboratories in 1982. In 1994, Boger and co-workers also reported a total 
synthesis of BLM A2.21  
Though bleomycin is not an enzyme, the interactions of BLM with oxygen 
possess some similarities to the activation mediated by the metalloenzyme cytochrome 
P450.22-24 There are two notable pathways for DNA strand cleavage both of which 
require activated Fe(II)•BLM (Figure 1.3). The specific mechanism involved in the 
degradation depends on the availability of oxygen (Figure 1.4). The frank strand scission 
pathway is favored by a high concentration of oxygen, whereas the mechanism shifts 
toward the alkali labile lesion pathway in a low oxygen environment.25-27 As the ratio of 
products depends on concentration of oxygen, both the pathways are believed to involve 
the common radical intermediate28,29 produced by abstraction of the C-4ʹ hydrogen atom 
from the deoxyribose of the susceptible nucleotide (Figure 1.4). 
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Figure 1.3. Proposed Catalytic Cycle for Activation of Bleomycin.30 
 
 
Figure 1.4. Bleomycin-mediated DNA Degradation by the Frank Strand Scission and 
Alkali-labile Lesion Pathways.5 
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The ability of BLM to mediate double-strand cleavage of DNA depends on the binding 
interactions between DNA and BLM. Double-strand cleavage of DNA by bleomycin was 
first studied systematically by the Povirk laboratory.31-34 Accordingly, a single molecule 
of BLM effects double-strand cleavage of DNA. After the first lesion generated on the 
DNA, the BLM is reactivated and the specificity of the DNA gets altered in the 
complementary strand which results in the second break at one of the two nucleotide 
positions opposite to the primary site of cleavage.35 However, recently Hecht and co-
workers reported a new mechanism of double-strand cleavage not previously described, 
which showed that many of the double-strand cleavages associated with the strongly 
bound hairpin DNAs results from two independent events rather than the coupled event 
(Figure 1.5).11 
The high valence iron complex is regenerated from sequestered hydroxyl radical 
analogous to the propagation in lipid peroxidation. Double-strand cleavages are 
refractory to repair by DNA repair enzymes and, hence, is highly cytotoxic, thereby 
making bleomycin selective and cytotoxic.35  
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Figure 1.5. Proposed Mechanism for Double-strand Cleavage of DNA.11,35 
 
In spite of its therapeutic efficiency, a part of the drug undergoes catabolism to 
deamido bleomycin by cysteine proteinase bleomycin hydrolase36-39 (Figure 1.6). Though 
in earlier reports, deamido bleomycin was asserted to possess no antitumor activity, it 
was later found to retain one-half of its ability to mediate single strand scission and one-
eighth of its ability to mediate double-strand scission.40 
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Figure 1.6. Catabolism of Bleomycin to Deamido Bleomycin.40 
 
Though bleomycin has proved to be an excellent therapeutic agent for cancer 
chemotherapy, a significant barrier to its widespread clinical use is a side effect involving 
lung fibrosis.41 This raises the question of the requirement for a greater understanding of 
the chemistry associated with BLM.  
 
1.3. Carbohydrates 
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numerous crucial roles in living systems. In principle, they are hydrates of carbon and can 
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The various roles of carbohydrates in the biological processes, apart from being a primary 
source of energy (starch and glycogen), were not discovered until recently due to the 
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important polymers.42 With time, the detailed and closer examination of cellular 
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 The cell surface is covered by a carbohydrate-rich matrix consisting of 
glycoproteins, glycolipids and proteoglycans, known as glycocalyx.43 The glycoproteins 
are generally large proteins present on the cell surface coupled with sugar residues 
(Figure 1.7). The majority of glycoproteins are formed by post-translational modification 
of the protein through glycosylation on the amide nitrogen of the side chain of asparagine 
(N-glycosylation) or the hydroxy group containing side chain of hydroproline, serine, 
threonine or hydrolysine (O-glycosylation).44 Glycolipids are also found on the cell 
surface and are composed of hydrophilic saccharides anchored to the hydrophobic lipid 
cell membrane.45,46 However, proteoglycans are the major components of extracellular 
matrix, consisting of the core proteins carrying large polysaccharide units (more than 100 
monosaccharides) dangling outside the cell membrane.47  
 
Figure 1.7. The Major Monomeric Monosaccharide Constituents Found in 
Glycoconjugates: Glycoproteins, Glycolipids and Proteoglycans. 
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that involves the interaction of the receptors on the cell surface with their ligands, which 
was first described as “lock-and-key” hypothesis by Emil Fischer in 1894.50 Receptor–
ligand interaction is effected by the organization and activity of the receptor, which is 
influenced by the bulky constituents of the glycocalyx. In addition, the larger 
glycoproteins can influence protein sorting, endocytosis, and neurological and 
immunological developments.51-55   
 Due to the diverse biological functions associated with the glycan, a 
comprehensive understanding of protein–carbohydrate interactions is vital in order to 
study the biological processes.56,57 In nature, there are several carbohydrate-binding 
proteins which are mainly classified as lectins and antibodies. The lectins have high 
affinity towards carbohydrates and bind them reversibly through their carbohydrate 
recognition domains. They have evolved to recognize the specific carbohydrate at the 
surface of the cell to mediate cell–cell adhesion, trafficking, triggering immune responses 
and cell signaling.58-61 Antibodies are glycoproteins secreted by the plasma cells, which 
are used by the immune system and are directed towards cell surface glycans. Different 
glycan signatures are expressed by different cells and have a vital role clinically.62 One 
such example for antibody–carbohydrate interaction is represented by the blood group 
ABO antigen–antibody interaction. The different structure of glycan chains is responsible 
for the generation of different antigens which forms the ABO blood group system (Figure 
1.8) and failure of unmatched blood transfusions.63,64 
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Figure 1.8. ABO Blood Group System Showing the Glycan Chains That Determine the 
Blood Type.63 
 
 Many proteins bind to the glycan ligands through polyvalent interactions and 
possess multiple binding sites.65 The binding efficiency in the case of polyvalent 
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the site of binding. On the basis of these interactions, many scaffolds were developed for 
drug delivery, diagnosis and other therapeutic purposes such as cyclodextrins, chitins, 
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by O-GlcNAcase (OGA). The cycling of O-GlcNAc in proteins depends on the balance 
of activity of OGT and OGA, and plays a crucial role in control of cellular processes.69-73 
Excessive O-GlcNAc substitution is a general feature associated with cancer.74-78 As a 
result of cancer, the energy metabolism of the cell shifts from oxidative phosphorylation 
to a less efficient energy pathway involving glycolysis; this shift is known as the 
Warburg effect.79-81 This results in an increase in the demand for glucose in the cell and 
eventually increases the uptake of glucose and glucosamine. Further, the levels of the 
glucose transporters and glycolytic enzymes can be upregulated by Kras oncogene. As a 
result of the increase in HBP flux, the level of UDP-GlcNAc increases and results in 
hyper-O-GlcNAcylation.82 The reduction of hyper-O-GlcNAcylation, however, inhibits 
cellular proliferation and results in apoptotic cell death.73  
 Recently, it has been reported that the surface of the glycocalyx in the cancer cells 
are covered with bulky glycoproteins. These bulky substituents help to facilitate the 
metastatic spread of cancer cells and to regulate cell survival.55,83 
 
1.4. Protein Biosynthesis 
 Proteins are the biochemical polymeric macromolecules made up of amino acid 
residues that play a crucial role in a vast array of cellular processes including DNA 
replication, catalyzing metabolic reactions and the internalization of molecules in the cell. 
Each protein contains a signature sequence of amino acid residues that arranges itself into 
a specific three-dimensional structure and thereby contributes to the structure and activity 
of the protein. In nature, the genetic information encoded in a messenger RNA (mRNA) 
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is translated into the protein by the cellular organelle called a ribosome. The ribosome is 
a large nucleoprotein complex made up of a complex array of ribosomal RNAs (rRNAs) 
and proteins. The ribosome is comprised of two subunits, denoted as 30S and 50S in 
bacteria.84,85 Each subunit in the ribosome has three sites for binding transfer RNA 
(tRNA), namely the A-site (aminoacyl-tRNA binding site), P-site (peptidyl-tRNA 
transfer site) and E-site (exit site for deacylated tRNA). Each tRNA decodes the genetic 
information by recognizing a set of three nucleotides known as a codon (triplet 
sequence), which is complementary to tRNA anticodon, and linking the nucleotide 
sequence with amino acid residues found at the opposite end of the tRNA. The high 
fidelity of protein synthesis is due to accurate codon–anticodon base pairing among the 
different RNAs during the decoding process.86 
 The translation of mRNA proceeds through three distinct steps, namely initiation, 
elongation and termination. The process begins with activation of tRNA with its cognate 
amino acid by its aminoacyl-tRNA synthetase. Initiation of protein translation involves 
the binding of the 30S ribosomal subunit with the mRNA and aminoacylated tRNA with 
the rRNA having the base pairs complementary to the Shine–Dalgarno sequence of the 
bound mRNA.84 This event is followed by binding of the 50S ribosomal subunit to the 
30S subunit, affording the 70S ribosomal complex. The formation of initiation complex 
requires initiation factors (IF1, IF2 and IF3). Generally, the initiation codon translated is 
AUG, which codes for methionine. Only the activated form N-formylmethionine is able 
to form the initiation complex and occupies the P-site of ribosomal subunit. After 
initiation, the empty A-site of the ribosomal subunit is charged with aminoacyl-tRNA 
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having anticodon corresponding to the next codon on mRNA. This event is conducted 
with the help of GTP and elongation factor EF-Tu, the latter of which is recharged by 
another elongation factor EF-Ts. The α-amino group of the aminoacyl-tRNA present in 
the A-site mediates a nucleophilic attack on the carbonyl carbon of the adjacent nascent 
peptide in P-site and results in transfer of the amino group to the tRNA in the A site 
thereby elongating the peptide chain (Figure 1.9). Subsequently, the tRNAs in the A-site 
and P-site are translocated to the P-site and E-site, respectively, with the help of 
elongation factor EF-G.  
 
Figure 1.9. Peptide Bond Formation During Protein Translation (R1, R2 and R3 are the 
side chain substituents in the amino acids).84 
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 This event is followed by release of the tRNA from E-site and binding of the next 
aminoacylated-tRNA, having anticodon corresponding to the next codon on mRNA, to 
the vacant A-site.84,87 The process of elongation continues until the termination is 
signaled by the presence of one of the stop codons (UAG, UAA or UGA) on mRNA. The 
presence of the stop codon in the A-site results in the binding of the release factors (RF1, 
RF2 and RF3) and eventually triggers the release of the nascent polypeptide and 
dissociation of ribosomal complex into 50S and 30S subunits.87 
 
1.5. Site-specific Incorporation of Unnatural Amino Acids into Proteins 
In nature, there are 20 proteinogenic amino acids and the different order in 
arrangement of these resides in proteins gives rise to an array of different proteins with a 
variety of biological roles. To study protein structure, function, dynamics and 
intermolecular interactions, unnatural amino acids can be introduced into the proteins 
using misacylated suppressor tRNAs.88-91 This technique has developed into a very 
powerful tool and involves site-directed mutagenesis of DNA to replace the codon for a 
specific amino acid of interest with a nonsense codon (Figure 1.10).  
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Figure 1.10. Strategy for the Site-specific Incorporation of Unnatural Amino Acids Into 
Proteins In Vitro.84 
 
The translation of a stop codon by circumventing the effects of the release factors 
responsible for the termination of protein synthesis is referred to as suppression event. 
The nonsense codons used for this purpose are mainly UAG (amber)88, UAA (opal)92 and 
UGA (ochre).93 Hecht and co-workers first developed the general technique for 
misacylation of the suppressor tRNA comprising the anticodon complementary to the 
nonsense codon by ligating a tRNA, lacking the 3ʹ-terminal cytidine and adenosine 
moieties, to the aminoacylated dinucleotide pCpA with the help of T4 RNA ligase.94-96 
Later, Schultz and co-workers modified the method by replacing the aminoacylated 
dinucleotide pCpA with dinucleotide pdCpA that is now extensively used for 
misacylation of tRNA.97,98 This technology has proven revolutionary in the field of 
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protein engineering and helped in the incorporation of a wide variety of unnatural amino 
acids in proteins with novel properties. Further, Hecht and co-workers demonstrated that 
the modification of the 23S rRNA in bacteria can dramatically changes the ribosomal 
architecture and permit the incorporation of D-amino acids and β-L-amino acids.99-102 
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CHAPTER 2 
SYNTHESIS OF BLEOMYCIN SACCHARIDE CONJUGATES FOR IMAGING 
STUDIES 
2.1. Introduction  
2.1.1. Synthesis of Bleomycin Saccharide–dye Conjugates for Selective Targeting of 
Cancer Cells 
For many years the role of the disaccharide moiety in bleomycin was a matter of 
debate. It was postulated that the C-3 carbamoyl group attached to the mannose is 
involved in metal binding as the sixth ligand (Figure 2.1) and that the sterically hindered 
disaccharide forms a protective pocket to shield the reactive radical intermediates.103-106  
      
Figure 2.1. Proposed Model for Metal Coordination of Fe(II)•BLM.104 
 
However, the documented DNA cleavage activity of deglycoBLM in a cell free 
system rendered the involvement of the sugar in metal binding moot since deglycoBLM 
has no sugar.107,108 In parallel, extensive in vivo imaging studies were carried out with 
57Co-BLM and 111In-BLM complexes.109,110 Later, a new modified imaging agent 
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BLEDTA, containing an ethylenedinitrilotetraacetic acid (EDTA) moiety attached to the 
C-terminal end of BLM A2 was developed and 111In-BLEDTA was used successfully to 
image several carcinomas in vivo. These studies failed to show comparably effective 
imaging for 111In-deglycoBLEDTA.111-113 Thus, these results strongly implied that the 
carbohydrate moiety in bleomycin could possibly play a role in cellular recognition and 
internalization of the drug. In order to further study the role of the carbohydrate moiety, 
our laboratory designed a targeting experiment in which cancer cells were treated with 
microbubbles that had been derivatized with bleomycin.10 
Microbubbles are lipid membranes made up of albumin or other materials, and 
enclosing a gaseous core such as air, nitrogen or a perfluorocarbon (Figure 2.2). They are 
used as contrast agents in ultrasonography.114 The surface of microbubbles that has been 
modified with streptavidin was used to bind biotin–BLM A5 and biotin–deglycoBLM A5 
(Figure 2.3) through a biotin–streptavidin specific interaction. The derivatized 
microbubbles were then incubated with cultured MCF-7 breast cancer cells and MCF-
10A normal breast cells and imaged using a Zeiss Axiovert 200M microscope.10 
 
Figure 2.2. Magnified Picture of the Surface of Microbubble Derivatized BLM A5.10 
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Figure 2.3. Structures of Biotin Derivatized Bleomycin A5 and Deglycobleomycin A5.10 
 
 The BLM–microbubble conjugate was observed to adhere selectively to MCF-7 
cells, but the deglycoBLM conjugate lacking the sugar moiety failed to show any cell 
attachment (Figures 2.4a and 2.4d). Lack of cell attachment was observed for MCF-10A 
cells incubated with BLM conjugated microbubbles and MCF-7 cells incubated with 
underivatized microbubbles (Figures 2.4b and 2.4c).  The inability of deglycoBLM to 
bind to cancer cells in comparison to BLM established the requirement of the 
carbohydrate moiety for targeting cancer cells. As the BLM–microbubble conjugate was 
derivatized with multiple copies of BLM, the interaction observed by the binding 
experiment might have been facilitated by the polyvalent nature of the interaction. 
However, the possible mechanism of cellular uptake of bleomycin and whether the BLM 
disaccharide moiety alone was sufficient to mediate internalization remained unresolved. 
To address these issues, fluorescently labeled BLMs and carbohydrates were synthesized 
and internalization was studied microscopically.18  
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Figure 2.4. Microscopic Images of Microbubble Experiment: (a) Microscopic image of 
MCF-7 breast cancer cells treated with BLM A5 derivatized microbubbles. (b) 
Microscopic image showing MCF-10A normal breast cells treated with BLM A5 
derivatized microbubbles. (c) Microscopic image of MCF-7 breast cancer cells treated 
with underivatized microbubbles. (d) Microscopic image showing MCF-7 breast cancer 
cells treated deglycoBLM A5 derivatized microbubbles.10  
 
 Classically, in a fluorescence microscopy experiment, the fluorescent tag or label is 
attached chemically to the molecule of interest to enable its detection following 
incubation with the target cell lines. Fluorescence microscopy is then used to image the 
chemical tag localized in the cell. In order to choose the correct reporter, the fluorescent 
dye should not bind to the cell on its own. Also, it should have sufficient fluorescence 
signal strength to be detectable above the autofluorescence of the cells studied. Cy5** 
was chosen as the reporter after many trials115 and was attached to BLM A5, 
deglycoBLM A5 and BLM disaccharide (Figure 2.5).18 The conjugates were incubated 
a b 
c d 
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with breast, prostate, colon and lung cell lines, as well as their matched normal cell lines, 
and were imaged using a Zeiss Axiovert microscope. Both BLM–Cy5** (2.2a) and BLM 
disaccharide–Cy5** (2.3) showed selective uptake in the MCF-7 breast cancer cells 
relative to matched normal cells (Figure 2.6 and Figure 2.7). Similar results were also 
obtained in the case of DU-145 prostate cells and matched normal prostate cells (Figure 
2.8 and Figure 2.9).18 
 
  
Figure 2.5. Structures of BLM–Cy5** (2.2a), DeglycoBLM–Cy5** (2.2b) and BLM 
Disaccharide–Cy5** (2.3).18 
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Figure 2.6. Comparison of the Binding/Uptake of BLM–Cy5** (2.2a), DeglycoBLM–
Cy5** (2.2b) and BLM Disaccharide–Cy5** (2.3) in MCF-7 Breast Cancer Cells and 
Matched Normal Breast Cells.18 
 
 
Figure 2.7. Quantification of the Binding/Uptake of BLM–Cy5** (2.2a), DeglycoBLM–
Cy5** (2.2b) and BLM Disaccharide–Cy5** (2.3) in MCF-7 Breast Cancer Cells and 
Matched Normal Breast Cells.18 
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Figure 2.8. Comparison of the Binding/Uptake of BLM–Cy5** (2.2a), DeglycoBLM–
Cy5** (2.2b) and BLM Disaccharide–Cy5** (2.3) in DU-145 Prostate Cancer Cells and 
Matched Normal Prostate Cells.18 
 
 
 
Figure 2.9. Quantification of the Binding/Uptake of BLM–Cy5** (2.2a), DeglycoBLM–
Cy5** (2.2b) and BLM Disaccharide–Cy5** (2.3) in DU-145 Prostate Cancer Cells and 
Matched Normal Prostate Cells.18 
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DeglycoBLM–Cy5** (2.2b), lacking the disaccharide moiety showed no uptake 
in any cell line, which was consistent with the results obtained from the microbubble 
experiment.18 Hence, the targeting ability of the carbohydrate domain of BLM along with 
the sufficiency of the sugar to internalize the reporter molecule can be potentially utilized 
to develop a better therapeutic agent or drug delivery vehicle for chemotherapy. To 
further understand the importance of the carbohydrate domain of BLM and explore the 
participation of the carbamoyl moiety, a library of disaccharide–Cy5** conjugates was 
synthesized (Figure 2.10). 
 
Figure 2.10. Library of Disaccharide–dye Conjugates 2.3–2.7 Synthesized and 
Evaluated. (The synthesis of 2.6 and 2.7 were carried out by Dr. Manikandadas 
Mathilakathu Madathil).116 
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demonstrate the importance of carbamoyl moiety in selective tumor cell targeting and the 
effect of trimeric carbohydrate cluster of BLM monosaccharide on cell targeting, 
mannose (decarbamoyl BLM monosaccharide) conjugated to Cy5** (2.9) and a trimer 
cluster of BLM monosaccharide conjugated to Cy5** (2.10) were synthesized (Figure 
2.11) and evaluated for their tumor cell targeting ability. 
  
Figure 2.11. Structures of BLM Monosaccharide–Cy5** (2.8), Decarbamoyl BLM 
Monosaccharide–Cy5** (2.9) and BLM Monosaccharide–Cy5** Trimer (2.10) 
Synthesized and Evaluated.117 
 
To further explore the importance of the carbamoyl moiety and its positioning in 
the monosaccharide subunit, efforts were then extended to synthesize a library of 
monosaccharides with modifications of the carbamoyl group and alteration of its position 
on the mannose ring (Figure 2.12). 
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Figure 2.12. Library of Monosaccharide–dye Conjugates 2.11–2.16 Synthesized and 
Evaluated. 
 
Though the reporter dye Cy5** was affording excellent results, the lack of 
availability of the dye resulted in a search for a replacement dye with similar properties. 
Hence, a number of commercially available dyes with similar extinction coefficients, and 
absorption and emission spectra to Cy5** were selected and conjugated with BLM 
monosaccharide (Figure 2.13) and later with other saccharides (Figure 2.14). 
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Figure 2.13. Structures of Different Monosaccharide–dye Conjugates 2.17–2.22 
Synthesized for Selection of a Dye to Replace Cy5**. 
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Figure 2.14. Series of Additional Dye Conjugates 2.23–2.28 Synthesized and Evaluated. 
 
To explore the modular nature of BLM suggested by diminished cytotoxicity of 
deglycoBLM in comparison to BLM, different BLM analogues were prepared in which 
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2.31 and 2.32 were synthesized by Dr. Benjamin R. Schroeder.119 Later, to study the 
cellular uptake of the modified BLMs, their dye conjugates 2.30, 2.33 and 2.34 were 
synthesized and evaluated (Figures 2.15 and 2.16). 
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Figure 2.15. Structures of a Modified BLM With a C-terminal Disaccharide 2.29 and its 
Conjugate With Cy5** 2.30 Synthesized and Evaluated. 
 
 
Figure 2.16. Structures of Modified BLMs With the Disaccharide Attached to Threonine 
Moiety 2.31 and 2.32 (synthesized by Dr. Benjamin R. Schroeder),119 and Their 
Fluorescent Dye Conjugates 2.33 and 2.34 Synthesized and Evaluated. 
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2.1.2. Synthesis of Fluorinated Saccharides for Imaging Studies 
 
 
In the field of nuclear medicine, the radioisotopically labeled drugs are used for 
diagnosis of many diseases like cancer.120 The molecular imaging technique in which 
compounds labeled with positron emitting radioisotopes are used to produce three-
dimensional images of the functional processes in the body is known as PET. The 
radiolabeled molecules are retained in the tissues and the tomographic images of the 
biodistribution within the body are generated by detection of the gamma rays.121 
Clinically, 18F-FDG (2-[18F]-fluoro-2-deoxy-D-glucose) has been extensively used for 
various PET studies. 18F-FDG is a glucose analogue in which C-2 carbon has a fluoride 
atom in place of the hydroxyl group present in glucose. It undergoes receptor mediated 
transport and phosphorylation but cannot undergo further metabolism like glucose.122 The 
higher uptake in tumor tissues than in normal tissues because of increased glycolysis 
helps in strong signal intensity in PET imaging (Figure 2.17).123 
 
Figure 2.17. PET-CT Image of Breast Ductal Carcinoma Treated With 18F-FDG.123 
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As described earlier, due to the unique ability of BLM disaccharide to target 
tumors,18 it represents a potentially attractive PET biomarker enabling possible cancer 
localization, their biodistribution, in vivo quantification of metastatic cells and eventual 
elimination. Hence, the non-radioactive fluorinated disaccharides were synthesized as 
non-radioactive reference compounds for disaccharide PET biomarkers (Figure 2.18). 
 
 
Figure 2.18. Structures of Fluorinated BLM Disaccharide 2.35 and Fluorinated 
Decarbamoyl BLM Disaccharide 2.36 Synthesized. 
 
2.2. Results 
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2.4 and 2.5 were effected by the coupling of gulose glycosyl acceptor with corresponding 
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homologation of commercially available L-xylose following Dondoni’s method (Scheme 
2.1).124 L-xylose (2.37) was fully protected as dithioacetal 2.38 in 65% yield, the latter of 
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67% yield.  Aldehyde 2.39 was immediately coupled with 2-(trimethylsilyl)thiazole 
(2.40)125 followed by desilylation to afford the alcohol 2.41 in 60% yield. The free 
hydroxyl group of 2.41 was protected as benzyl ether 2.42 in 60% yield. The thiazole ring 
of 2.42 was then converted into aldehyde 2.43 in 94% yield through a series of 
transformations. Acetal deprotection followed by exhaustive acetylation of aldehyde 2.43 
afforded tetra-O-acetyl-2-O-benzyl-L-gulopyranoside (2.44) in 60% yield. Reductive 
debenzylation of gulopyranoside 2.44 gave the gulose acceptor 2.45 in 98% yield. 
 
Scheme 2.1. Synthesis of the Gulose Glycosyl Acceptor 2.45. 
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methylmannopyranoside (2.46) following reported procedures with slight modifications 
(Scheme 2.2).21 The synthesis began with protection of α-D-methylmannopyranoside 
O OH
OH
EtSH, conc. HCl
Acetone
(65%)
HgCl2, HgO
Acetone-H2O
(67%)
1. MeOTf, Acetonitrile
2. NaBH4, MeOH
3. CuO, CuCl2.2H2O,
    Acetonitrile, H2O
2.37
BnBr, NaH
DMF
(60%)
2.41 2.42
2.45
O
CH(SEt)2
O
O
O
HO
OH
O
CHO
O
O
O
2.38 2.39
1. DCM,
(60%)
O
O
O
O
N
S
OH
O
O
O
O
N
S
OBn
2.43
O
O
O
O
CHO
OBn
O
OBn
2.44
OAc
AcO
OAc
O
OH
OAc
AcO
OAc1. AcOH, H2O
2. Ac2O, pyridine
Me3Si
N
S
2. THF, Bu4NF•3H2O
2.40
H2, Pd/COAc OAc
(94%)
(60%) (98%)
 
 
34 
(2.46) as the benzylidene acetal 2.47 in 70% yield. Selective benzylation of acetal 2.47 at 
the C-3 position using Bu2SnO afforded alcohol 2.48 in 68% yield. Deprotection of the 
acetal and exhaustive acetylation of alcohol 2.48 gave peracetylated mannose 2.49 in 
85% yield. Debenzylation using Pd(OH)2/C (Pearlman’s catalyst) yielded 2.50 in 98% 
yield. C-3 alcohol 2.50 was then activated as the p-nitrophenyl carbonate (2.51) in 81% 
yield, the latter of which was subjected to aminolysis with ammonia, yielding carbamate 
2.52 in 94% yield. The anomeric acetate of carbamate 2.52 was removed selectively 
using hydrazine acetate to afford alcohol 2.53 in 76% yield. Alcohol 2.53 was 
subsequently activated as a diphenyl phosphate ester in presence of DMAP and dry 
triethylamine to obtain the activated mannose phosphate 2.54 in 92% yield.126 
 
Scheme 2.2. Synthesis of the Activated C-3-carbamoylmannose Glycosyl Donor 2.54. 
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Activated mannose donor 2.54 was coupled with the gulose acceptor 2.45 in the 
presence of TMSOTf to afford peracetylated BLM disaccharide 2.55 in 66% yield 
(Scheme 2.3).21 The anomeric acetate of disaccharide 2.55 was selectively cleaved using 
hydrazine acetate to afford the corresponding alcohol, the latter of which was activated as 
a diphenyl phosphate ester 2.56 in presence of DMAP and dry triethylamine in 65% yield 
over two steps. Activated phosphate ester 2.56 was then coupled to a commercially 
available linker that had been protected as the benzyloxycarbonyl (CBz) derivative 2.57 
to afford BLM disaccharide–linker 2.58 in 67% yield. Deacetylation of the acetates 
followed by debenzylation afforded the primary amine 2.59 (quantitative yield), the latter 
of which was conjugated with the N-hydroxysuccinimide (NHS) ester of Cy5** (2.60)127 
to provide the BLM disaccharide–Cy5** conjugate (2.3) in 35% yield.18 
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Scheme 2.3. Synthesis of the BLM Disaccharide–Cy5** (2.3). 
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reduction of the acetal at the C-2 and C-3 positions of both exo and endo isomers of 
acetal 2.61 with DIBAL-H in presence of 5% aluminum chloride afforded alcohol 2.62 in 
65% and 72% yield, respectively.129 Deprotection of the acetal followed by exhaustive 
acetylation of alcohol 2.62 gave peracetylated mannose 2.63 in 57% yield. The anomeric 
acetate of mannose 2.63 was selectively cleaved by hydrazine acetate to afford the 
alcohol, the latter of which was subsequently activated as a diphenyl phosphate ester in 
the presence of DMAP and dry triethylamine to obtain the activated mannose phosphate 
2.64 in 55% yield over two steps. 
 
Scheme 2.4. Synthesis of the Activated C-2-O-benzylmannose Glycosyl Donor 2.64. 
 
Coupling of activated mannose donor 2.64 with the gulose acceptor 2.45 in the 
presence of TMSOTf afforded disaccharide 2.65 in 56% yield (Scheme 2.5). 
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C-2 alcohol 2.66 was then activated as the p-nitrophenyl carbonate (2.67) in 86% yield, 
the latter of which was subjected to aminolysis with ammonia yielding carbamate 2.68 
with 92% yield. The anomeric acetate of disaccharide 2.68 was selectively cleaved by 
hydrazine acetate to afford the corresponding alcohol, the latter of which was activated as 
a diphenyl phosphate ester 2.69 in the presence of DMAP and dry triethylamine in 43% 
yield over two steps. Activated phosphate ester 2.69 was then coupled to the linker 
protected as the benzyloxycarbonyl (CBz) derivative 2.5718 to afford BLM disaccharide–
linker 2.70 in 39% yield. Deacetylation of the acetates followed by debenzylation gave 
the primary amine 2.71 (quantitative yield), the latter of which was treated with the NHS 
ester of Cy5** (2.60)127 to provide the modified disaccharide–Cy5** conjugate 2.4 in 
35% yield. 
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Scheme 2.5. Synthesis of the C-2-carbamoylmannose Modified Disaccharide–Cy5** 2.4. 
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acceptor 2.45. The synthesis began with regioselective reductive ring opening of acetal 
2.47 in presence of CoCl2 and BH3•THF to afford alcohol 2.72 in 99% yield (Scheme 
2.6).130 Exhaustive acetylation of alcohol 2.72 in acidic medium gave peracetylated 
mannose 2.73 in 79% yield. Debenzylation using Pd(OH)2/C (Pearlman’s catalyst) 
yielded alcohol 2.74 in 84% yield. C-4 alcohol 2.74 was then activated as the p-
nitrophenyl carbonate (2.75) in 74% yield, the latter of which was subjected to 
aminolysis with ammonia yielding carbamate 2.76 in 87% yield. The anomeric acetate of 
carbamate 2.76 was removed selectively using hydrazine acetate to afford alcohol 2.77 in 
100% yield, the latter of which was subsequently activated as a diphenyl phosphate ester 
in the presence of DMAP and dry triethylamine to obtain the activated mannose 
phosphate 2.78 in 56% yield. 
 
Scheme 2.6. Synthesis of the Activated C-4-carbamoylmannose Glycosyl Donor 2.78. 
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Activated mannose donor 2.78 was coupled with gulose acceptor 2.45 in the 
presence of TMSOTf to afford disaccharide 2.79 in 51% yield (Scheme 2.7). Selective 
removal of the anomeric acetate of disaccharide 2.79 followed by activation as a diphenyl 
phosphate ester in the presence of DMAP and dry triethylamine afforded glycosyl donor 
2.80 in 43% yield over two steps. Activated glycosyl phosphate 2.80 was then coupled to 
the linker protected as a benzyloxycarbonyl (CBz) derivative 2.5718 to afford 
disaccharide–linker 2.81 in 39% yield. Deacetylation of the acetates followed by 
debenzylation gave primary amine 2.82 (quantitative yield), the latter of which was 
subsequently conjugated with the NHS ester of Cy5** (2.60)127 to afford the modified 
disaccharide–Cy5** conjugate 2.5 in 32% yield. 
 
Scheme 2.7. Synthesis of the C-4-carbamoylmannose Modified Disaccharide–Cy5** 2.5. 
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As a part of our ongoing investigation of whether the BLM disaccharide was 
actually the simplest structural entity conferring the tumor targeting ability of BLM, 
BLM monosaccharide–Cy5** (2.8) was synthesized. Mannose glycosyl donor 2.54 was 
coupled to the linker protected as the benzyloxycarbonyl (CBz) derivative 2.5718 to 
afford BLM monosaccharide–linker 2.83 in 96% yield (Scheme 2.8). Deacetylation of the 
acetates followed by debenzylation of the primary amine of 2.83 gave amine 2.84 
(quantitative yield), the latter of which was treated with the NHS ester of Cy5** (2.60)127 
to give the BLM monosaccharide–Cy5** (2.8) in 36% yield.  
 
Scheme 2.8. Synthesis of the BLM Monosaccharide–Cy5** (2.8). 
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methylmannopyranoside (2.46) gave mannose derivative 2.85 in 94% yield (Scheme 
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subsequently activated as a diphenyl phosphate ester in the presence of DMAP and dry 
triethylamine to obtain the activated mannose phosphate 2.86 in 80% yield over two 
steps.132 Mannose glycosyl donor 2.86 was coupled with the linker protected as the 
benzyloxycarbonyl (CBz) derivative 2.5718 to afford decarbamoyl BLM 
monosaccharide–linker 2.87 in 37% yield. Deacetylation followed by debenzylation of 
the primary amine of 2.87 gave amine 2.88 (quantitative yield), the latter of which was 
then conjugated with the N-hydroxysuccinimide (NHS) ester of Cy5** (2.60)127 to give 
decarbamoyl BLM monosaccharide–Cy5** (2.9) in 36% yield.  
 
Scheme 2.9. Synthesis of Decarbamoyl BLM Monosaccharide–Cy5** (2.9). 
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The synthesis commenced with debenzylation of the primary amine of 2.83 to give amine 
2.89 in 100% yield. Compound 2.89 was conjugated to the NHS ester of protected 
trimer–linker 2.90118 to afford BLM monosaccharide trimer linker 2.91 in 40% yield 
(Scheme 2.10). Complete deacetylation followed by debenzylation of the primary amine 
of 2.91 gave trimer cluster linker amine 2.92 quantitatively. Coupling of trimer linker 
amine 2.92 with the NHS ester of Cy5** (2.60)127 provided the BLM monosaccharide–
Cy5** trimer conjugate 2.10 in 33% yield. 
 
Scheme 2.10. Synthesis of the BLM Monosaccharide–Cy5** Trimer (2.10). 
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synthesized. The synthesis of C-2 modified monosaccharide–Cy5** began with the 
coupling of mannose donor 2.64 with the linker protected as the phthalimide derivative 
2.93133 to afford monosaccharide–linker 2.94 in 79% yield (Scheme 2.11). Debenzylation 
using Pd(OH)2/C (Pearlman’s catalyst) yielded alcohol 2.95 in 82% yield. C-2 alcohol 
2.95 was then activated as the p-nitrophenyl carbonate (2.96) in 73% yield. Subsequently, 
carbonate 2.96 was subjected to aminolysis with methylamine, dimethylamine, 
butylamine, pyrrolidine and hexylamine to afford C-2 methylcarbamate 2.97 in 89% 
yield, C-2 dimethylcarbamate 2.98 in 80% yield, C-2 butylcarbamate 2.99 in 73% yield, 
C-2 pyrrolidinylcarbamate 2.100 in 96% yield and C-2 hexylcarbamate 2.101 in 62% 
yield. Deacetylation of the acetates followed by deprotection of the phthalimide group 
using hydrazine hydrate afforded amine–linkers 2.102, 2.103, 2.104, 2.105 and 2.106 in 
100%, 100%, 98%, 95% and 99% yields, respectively. Amines 2.102, 2.103, 2.104, 2.105 
and 2.106 were conjugated with NHS ester of Cy5** (2.60)127 to give modified 
monosaccharide–Cy5** conjugates 2.11, 2.12, 2.13, 2.14 and 2.15 in 25%, 22%, 52%, 
54% and 21% yields, respectively.  
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Scheme 2.11. Synthesis of the C-2-carbamoyl Modified Monosaccharide–Cy5** 2.11–
2.15. 
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mannose phosphate 2.107 in 42% yield over two steps. Mannose donor 2.107 was then 
coupled with the linker protected as the phthalimide derivative 2.93133 to afford 
monosaccharide–linker 2.108 in 60% yield (Scheme 2.12). Debenzylation using 
Pd(OH)2/C (Pearlman’s catalyst) yielded the alcohol 2.109 in 61% conversion, the latter 
of which was activated as the p-nitrophenyl carbonate (2.110) in 88% yield. Carbonate 
2.110 was subjected to aminolysis with methylamine to afford C-2 methylcarbamate 
2.111 in 85% yield. Deacetylation followed by deprotection of the phthalimide group 
using hydrazine hydrate afforded amine–linker 2.112 in 73% yield, the latter of which 
was conjugated with the NHS ester of Cy5** (2.60)127 to give modified monosaccharide–
Cy5** conjugate 2.16 in 30% yield. 
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Scheme 2.12. Synthesis of the C-3-methylcarbamoyl Modified Monosaccharide–Cy5** 
2.16. 
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the NHS ester of Cy5.5GE (2.118) gave BLM monosaccharide–sulphoCy5 conjugate 
(2.17), BLM monosaccharide–Cy5 conjugate (2.18), BLM monosaccharide–Cy7 
conjugate (2.19), BLM monosaccharide–AF647 conjugate (2.20), BLM monosaccharide–
Cy5GE conjugate (2.21) and BLM monosaccharide–Cy5.5GE conjugate (2.22) in 10%, 
30%, 19%, 48%, 72% and 44% yields, respectively.  
 
Scheme 2.13. Synthesis of BLM Monosaccharide–dye Conjugates 2.17–2.22. 
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The primary amine of decarbamoyl BLM monosaccharide–linker 2.88 was also 
coupled with the NHS ester of Cy5 (2.114) to give decarbamoyl BLM monosaccharide–
Cy5 conjugate (2.23) in 23% yield (Scheme 2.14). Similarly, the primary amine of BLM 
disaccharide–linker 2.59 was coupled with the NHS ester of Cy5 (2.114) and the NHS 
ester of Cy5GE (2.117) to give BLM disaccharide–Cy5 conjugate (2.24) and BLM 
disaccharide–Cy5GE conjugate (2.25)115 in 31% and 27% yields, respectively (Scheme 
2.15). 
 
Scheme 2.14. Synthesis of Decarbamoyl BLM Monosaccharide–Cy5 (2.23). 
 
 
Scheme 2.15. Synthesis of BLM Disaccharide–dye Conjugates 2.24 and 2.25. 
 
Activated mannose donor 2.86 was coupled with the gulose acceptor 2.45 in the 
presence of TMSOTf to afford peracetylated disaccharide 2.119 in 67% yield (Scheme 
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phosphate 2.120 was then coupled with the linker protected as the benzyloxycarbonyl 
(CBz) derivative 2.5718 to afford decarbamoyl BLM disaccharide–linker 2.121 in 70% 
yield.118 Deacetylation of the acetates followed by debenzylation of the primary amine of 
2.121 gave amine 2.122, the latter of which was coupled with the NHS ester of Cy5 
(2.114) and the NHS ester of Cy5GE (2.117) to give decarbamoyl BLM disaccharide–Cy5 
conjugate (2.26) and decarbamoyl BLM disaccharide–Cy5GE conjugate (2.27) in 23% and 
44% yields, respectively. 
 
Scheme 2.16. Synthesis of Decarbamoyl BLM Disaccharide–dye Conjugates 2.26 and 
2.27. 
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The primary amine in the C-substituent of Cu(II)•BLM A5 (2.123) was coupled 
with the NHS ester of Cy5GE (2.117) to give Cu(II)•BLM–Cy5GE conjugate 2.124 in 22% 
yield (Scheme 2.17), the latter of which was demetallated using 15% EDTA to afford 
BLM–Cy5GE (2.28) in 94% yield.115 
 
Scheme 2.17. Synthesis of BLM–Cy5GE (2.28). 
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the p-nitrophenyl carbonate to give carbamate 2.125 in 73% yield. The carbonate was 
then coupled with Cu(II)•deglycoBLM (2.123). The resulting intermediate was 
deprotected by the use of hydrazine to afford modified Cu(II)•BLM 2.126 in 31% 
yield.118 The latter was then subjected to demetallation with 15% EDTA to afford 
modified BLM 2.29 in 40% yield. 
 
 
Scheme 2.18. Synthesis of Modified BLM 2.29 
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To study the cellular uptake of modified BLMs, the dye-labeled analogues were 
prepared. The synthesis of dye-labeled analogue 2.30 began with the coupling of the 
activated NHS ester of acid 2.127 with Cu(II)•deglycoBLM (2.123) to afford modified 
linker BLM 2.128 in 15% yield over two steps (Scheme 2.19). The Fmoc group of linker 
BLM 2.128 was removed using 20% piperidine in DMF followed by coupling with 
carbonate 2.125 to provide modified linker BLM–disaccharide 2.129 in 32% yield over 
two steps. The deprotection of Boc group followed by coupling with the NHS ester of 
Cy5** (2.60)127 gave conjugate 2.130 in 17% yield over two steps. The demetallation of 
conjugate 2.130 with 15% EDTA afforded modified BLM–Cy5** 2.29 in 40% yield. 
 
Scheme 2.19. Synthesis of Modified BLM–Cy5** Conjugate 2.30. 
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The syntheses of dye labeled analogues of modified BLMs 2.31119 and 2.32119 
started by metallation of each with CuCl2, followed by coupling with the NHS ester of 
Cy5** (2.60),127 the latter of which afforded conjugates 2.131 and 2.132 in 37% and 36% 
yields, respectively (Scheme 2.20). Successive demetallation of 2.131 and 2.132 using 
15% EDTA afforded modified BLM–Cy5** conjugates 2.33 and 2.34 in 67% and 42% 
yields, respectively. 
 
Scheme 2.20. Synthesis of Modified BLM–Cy5** Conjugates 2.33 and 2.34. 
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2.2.2. Biological Evaluation of Fluorescent Carbohydrate Conjugates 
 
The natural disaccharide moiety in BLM is comprised of D-mannose and L-
gulose monosaccharide subunits. The importance of the disaccharide moiety of the 
bleomycin in the tumor cell selectivity has been well documented by the microbubble10 
and fluorescent microscopy experiments.18 To better study the importance of the 
carbamoyl moiety, a library of disaccharide–dye conjugates was synthesized (Figure 
2.10). Cy5** was used as the fluorescent probe; it was the perfect dye candidate for the 
study as it has negligible cell surface affinity and is soluble in aqueous media due to the 
presence of four sulfonate groups. The cell binding/uptake of BLM disaccharide–Cy5** 
conjugate (2.3), and the newly synthesized disaccharide–Cy5** conjugates 2.4–2.7 
(Figure 2.10) by A549 lung carcinoma cells, DU-145 prostate carcinoma cells, A498 
kidney carcinoma cells, and BxPC-3 pancreatic carcinoma cells were quantified by 
fluorescence imaging. 
Disaccharide conjugate 2.4, having a unmodified carbamoyl group at the C-2 
position of D-mannose (Figure 2.10) showed comparable binding/uptake relative to the 
natural disaccharide conjugate 2.3 in all the cancer cell lines tested except BxPC-3 
pancreatic cancer cells (Figure 2.19). Disaccharide conjugate 2.6 having an N-methylated 
carbamoyl group at the C-2 position of D-mannose exhibited best binding/uptake in all 
tested cancer cell lines, especially in BxPC-3 pancreatic cancer cells. Disaccharide 
conjugate 2.7 having an N-methylated carbamoyl group at the C-3 position of D-mannose 
also showed excellent binding/uptake characteristics, almost comparable to disaccharide 
conjugate 2.6 in A498 kidney cancer cells and BxPC-3 pancreatic cancer cells, but much 
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lower in A549 lung cancer cells and DU-145 prostate cancer cells. In comparison, 
disaccharide conjugate 2.5 having an unmodified carbamoyl group at the C-4 position of 
D-mannose exhibited relatively poor binding/uptake in all of the tumor cell lines tested, 
underscoring the importance of the position and orientation of the carbamoyl group in the 
BLM disaccharide. This was especially true for the BxPC-3 pancreatic cancer and A498 
kidney cancer cell lines. All of the disaccharide–dye conjugates exhibited negligible 
binding/uptake in normal cells (data not shown), highlighting the role of the disaccharide 
and carbamoyl moiety in the cancer cell selectivity of BLM. 
 
 
Figure 2.19. Comparison of the Binding/Uptake of BLM Disaccharide–Cy5** Conjugate 
(2.3) and Modified Disaccharide–Cy5** Library Conjugates 2.4−2.7 in Four Cancer Cell 
Lines. (The cells were treated with 25 µM of BLM disaccharide–Cy5** conjugate (2.3) 
or disaccharide–Cy5** conjugates 2.4–2.7 at 37 °C for 1 h, washed with phosphate 
buffered saline (PBS), and fixed with 4% paraformaldehyde. The cell nuclei were stained 
with diamidino-2-phenylindole (DAPI). Fluorescence imaging was carried out with a 2 s 
exposure time. The experiment was carried out by Dr. Zhiqiang Yu). 
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Carbamoylmannose conjugated to Cy5** was synthesized (Figure 2.11) to 
evaluate its effect on cellular internalization. Six cancer cell lines were cultured on 16-
well glass chamber slides for 48 h and the cell binding/uptake of BLM monosaccharide–
Cy5** (2.8) was compared to BLM disaccharide–Cy5** (2.3) conjugate (Figure 2.10). 
The cells were stained with DAPI to permit evaluation of localization of the conjugates 
relative to the cell nuclei. It was clear that both BLM monosaccharide–Cy5** (2.8) and 
BLM disaccharide–Cy5** (2.3) conjugates underwent significant binding and uptake in 
all six cell lines (Figure 2.20). The binding/uptake was found to be specific for the cancer 
cell lines, as compared with matched normal controls (data not shown). Quantification of 
the data revealed that the binding/uptake of the BLM monosaccharide–Cy5** (2.8) was 
much (~2-fold) greater than that of BLM disaccharide–Cy5** (2.3) in A549 lung cancer 
cells, A498 kidney cancer cells, and MCF-7 breast carcinoma cells. The binding/uptake 
was almost identical for BT-474 breast ductal carcinoma cells and BxPC-3 pancreas 
cells. In comparison, the uptake exhibited by the BLM disaccharide–Cy5** (2.3) was 
much greater than that of monosaccharide 2.8 in DU-145 prostate cancer cells. 
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Figure 2.20. Comparison of the Binding/Uptake of BLM Monosaccharide–Cy5** (2.8) 
and BLM Disaccharide–Cy5** (2.3) Conjugates in Six Cancer Cell Lines. (The cells 
were treated with 25 µM BLM monosaccharide–Cy5** (2.8) or BLM disaccharide–
Cy5** (2.3) at 37 °C for 1 h, washed with phosphate buffered saline (PBS), and fixed 
with 4% paraformaldehyde. The cell nuclei were stained with diamidino-2-phenylindole 
(DAPI). Fluorescence imaging was carried out with a 3 s exposure time. The experiment 
was carried out by Dr. Zhiqiang Yu). 
 
To better define the importance of the carbamoyl group in cellular recognition, 
binding, and internalization, an experiment was conducted in which BLM 
monosaccharide–Cy5** (2.8) and decarbamoyl BLM monosaccharide–Cy5** (2.9) 
conjugates (Figure 2.11) were treated with four cancer cell lines and evaluated for 
cellular localization using fluorescent microscopy. None of the four cancer cell lines 
bound decarbamoyl BLM monosaccharide–Cy5** (2.9) to a significant extent, indicating 
that the carbamoyl group is essential for cell surface receptor interaction and uptake in 
these tumor cell lines (Figure 2.21).   
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Figure 2.21. Comparison of the Binding/Uptake of Decarbamoyl BLM Monosaccharide–
Cy5** (2.9) and BLM Monosaccharide–Cy5** (2.8) Conjugates in Four Cancer Cell 
Lines. (The cells were treated with 25 µM decarbamoyl BLM monosaccharide–Cy5** 
(2.9) or BLM monosaccharide–Cy5** (2.8) at 37 °C for 1 h, washed with phosphate 
buffered saline (PBS), and fixed with 4% paraformaldehyde. The cell nuclei were stained 
with diamidino-2-phenylindole (DAPI). Fluorescence imaging was carried out with a 3 s 
exposure time. The experiment was carried out by Dr. Zhiqiang Yu). 
 
Cellular receptors responsible for carbohydrate binding frequently exhibit 
multivalency. Accordingly, the cellular targeting and uptake of the Cy5** conjugate 
containing a cluster of three carbamoylmannose molecules (2.10) was studied. The BLM 
monosaccharide–Cy5** conjugate (2.8) and the BLM monosaccharide–Cy5** trimer 
(2.10) (Figure 2.11) were studied in six cancer cell lines. The quantified data reflect the 
(1.6–2.3-fold) greater binding/uptake of the BLM monosaccharide–Cy5** trimer (2.10) 
compared to the BLM monosaccharide–Cy5** conjugate (2.8) in all six cancer cell lines, 
consistent with multivalent targeting of the putative cell surface carbohydrate receptors 
(Figure 2.22).   
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Figure 2.22. Comparison of the Binding/Uptake of BLM Monosaccharide–Cy5** (2.8) 
and BLM Monosaccharide–Cy5** Trimer (2.10) Conjugates in Six Cancer Cell Lines. 
(The cells were treated with 25 µM BLM monosaccharide–Cy5** (2.8) or BLM 
monosaccharide–Cy5** trimer (2.10) at 37 °C for 1 h, washed with phosphate buffered 
saline (PBS), and fixed with 4% paraformaldehyde. The cell nuclei were stained with 
diamidino-2-phenylindole (DAPI). Fluorescence imaging was carried out with a 3 s 
exposure time. The experiment was carried out by Dr. Zhiqiang Yu). 
 
One interesting aspect of the cellular interaction of the BLM disaccharide–Cy5** 
conjugate (2.3) with cancer cells was found to be its temperature-dependent 
binding/uptake by cultured MCF-7 breast cancer cells.18 In order to test the mechanism of 
uptake of the BLM monosaccharide–Cy5** conjugate (2.8), the uptake was measured in 
seven cell lines at both 4 °C and 37 °C. The uptake measured at 4 °C after 1 h was similar 
to that observed at 37 °C (Figure 2.23), suggesting that the mechanism of internalization 
of the BLM monosaccharide–Cy5** conjugate (2.8) apparently differs from that of the 
BLM disaccharide–Cy5** conjugate (2.3), at least in this regard. 
 
0 
40 
80 
120 
160 
200 
A498 A549 BxPC-3 DU-145 BT-474 MCF-7 
m
ea
n 
pi
xe
l i
nt
en
si
ty
 
cell lines 
2.8 
2.10 
 
 
62 
 
Figure 2.23. Effect of the Incubation Temperature on the Internalization of BLM 
Monosaccharide–Cy5** Conjugate (2.8) in Seven Cancer Cell Lines. (The cells were 
treated with 25 µM BLM monosaccharide–Cy5** (2.8) at 4 °C or 37 °C for 1 h, washed 
with phosphate buffered saline (PBS), and fixed with 4% paraformaldehyde. The cell 
nuclei were stained with diamidino-2-phenylindole (DAPI). Fluorescence imaging was 
carried out with a 2 s exposure time. The experiment was carried out by Dr. Zhiqiang 
Yu). 
 
The present study was undertaken to further explore the effects of modifications 
of the carbamoyl moiety in alternative locations within the carbamoylmannose moiety of 
BLM. The cell binding/uptake of BLM monosaccharide–Cy5** conjugate (2.8) (Figure 
2.11), and the modified monosaccharide–Cy5** conjugates 2.11–2.16 (Figure 2.12) were 
studied in four cancer cell lines. It was clear that monosaccharide conjugates 2.11 and 
2.13 having an N-methylated carbamoyl group and an N-butylated carbamoyl group at 
the C-2 position of D-mannose, respectively, both underwent significantly high 
binding/uptake relative to BLM monosaccharide–Cy5** (2.8) in all four cancer cell lines 
(Figure 2.24). The quantification data also revealed that monosaccharide conjugates 2.12 
and 2.14 having N,N-dimethylated carbamoyl group and an N,N-pyrrolidinyl carbamoyl 
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group at the C-2 position of D-mannose, respectively, exhibited relatively poor 
binding/uptake in all of the tumor cell lines tested, underscoring the importance of the 
substitution and electron density on the cell binding/uptake. However, monosaccharide 
conjugate 2.15, having an N-hexylated carbamoyl group at the C-2 position of D-
mannose showed high binding/uptake in BxPC-3 pancreatic cancer lines and much lower 
binding/uptake in A549 lung cancer cells and DU-145 prostate cancer cells. In the case of 
MCF-7 breast cancer cells, it showed moderate binding/uptake. Monosaccharide 
conjugate 2.16, having an N-methylated carbamoyl group at the C-3 of D-mannose 
exhibited considerably lower binding/uptake relative to BLM monosaccharide–Cy5** 
conjugate 2.8 and monosaccharide conjugate 2.11 in A549 lung cancer cells, DU-145 
prostate cancer cells and MCF-7 breast cancer cells which is consistent with the results 
obtained in case of the disaccharide conjugates 2.6 and 2.7 (Figure 2.12) having an N-
methylated carbamoyl group at the C-2 and C-3 positions of D-mannose subunit, 
respectively. The binding/uptake was almost identical to the uptake exhibited by 
monosaccharide conjugate 2.11 in BxPC-3 pancreatic cancer cells.  
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Figure 2.24. Comparison of the Binding/Uptake of Modified Monosaccharide–Cy5** 
Library Conjugates 2.11–2.16 in Four Cancer Cell Lines. (The cells were treated with 25 
µM of monosaccharide–Cy5** conjugates 2.11–2.16 at 37 °C for 1 h, washed with 
phosphate buffered saline (PBS), and fixed with 4% paraformaldehyde. The cell nuclei 
were stained with diamidino-2-phenylindole (DAPI). Fluorescence imaging was carried 
out with a 3 s exposure time. The experiment was carried out by Dr. Zhiqiang Yu). 
 
Cyanine dye Cy5** produced excellent reproducible results, but due to the lack of 
availability of Cy5** dye several commercially available dyes with similar extinction 
coefficients, absorption and emission spectra to Cy5** were coupled with the BLM 
monosaccharide and tested for binding/uptake in the cancer cells. BLM monosaccharide–
Cy5 (2.18) and BLM monosaccharide–Cy5GE (2.21) conjugates (Figure 2.13) showed 
significant intensity of binding/uptake in all of the tested cancer cell lines (Figure 2.25). 
The binding/uptake observed was very low for BLM monosaccharide–sulphoCy5 (2.17), 
BLM monosaccharide–Cy7 (2.19) and BLM monosaccharide–Cy5.5GE (2.22) in all of the 
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tested cancer cell lines. However, the binding/uptake of the BLM monosaccharide–
AF647 (2.20) was high in A549 lung cancer cells and A498 kidney cancer cells, but the 
uptake was non evenly distributed throughout the cells. Hence, Cy5 and Cy5GE were 
selected as promising candidates for the future experiments. 
 
 
Figure 2.25. Comparison of the Binding/Uptake of BLM Monosaccharide–dye 
Conjugates 2.17–2.22 in Three Cancer Cell Lines. (The cells were treated with 25 µM 
BLM monosaccharide–dye conjugates 2.17–2.22 at 37 °C for 1 h, washed with phosphate 
buffered saline (PBS), and fixed with 4% paraformaldehyde. The cell nuclei were stained 
with diamidino-2-phenylindole (DAPI). Fluorescence imaging was carried out with a 3 s 
exposure time. The experiment was carried out by Justin Kaye). 
 
Due to significantly higher uptake of the BLM monosaccharide–Cy5 conjugate 
2.18 observed in comparison to the other conjugates, the cell binding/uptake of BLM 
monosaccharide–Cy5 conjugate (2.18) and free dye Cy5, used as a control, were studied 
in A549 lung cancer cells, A498 kidney cancer cells and DU-145 prostate cancer cells. 
The free dye Cy5 showed significant background binding/uptake in all of the cell lines 
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(Figure 2.26). The uptake of Cy5 dye was almost half that of the binding of BLM 
monosaccharide–Cy5 conjugate (2.18) in DU-145 prostate cancer cells and was 
permeable to the cell membrane on its own to some extent.  
 
 
Figure 2.26. Comparison of the Binding/Uptake of BLM Monosaccharide–Cy5 (2.18) 
and the Free Dye Cy5 in A549 Lung Cancer Cells, A498 Kidney Cancer Cells and DU-
145 Prostate Cells. (The cells were treated with 25 µM BLM monosaccharide–Cy5 (2.18) 
or Cy5 dye at 37 °C for 1 h, washed with phosphate buffered saline (PBS), and fixed with 
4% paraformaldehyde. The cell nuclei were stained with diamidino-2-phenylindole 
(DAPI). Fluorescence imaging was carried out with a 3 s exposure time. The experiment 
was carried out by Justin Kaye). 
 
As the free dye Cy5 was significantly permeable to the cell membrane on its own, 
which likely reflected the absence of any polar negatively charged sulfonate group, 
Cy5GE was next chosen. The cell binding/uptake of BLM monosaccharide–Cy5GE (2.21) 
(Figure 2.13) was compared to BLM disaccharide–Cy5GE (2.25)115 (Figure 2.14) in A549 
lung cancer cells and BxPC-3 prostate cancer cells and their matched normal cells. BLM 
monosaccharide–Cy5GE (2.21) and BLM disaccharide–Cy5GE (2.25) underwent 
significant binding and uptake in both cancer cell lines (Figure 2.27). There was no 
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binding/uptake observed for the matched normal controls cells. The binding/uptake of the 
BLM monosaccharide–Cy5GE (2.21) was much (~2-fold) greater in A498 kidney cancer 
cells and lower than BLM disaccharide–Cy5GE (2.25) conjugate in case of DU-145 
prostate cancer cells which was consistent with the results obtained in case of the Cy5** 
conjugates of BLM monosaccharide (2.8) (Figure 2.11) and BLM disaccharide (2.3) 
(Figure 2.10). 
  
 
Figure 2.27. Comparison of the Binding/Uptake of BLM Monosaccharide–Cy5GE (2.21) 
and BLM Disaccharide–Cy5GE (2.25) Conjugates in A498 Kidney Cancer Cells and 
BxPC-3 Pancreatic Cancer Cells and Their Matched Normal Cells. (The cells were 
treated with 25 µM BLM monosaccharide–Cy5GE (2.21) or BLM disaccharide–Cy5GE 
(2.25) at 37 °C for 1 h, washed with phosphate buffered saline (PBS), and fixed with 4% 
paraformaldehyde. The cell nuclei were stained with diamidino-2-phenylindole (DAPI). 
Fluorescence imaging was carried out with a 3 s exposure time. The experiment was 
carried out by Justin Kaye). 
 
To further confirm the impermeable nature of the Cy5GE conjugates to the cell 
membrane on its own, the decarbamoyl BLM monosaccharide–Cy5GE (2.27) conjugate 
(Figure 2.14) was used to three cancer cell lines and was compared with BLM 
monosaccharide–Cy5GE (2.21) and BLM disaccharide–Cy5GE (2.25). None of the three 
cell lines showed any binding/uptake in case of decarbamoyl BLM monosaccharide–
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Cy5GE (2.27), while both BLM monosaccharide–Cy5GE (2.21) and BLM disaccharide–
Cy5GE (2.25) conjugates showed significant binding/uptake in all tested cancer cell lines 
(Figure 2.28). These results are consistent with the results obtained in case of the 
respective Cy5** conjugates of BLM monosaccharide (2.8), BLM disaccharide (2.3) and 
decarbamoyl BLM disaccharide (2.9).  
 
 
Figure 2.28. Comparison of the Binding/Uptake of BLM Monosaccharide–Cy5GE (2.21), 
BLM Disaccharide–Cy5GE (2.25) and Decarbamoyl BLM Disaccharide–Cy5GE (2.27) 
Conjugates in A498 Kidney Cancer Cells, DU-145 Prostate Cancer Cells and A549 Lung 
Cells. (The cells were treated with 25 µM BLM monosaccharide–Cy5GE (2.21) or BLM 
disaccharide–Cy5GE (2.25) or decarbamoyl BLM disaccharide–Cy5GE (2.27) at 37 °C for 
1 h, washed with phosphate buffered saline (PBS), and fixed with 4% paraformaldehyde. 
The cell nuclei were stained with diamidino-2-phenylindole (DAPI).  Fluorescence 
imaging was carried out with a 3 s exposure time. The experiment was carried out by 
Justin Kaye). 
 
To better define the possible modular nature of bleomycin as an antitumor agent, 
derivatives of deglycoBLM in which the BLM disaccharide is attached to the C-terminal 
substituent (2.29)118 (Figure 2.15) or to the threonine moiety of deglycoBLM (2.32)119 
were prepared (Figure 2.16). The cytotoxicity of the BLM analogues was determined by 
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use of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as a vital 
dye in DU-145 prostate cancer cells. It was clear from the assay that BLM A5 was the 
most potent of the derivatives, whereas BLM analogue 2.29, containing the BLM 
disaccharide attached to the C-terminal substituent, was less cytotoxic than BLM A5 but 
significantly more cytotoxic than deglycoBLM or BLM analogue 2.32, containing the 
BLM disaccharide attached to the threonine moiety (Figure 2.29). DeglycoBLM A5, 
lacking the tumor-targeting disaccharide, was cytotoxic to DU-145 cells but much less 
than BLM A5 or BLM analogue 2.32.  
 
Figure 2.29. Dose-dependent Effects of Modified BLM Analogues 2.29, 2.31 and 2.32 
on the Viability of Cultured DU-145 Prostate Cancer Cells. (The experiment was carried 
out by Imran Ghare). 
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To provide additional evidence in support of the basis for expression of 
cytotoxicity by glycosylated deglycoBLMs, the cytotoxic derivatives 2.29 and 2.32 were 
conjugated to the cyanine dye Cy5**. The modified BLM–Cy5** conjugates 2.30 
(Figure 2.15) and 2.34 (Figure 2.16) were studied in DU-145 prostate cancer cells and 
PZ-HPV-7 normal prostate cells. It was clear from the quantification data that BLM–
Cy5** conjugate (2.2a) was internalized most efficiently in DU-145 prostate cancer cells, 
while uptake of deglycoBLM–Cy5** (2.2b) was the least efficient (Figure 2.30). The 
modified BLM–Cy5** conjugate 2.30 was internalized more efficiently than the 
modified BLM–Cy5** conjugate 2.34 but less efficiently than that of BLM–Cy5** 
(2.2a). None of the conjugates showed any binding/uptake in PZ-HPV-7 normal prostate 
cells. Thus, the rank order of uptake of these conjugates was precisely the same as the 
rank order of observed cytotoxicities toward DU-145 prostate cancer cells. 
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Figure 2.30. Comparison of the Binding/Uptake of BLM–Cy5** (2.2a), DeglycoBLM–
Cy5** (2.2b), and Modified BLM–Cy5** Conjugates 2.30 and 2.34 in DU-145 Prostate 
Cancer Cells and PZ-HPV-7 Normal Prostate Cells. (The cells were treated with 25 µM 
Cy5** conjugates (2.2a, 2.2b, 2.30 and 2.34) at 37 °C for 1 h, washed with phosphate 
buffered saline (PBS), and fixed with 4% paraformaldehyde. The cell nuclei were stained 
with diamidino-2-phenylindole (DAPI). Fluorescence imaging was carried out after a 3 s 
exposure. The experiment was carried out by Dr. Zhiqiang Yu). 
 
2.2.3. Synthesis of Fluorinated Saccharides 
To extend the application of tumor targeting by BLM saccharides, the fluorinated 
disaccharides were synthesized as references for the preparation of the radiolabeled 18F-
saccharide PET biomarkers for tumor diagnostic studies. The synthesis of fluorinated 
BLM disaccharide started with the coupling of activated disaccharide phosphate ester 
2.56 with the commercially available linker 2.133 to afford BLM disaccharide–linker 
2.134 in 68% yield (Scheme 2.21). Debenzylation of disaccharide 2.134 gave the free 
alcohol, the latter of which was fluorinated with XtalFluor-E134 to give fluorinated 
disaccharide 2.135 in 54% yield over two steps. Complete deacetylation with sodium 
methoxide in methanol afforded fluorinated BLM disaccharide 2.35 in quantitative yield. 
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Scheme 2.21. Synthesis of Fluorinated BLM Disaccharide 2.35. 
 
Similarly, the fluorinated decarbamoyl BLM disaccharide was synthesized by 
coupling phosphate ester 2.120 with the commercially available linker 2.133 to afford 
decarbamoyl BLM disaccharide–linker 2.136 in 69% yield (Scheme 2.22). Debenzylation 
of disaccharide 2.136 followed by fluorination with XtalFluor-E134 afforded fluorinated 
disaccharide 2.137 in 38% yield over two steps. Complete deacetylation with sodium 
methoxide in methanol afforded fluorinated decarbamoyl BLM disaccharide 2.36 in 90% 
yield. 
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Scheme 2.22. Synthesis of Fluorinated Decarbamoyl BLM Disaccharide 2.36. 
 
2.3. Discussion 
The present study was designed to investigate the contributions of the 
carbohydrate moiety of bleomycin to the cytotoxic and DNA cleaving actions of this 
clinically utilized antitumor antibiotic. DeglycoBLM, the analogue of bleomycin lacking 
the carbohydrate moiety, has been fairly extensively exploited and demonstrated to 
cleave duplex DNA using the same chemistry as BLM and with analogous sequence 
selectivity.12,107,108 However, the supercoiled DNA relaxation efficiency of deglycoBLM 
is (2–3-fold) less than for BLM, and much less double-strand cleavage is relevantly 
observed for deglycoBLM.107,108,135-139 Two studies in which the disaccharide moiety of 
BLM was replaced with a single sugar resulted in BLM analogues with diminished 
potency of DNA cleavage140,141 as well as a lesser ability to cleave RNA.141 Thus, the 
disaccharide moiety attached to BLM via β-hydroxyhistidine significantly potentiates 
DNA cleavage. 
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It was initially uncertain whether the diminished cytotoxic potential of 
deglycoBLM107,108,135-139 was due to diminished potency of DNA cleavage, lack of 
significant double-strand cleavage, or lack of tumor cell targeting and uptake. The recent 
study from our laboratory documenting tumor targeting and uptake by the disaccharide 
moiety itself18 highlights the ambiguity intrinsic to defining the role(s) of the BLM 
disaccharide. In order to gain insights into possible roles of the disaccharide, a library of 
disaccharide–Cy5** conjugates was synthesized. 
The synthesis of different disaccharide–dye conjugates started with the coupling 
of the gulose glycosyl acceptor with the corresponding mannose donor. The gulose 
glycosyl acceptor was obtained from L-xylose following Dondoni’s method (Scheme 
2.1).124 At first, L-xylose (2.37) was fully protected as dithioacetal 2.38, the latter of 
which was selectively converted into aldehyde 2.39 in presence of Hg(II). Due to the 
unstable nature of aldehyde 2.39, it was immediately coupled with 2-
(trimethylsilyl)thiazole (2.40)125 and desilylated to afford alcohol 2.41. The protection of 
the free hydroxyl group as benzyl ether 2.42 and subsequent cleavage of the thiazole ring 
to provide a formyl group gave aldehyde 2.43. Acetal deprotection followed by 
peracetylation of aldehyde 2.43 gave pyranoside 2.44, the latter of which was 
debenzylated to give gulose acceptor 2.45. 
The synthesis of mannose donor 2.54 was achieved following reported procedures 
with slight modifications (Scheme 2.2).21 The synthesis began with protection of 
commercially available α-D-methylmannopyranoside (2.46) as its benzylidene acetal 
2.47 followed by selective benzylation at C-3 position using Bu2SnO to give alcohol 
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2.48. Acetal deprotection of alcohol 2.48 followed by exhaustive acetylation gave 
peracetylated mannose 2.49, the latter of which was debenzylated using Pd(OH)2/C 
(Pearlman’s catalyst) to yield C-3 alcohol 2.50. Activation of the alcohol as its p-
nitrophenyl carbonate (2.51) followed by aminolysis with ammonia gave carbamate 2.52. 
Selective deacetylation at the anomeric position of carbamate 2.52 with hydrazine acetate 
afforded alcohol 2.53. Subsequent activation of alcohol 2.53 as a diphenyl phosphate 
ester in the presence of DMAP and dry triethylamine gave the activated mannose 
phosphate 2.54,126 the latter of which was then coupled with gulose acceptor 2.45 in the 
presence of TMSOTf to afford peracetylated BLM disaccharide 2.55 (Scheme 2.3).21 
Selective deacetylation at anomeric position of disaccharide 2.55 with hydrazine acetate, 
followed by activation as a diphenyl phosphate ester in presence of DMAP and dry 
triethylamine, gave activated ester 2.56. Activated phosphate ester 2.56 was then 
conjugated with the benzyloxycarbonyl (CBz) protected commercially available linker 
derivative 2.57 to afford BLM disaccharide–linker 2.58. Complete deacetylation of the 
acetates followed by debenzylation afforded primary amine 2.59, the latter of which was 
conjugated with the NHS ester of Cy5** (2.60)127 to provide the BLM 
disaccharide−Cy5** conjugate (2.3).18 
During the synthesis of C-2 carbamoylmannose modified disaccharide–Cy5**, a 
similar coupling strategy of activated C-2 carbamoylmannose with gulose acceptor 2.45 
was tried. Several attempts were made to isolate the coupled C-2 disaccharide but each 
time a cyclic carbamate by-product was formed due to attack of the C-2 carbamoyl amine 
on the activated C-1 carbon. Finally, a new strategy was developed, involving the 
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introduction of the carbamoyl group later in synthesis after formation of the disaccharide. 
The synthesis of C-2 modified mannose donor 2.64 began with protection of α-D-
methylmannopyranoside (2.46) as dibenzylidene acetal 2.61 in two isomeric forms, exo 
and endo, the latter of which were easily separable by crystallization (Scheme 2.4).128 
Selective reduction of the acetal at the C-2 and C-3 positions of both the isomers of 2.61 
with DIBAL-H in the presence of aluminium chloride afforded the C-3 alcohol 2.62,129 
the latter of which was acetylated in presence of concentrated H2SO4 to gave 
peracetylated mannose 2.63. The selective cleavage of anomeric acetate of 2.63 with 
hydrazine acetate followed by activation as a diphenyl phosphate ester in presence of 
DMAP and dry triethylamine gave the activated mannose phosphate 2.64. Coupling of 
activated mannose donor 2.64 with gulose acceptor 2.45 in the presence of TMSOTf 
afforded disaccharide 2.65 (Scheme 2.5). The latter was debenzylated using Pd(OH)2/C 
(Pearlman’s catalyst) to give alcohol 2.66. C-2 alcohol 2.66 was then activated as the p-
nitrophenyl carbonate (2.67) and subjected to aminolysis with ammonia to give 
carbamate 2.68. The selective removal of the anomeric acetate of disaccharide 2.68, 
followed by activation as a diphenyl phosphate ester in presence of DMAP and dry 
triethylamine, gave activated ester 2.69. Compound 2.69 was coupled to 
benzyloxycarbonyl (CBz) protected linker 2.5718 to afford BLM disaccharide–linker 2.70. 
Complete deacetylation of the acetates followed by debenzylation gave primary amine 
2.71, the latter of which was treated with the NHS ester of Cy5** (2.60)127 to provide the 
modified disaccharide–Cy5** conjugate 2.4. 
The synthesis of C-4 carbamoylmannose modified disaccharide–Cy5** was 
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achieved using the same strategy as for the natural disaccharide. The synthesis started 
with regioselective reductive ring opening of acetal 2.47 in presence of CoCl2 and 
BH3•THF to afford alcohol 2.72 (Scheme 2.6).130 Exhaustive acetylation of alcohol 2.72 
in acidic medium gave peracetylated mannose 2.73, the latter of which was debenzylated 
using Pd(OH)2/C (Pearlman’s catalyst) to give the alcohol 2.74. C-4 alcohol 2.74 was 
then activated as the p-nitrophenyl carbonate (2.75) and subjected to aminolysis with 
ammonia to form the carbamate 2.76. Selective deprotection of the anomeric acetate with 
hydrazine acetate followed by activation as a diphenyl phosphate ester in presence of 
DMAP and dry triethylamine gave the activated mannose phosphate 2.78. This activated 
mannose donor was then coupled with gulose acceptor 2.45 in the presence of TMSOTf 
to afford disaccharide 2.79 (Scheme 2.7). Selective removal of the anomeric acetate of 
disaccharide 2.79, followed by activation as a diphenyl phosphate ester, afforded glycosyl 
donor 2.80, the latter of which was coupled to the benzyloxycarbonyl (CBz) protected 
linker 2.5718 to afford disaccharide–linker 2.81. Complete deacetylation of the acetates 
followed by debenzylation gave primary amine 2.82, the latter of which was subsequently 
conjugated with the N-hydroxysuccinimide (NHS) ester of Cy5** (2.60)127 to afford the 
modified disaccharide–Cy5** conjugate 2.5. 
In order to find the simplest structural entity capable of mediating tumor cell 
targeting, the BLM monosaccharide–Cy5** (2.8) was synthesized. Mannose glycosyl 
donor 2.54 was coupled to the benzyloxycarbonyl (CBz) protected linker 2.5718 to afford 
BLM monosaccharide–linker 2.83 (Scheme 2.8). Complete deacetylation of the acetates 
followed by debenzylation of primary amine of 2.83 gave amine 2.84, the latter of which 
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was treated with the NHS ester of Cy5** (2.60)127 to generate the BLM monosaccharide–
Cy5** conjugate (2.8).  
To confirm the necessity of the carbamoyl moiety for selective tumor cell 
targeting, the decarbamoyl BLM monosaccharide–Cy5** (2.9) lacking the carbamoyl 
group at C-3 of the mannose residue was also synthesized. Exhaustive acetylation of α-D-
methylmannopyranoside (2.46) gave peracetylated mannose 2.85131 (Scheme 2.9), the 
latter of which was converted into activated mannosyl phosphate 2.86 by selective 
removal of anomeric acetate and subsequent activation as a diphenyl phosphate ester in 
presence of DMAP and dry triethylamine.132 This mannose glycosyl donor 2.86 was 
coupled with the benzyloxycarbonyl (CBz) protected linker 2.5718 to afford decarbamoyl 
BLM monosaccharide–linker 2.87. Complete deacetylation of the acetates followed by 
debenzylation of the primary amine of 2.87 gave amine 2.88, the latter of which was 
conjugated to the NHS ester of Cy5** (2.60)127 to afford decarbamoyl BLM 
monosaccharide–Cy5** conjugate (2.9).  
To study the nature of the cell receptor–saccharide interaction, the fluorescently 
labeled trimeric carbohydrate cluster 2.10 was prepared. The synthesis commenced with 
debenzylation of the primary amine of 2.83 to give amine 2.89. Coupling of amine 2.89 
with the NHS ester of protected trimer–linker 2.90118 was very challenging. Several 
attempts were made to isolate the trimeric sugar cluster but very low yields were 
obtained. Finally, the reaction was optimized using three equivalents of amine 2.89 
relative to NHS ester of protected trimer–linker 2.90 affording BLM monosaccharide 
trimer linker 2.91 in better yield (Scheme 2.10). Complete deacetylation followed by 
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debenzylation of the primary amine in 2.91 gave trimer cluster linker amine 2.92. 
Coupling of trimer linker amine 2.92 with the NHS ester of Cy5** (2.60)127 provided the 
BLM monosaccharide–Cy5** trimer conjugate (2.10). 
In order to further explore the possible roles of the carbamoyl moiety of BLM in 
tumor cell targeting and modify the properties of the carbamoylmannose moiety, a library 
of monosaccharide–Cy5** conjugates was synthesized. The synthesis of the C-2 
modified monosaccharide conjugates started with the coupling of mannose donor 2.64 
with the phthalimide protected linker 2.93133 to afford monosaccharide–linker 2.94 
(Scheme 2.11). Debenzylation using Pd(OH)2/C (Pearlman’s catalyst) yielded the alcohol 
2.95, the latter of which was then activated as the p-nitrophenyl carbonate (2.96). 
Carbonate 2.96 was subjected to aminolysis with methylamine, dimethylamine, 
butylamine, pyrrolidine and hexylamine to afford C-2 methylcarbamate 2.97, C-2 
dimethylcarbamate 2.98, C-2 butylcarbamate 2.99, C-2 pyrrolidinylcarbamate 2.100 and 
C-2 hexylcarbamate 2.101, respectively. Complete deacetylation of the acetates followed 
by deprotection of the phthalimide group using hydrazine hydrate afforded amine–linkers 
2.102, 2.103, 2.104, 2.105 and 2.106, respectively, the latter of which were conjugated to 
the NHS ester of Cy5** (2.60)127 to give modified monosaccharide–Cy5** conjugates 
2.11-2.15, respectively. 
The synthesis of the C-3 modified monosaccharide conjugate 2.16 started with the 
selective deacetylation of the anomeric acetate of mannose 2.49 followed by activation as 
a diphenyl phosphate ester in presence of DMAP and dry triethylamine, giving the 
activated mannose phosphate 2.107 (Scheme 2.12). Mannose donor 2.107 was then 
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coupled to the phthalimide protected linker 2.93133 to afford monosaccharide–linker 
2.108. Debenzylation of 2.108 using Pd(OH)2/C (Pearlman’s catalyst) yielded alcohol 
2.109, the latter of which was then activated as the p-nitrophenyl carbonate (2.110). 
Aminolysis with methylamine then afforded C-2 methylcarbamate 2.111. Complete 
deacetylation followed by deprotection of the phthalimide group using hydrazine hydrate 
afforded amine–linker 2.112, the latter of which was conjugated with the NHS ester of 
Cy5** (2.60)127 to give modified monosaccharide–Cy5** conjugate 2.16. 
In order to find a new dye with properties similar to Cy5**, several dyes were 
coupled to the free amine of BLM monosaccharide–linker 2.84 (Scheme 2.13). 
Conjugation of the primary amine in 2.84 to the NHS ester of sulphoCy5 (2.113), the 
NHS ester of Cy5 (2.114), the NHS ester of Cy7 (2.115), the NHS ester of Alexa Fluor 
647 (2.116), the NHS ester of Cy5GE (2.117) and the NHS ester of Cy5.5GE (2.118) gave 
BLM monosaccharide–sulphoCy5 conjugate (2.17), BLM monosaccharide–Cy5 
conjugate (2.18), BLM monosaccharide–Cy7 conjugate (2.19), BLM monosaccharide–
Alexa Fluor 647 conjugate (2.20), BLM monosaccharide–Cy5GE conjugate (2.21) and 
BLM monosaccharide–Cy5.5GE conjugate (2.22), respectively. Later, additional 
conjugates of the selected dyes (Cy5 and Cy5GE) were also synthesized. The primary 
amine of decarbamoyl BLM monosaccharide–linker 2.88 was also coupled with the NHS 
ester of Cy5 (2.114) to give decarbamoyl BLM monosaccharide–Cy5 conjugate (2.23) 
(Scheme 2.14). Similarly, the primary amine of BLM disaccharide–linker 2.59 was 
coupled with the NHS ester of Cy5 (2.114) and the NHS ester of Cy5GE (2.117) to give 
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BLM disaccharide–Cy5 conjugate (2.24) and BLM disaccharide–Cy5GE conjugate (2.25), 
115 respectively (Scheme 2.15).  
In order to obtain controls lacking uptake in any of the cancer cells, decarbamoyl 
BLM disaccharide conjugates were synthesized.130 Activated mannosyl donor 2.86 was 
coupled with gulose acceptor 2.45 in the presence of TMSOTf to afford peracetylated 
disaccharide 2.119 (Scheme 2.16).115 Selective deacetylation of the anomeric acetate of 
disaccharide 2.119 with hydrazine acetate afforded the corresponding alcohol, the latter 
of which was activated as a diphenyl phosphate ester 2.120 in presence of DMAP and dry 
triethylamine. Activated glycosyl phosphate 2.120 was then coupled with the 
benzyloxycarbonyl (CBz) protected linker 2.5718 to afford protected decarbamoyl BLM 
disaccharide–linker 2.121.118 Complete deacetylation followed by debenzylation of the 
primary amine of 2.121 gave amine 2.122, the latter of which was coupled with the NHS 
ester of Cy5 (2.114) and the NHS ester of Cy5GE (2.117) to give decarbamoyl BLM 
disaccharide–Cy5 conjugate (2.26) and decarbamoyl BLM disaccharide–Cy5GE conjugate 
(2.27), respectively. The primary amine of Cu•BLM A5 (2.123) was coupled with the 
NHS ester of Cy5GE (2.117) to give Cu•BLM–Cy5GE conjugate 2.124 (Scheme 2.17). 
This intermediate was demetallated using 15% EDTA to afford BLM–Cy5GE (2.28).115 
To test the hypothesis that BLM may be modular in nature, composed of a 
carbohydrate moiety responsible for tumor targeting and an aglycone that mediates DNA 
strand scission, different BLM analogues 2.29,118 2.31 and 2.32 were prepared containing 
BLM disaccharide at altered positions.119 The BLM analogues 2.31 and 2.32 were 
synthesized by Dr. Benjamin R. Schroeder.119 The C-terminal disaccharide substituted 
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bleomycin 2.29 was prepared following previously reported procedures (Scheme 2.18).118 
The synthesis began with the selective deacetylation of the anomeric acetate of 
disaccharide 2.55 using hydrazine acetate, followed by activation as the p-nitrophenyl 
carbonate (2.125). Carbonate 2.125 was then coupled with Cu(II)•deglycoBLMA5 
(2.123) and was deprotected by the use of hydrazine to afford C-terminal modified 
Cu(II)•BLM 2.126,118 the latter of which was then subjected to demetallation with 15% 
EDTA to afford modified BLM 2.29. The synthesis of the dye labeled analogue of C-
terminal disaccharide substituted bleomycin 2.30 started with the coupling of the 
activated NHS ester of acid 2.127 with Cu(II)•deglycoBLMA5 (2.123) to afford modified 
linker BLM 2.128 (Scheme 2.19). The Fmoc group of linker BLM 2.128 was removed 
using 20% piperidine in DMF, followed by coupling with activated carbonate 2.125 to 
provide modified linker BLM–disaccharide 2.129. The butyloxycarbonyl group of 
disaccharide 2.129 was removed using TFA and then coupled with the NHS ester of 
Cy5** (2.60)127 to give conjugate 2.130. Demetallation of conjugate 2.130 with 15% 
EDTA afforded modified BLM–Cy5** 2.30. The synthesis of dye labeled analogues of 
modified BLMs 2.31119 and 2.32119 started with metallation with CuCl2 followed by 
coupling with the NHS ester of Cy5** (2.60),127 which afforded conjugates 2.131 and 
2.132 (Scheme 2.20). Successive demetallation of 2.131 and 2.132 using 15% EDTA 
afforded modified BLM–Cy5** conjugates 2.33 and 2.34, respectively. 
The cell binding/uptake of the various dye–conjugates was analyzed using a Zeiss 
Axiovert 200M inverted microscope, having a 40× oil objective. The binding/cellular 
uptake of BLM disaccharide–Cy5** conjugate (2.3), and disaccharide–Cy5** conjugates 
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2.4–2.7 (Figure 2.10) in four cancer cell lines were quantified by fluorescence imaging. It 
was observed that disaccharide conjugate 2.6 having an N-carbamoyl group at the C-2 
position of D-mannose exhibited the best binding/uptake profile in all four cancer cell 
lines studied (Figure 2.19). The binding/uptake of disaccharide conjugate 2.4 having an 
unmodified carbamoyl group at the C-2 position of D-mannose was found to be 
comparable to the binding/uptake of natural disaccharide conjugate 2.3 in all of the 
cancer cell lines studied (Figure 2.19), but disaccharide conjugate 2.7 having an N-
carbamoyl group at the C-3 position of D-mannose showed significant binding in A498 
kidney cancer cells and BxPC-3 pancreatic cancer cells and rather poor binding in A549 
lung cancer cells and DU-145 prostate cancer cells. The binding/uptake of disaccharide 
conjugate 2.5 having an unmodified carbamoyl group at the C-4 position of D-mannose 
gave very poor results. It is obvious from the results that the position and orientation of 
the carbamoyl group in the BLM disaccharide is crucial for cell targeting. In common 
with the results of earlier studies,18 little dye was observed to be associated with the cell 
surface of any of the tumor cell lines studied. The lack of cell surface fluorescence is 
consistent with the interpretation that internalization/uptake of the disaccharide–dye 
conjugate is rapid relative to cell surface binding. This interpretation is supported by the 
observation that microbubbles whose surface had been derivatized covalently with 
multiple BLM or BLM disaccharide molecules bound selectively to cultured cancer cells 
but could not be internalized due to their large sizes. Hence, only cell surface binding 
with no uptake was observed in case of the microbubbles derivatized BLM or BLM 
disaccharide.18 
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The cell binding/uptake of BLM monosaccharide–Cy5** (2.8) (Figure 2.11) was 
compared to the BLM disaccharide–Cy5** (2.3) conjugate (Figure 2.10). The 
binding/uptake of BLM monosaccharide–Cy5** (2.8) was much (~2-fold) greater in 
A549 lung cancer cells, A498 kidney cancer cells and MCF-7 breast carcinoma cells, 
essentially identical for BT-474 breast ductal carcinoma cells and BxPC-3 pancreas cells 
and much lower in DU-145 prostate cancer cells (Figure 2.20).  The cell binding/uptake 
of decarbamoyl BLM monosaccharide−Cy5** conjugate (2.9) revealed that there was no 
uptake in any of the four cell lines tested. This confirmed that the carbamoyl group is 
indispensible for cell surface receptor interaction, and for facilitating selective cell uptake 
in tumor cells (Figure 2.21).   
The cellular targeting and uptake of the Cy5** conjugate containing a cluster of 
three carbamoylmannose molecules (2.10) (Figure 2.11) indicated that the binding/uptake 
of the BLM monosaccharide–Cy5** trimer (2.10) was (1.6–2.3-fold) greater than that of 
the BLM monosaccharide–Cy5** conjugate (2.8) in each of six cancer cell lines tested 
(Figure 2.22), suggesting the involvement of a multivalent cell surface carbohydrate 
receptor. As for the BLM disaccharide–Cy5** conjugate (2.3), the BLM 
monosaccharide–Cy5** conjugate (2.8) presumably first binds to a cell surface receptor 
followed by internalization. This model is supported by the results obtained with the 
BLM monosaccharide–Cy5** trimer (2.10), which showed enhanced uptake in each of 
six cell lines. The majority of fluorescence within the cells was found to colocalize with 
DAPI, suggesting that the conjugates were present within the nucleus. The increase in 
binding/uptake observed for the BLM monosaccharide−Cy5** trimer provides evidence 
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of the nature of the receptor, and a tool for further studying and exploiting the tumor 
targeting properties of 3-O-carbamoylmannose. 
The cell binding/uptake study of BLM monosaccharide–Cy5** (2.8) at different 
incubation temperatures (4 and 37 °C) was found to be quite similar (Figure 2.23), 
suggesting that the mechanism of cellular internalization of the BLM 
disaccharide−Cy5** conjugate (2.3), which exhibits temperature-dependent 
binding/uptake, may be different from the mechanism of cellular internalization of BLM 
monosaccharide−Cy5** conjugate (2.8), at least in this regard. 
The cell binding/uptake of BLM monosaccharide–Cy5** conjugate (2.8), and the 
modified monosaccharide–Cy5** conjugates 2.11–2.16 (Figure 2.12) showed that the 
monosaccharide conjugates 2.11 and 2.13 having N-methylated and N-butylated 
carbamoyl groups at the C-2 position of D-mannose exhibited best binding/uptake 
profiles in all six cancer cell lines (Figure 2.24). It was also evident that monosaccharide 
conjugates 2.12 and 2.14 having an N,N-dimethylated and N,N-pyrrolidinylated 
carbamoyl groups at the C-2 position of D-mannose, respectively, exhibitted almost no 
binding/uptake in any of the tumor cell lines tested. This result clearly establishes the 
involvement of steric factors in the cell surface binding interaction and internalization. 
Binding/uptake exhibited by the sterically hindered monosaccharide conjugate 2.15 
having an N-hexylated carbamoyl group at the C-2 position of D-mannose was very low 
in A549 lung cancer cells, DU-145 prostate cancer and MCF-7 breast cancer cells, but 
comparable to BLM monosaccharide–Cy5** (2.8) in the BxPC-3 pancreatic cancer line. 
The monosaccharide conjugate 2.16, having an N-methylated carbamoyl group at the C-3 
 
 
86 
position of D-mannose, exhibited considerably lower uptake than either the BLM 
monosaccharide–Cy5** conjugate (2.8) or monosaccharide conjugates 2.11 having an N-
methylated carbamoyl group at the C-2 position of D-mannose in A549 lung cancer cells 
and MCF-7 breast cancer cells. This was consistent with the results obtained for 
disaccharide conjugates 2.6 and 2.7 (Figure 2.10) having an N-methylated carbamoyl 
group at the C-2 and C-3 positions of D-mannose, respectively. The efficient cellular 
uptake of monosaccharide conjugates 2.11 and 2.13 make them potentially good 
candidates for targeted drug delivery or as in vivo imaging agents. 
Further, to choose an optimal fluorophore in lieu of Cy5**, several dye–
monosaccharide conjugates were tested for binding/uptake in cancer cells. It was found 
that BLM monosaccharide–Cy5 (2.18) and BLM monosaccharide−Cy5GE (2.21) (Figure 
2.13) conjugates showed the highest efficiency of binding and uptake in all the cancer 
cell lines tested (Figure 2.25). In case of the other dye–monosaccharide conjugates, the 
binding/uptake was either very low or not uniformly efficient for all cell lines studied. 
However, the free dye Cy5 itself showed significant background binding/uptake in 
representative cell lines (Figure 2.26). Hence, Cy5GE was chosen as the fluorophore to be 
used in future experiments. Subsequently, the cell binding/uptake of BLM 
monosaccharide–Cy5GE (2.21) (Figure 2.13) was compared to BLM disaccharide–Cy5GE 
(2.25) conjugate (Figure 2.14) in A549 lung cancer cells and BxPC-3 pancreatic cancer 
cell lines and their matched normal cells. The binding/uptake was observed to be 
significantly higher in both cancer cell lines relative to the binding/uptake observed for 
the matched normal controls cells (Figure 2.27). The binding/uptake of the BLM 
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monosaccharide–Cy5GE (2.21) was much (~2-fold) greater in A549 lung cancer cells than 
the disaccharide 2.25 and lower than BLM disaccharide–Cy5GE conjugate (2.25) in DU-
145 prostate cancer cells, consistent with the results obtained in the case of the Cy5** 
conjugates of BLM monosaccharide (2.8) (Figure 2.11) and BLM disaccharide (2.3) 
(Figure 2.10). These findings were further confirmed by the observation that the 
decarbamoyl BLM monosaccharide–Cy5GE conjugate (2.27) failed to show any 
binding/uptake in any of three cancer cell lines (Figure 2.28).  
It was evident from the MTT assay of the modified BLMs in DU-145 prostate 
cancer cells that BLM analogue 2.29118 (Figure 2.15) was less cytotoxic than BLM A5 but 
significantly more cytotoxic than deglycoBLM or BLM analogue 2.32119 (Figure 2.16); 
deglycoBLM A5, lacking the tumor-targeting disaccharide, was the least toxic (Figure 
2.29). To provide additional evidence in support of the basis for expression of 
cytotoxicity by glycosylated deglycoBLMs, the modified BLM–Cy5** conjugates 2.30 
and 2.34 were studied in four cancer cell lines. The result from the quantification data 
showed that the binding/uptake of modified BLM–Cy5** conjugate 2.30 (Figure 2.15) 
was higher than both deglycoBLM–Cy5** (2.2b) and the modified BLM–Cy5** 
conjugate 2.34 (Figure 2.16), but lower than that of BLM–Cy5** (2.2a) (Figure 2.30).   
Hence, the effect of inserting the BLM disaccharide to different positions of 
deglycoBLM was investigated. Attachment of BLM disaccharide to the β-
hydroxyhistidine moiety, as in the natural product, significantly amplified cytotoxicity 
toward cultured DU-145 prostate cancer cells (Figure 2.29). The relationship between 
cytotoxicity and BLM sugar-mediated uptake was confirmed by measuring the actual 
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extent of internalization of cytotoxic BLM analogues conjugation to the cyanine dye 
(Figure 2.30). These findings establish that BLM is a modular molecule, comprised of a 
tumor cell targeting moiety (the saccharide) attached to a cytotoxic DNA cleaving 
domain (the BLM aglycone) and further proves that BLM disaccharide plays a key role in 
the targeted cell surface binding followed by internalization of the drug. 
From the viewpoint of drug discovery, the current findings are of great interest. It 
was demonstrated that 3-O-carbamoyl-D-mannose, one of the two sugars present in the 
BLM disaccharide, is sufficient to mediate selective tumor targeting and internalization 
with absolute requirement of the carbamoyl moiety. The development of bleomycin 
analogues containing disaccharide such as 2.6 or monosaccharides such as 2.11 and 2.13 
or trivalent cluster of monosaccharide such as 2.10 in lieu of the normal BLM 
disaccharide 2.3 may show superior antitumor properties to those of BLM itself.  
Additionally, development of multivalent clusters of the disaccharide such as 2.6 or 
monosaccharides such as 2.11 and 2.13 with improved tumor targeting actions would 
provide more efficient delivery of attached cargoes similar to the promising strategy 
developed using antibodies in antibody–drug conjugates.142-144  
Another possibility for the utilization of optimized BLM saccharides might be to 
serve as PET biomarkers for tumor diagnostic studies. For this purpose, fluorinated BLM 
disaccharide was synthesized as a reference standard. The synthesis of fluorinated BLM 
disaccharide started by the coupling of activated disaccharide phosphate ester 2.56 with 
the benzyl protected linker 2.133 to afford BLM disaccharide–linker 2.134. 
Debenzylation of primary amine of 2.134 followed by fluorination with XtalFluor-E134 
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gave fluorinated disaccharide 2.135. Complete deacetylation with sodium methoxide in 
methanol afforded fluorinated BLM disaccharide 2.35. Similarly, the fluorinated 
decarbamoyl BLM disaccharide was synthesized by coupling phosphate ester 2.120 with 
the benzyl protected linker 2.133 to afford decarbamoyl BLM disaccharide–linker 2.136. 
Debenzylation of primary amine of 2.136 followed by fluorination with XtalFluor-E134 
afforded fluorinated disaccharide 2.137, the latter of which was deacetylated with sodium 
methoxide in methanol to afford fluorinated decarbamoyl BLM disaccharide 2.36. These 
analogues were sent to our collaborators for use as authentic standard. 
 
2.4. Experimental Procedures 
Materials. The chemicals used were purchased from Aldrich Chemical Co., Sigma 
Chemical Co. or Combi-Blocks and were used without further purification. Anhydrous 
methanol, DMF, acetonitrile and toluene were used as purchased. Tetrahydrofuran and 
dichloromethane were distilled from sodium/benzophenone and calcium hydride, 
respectively. The cyanine dye, Cy5** was obtained from our collaborator Dr. Michael 
Rishel at General Electric Co. SulphoCy5, Cy5 and Cy7 dyes were purchased from 
Lumiprobe Co., and Alexa Fluor 647 was purchased from Life Technologies Co. The 
cyanine dyes, Cy5GE and Cy5.5GE were purchased from General Electric Co. 
General Experimental Procedures. Reactions were carried out under an argon 
atmosphere in flame-dried glassware.  Flash column chromatography was carried out 
using silica gel (Silicycle R10030B, 60 particle size, 230-400 mesh), applying a low-
pressure stream of nitrogen or dry air.  Analytical thin layer chromatographic separations 
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were carried out on glass plates coated with silica gel (60 particle size F254, Silicycle 
TLG-R10011B-323) and were developed by immersing the plates in a solution of ceric 
ammonium molybdate (CAM) stain followed by heating with a heat gun.  
Instrumentation. HPLC was performed using an Agilent 1100 series instrument. 1H and 
13C NMR spectra were recorded on Varian Inova 400 MHz and 100 MHz, respectively, 
using CDCl3 as solvent and internal standard.  1H NMR and 13C NMR chemical shifts 
were reported relative to a residual CHCl3 at 7.26 ppm and 77.16 ppm, respectively. 
Splitting patterns are designated as s, singlet; br s, broad singlet; d, doublet; dd, doublet 
of doublets; dt, doublet of triplets; m, multiplet; q, quartet and quint, quintet. High 
resolution mass spectrometric data were obtained at the Arizona State University CLAS 
High Resolution Mass Spectrometry Facility or the Michigan State Mass Spectrometry 
Facility. 
 
2,3,4,5-Di-O-isopropylidene-L-xylose Diethyl Dithioacetal (2.38).124 To a vigorously 
stirred suspension of 10.0 g (66.6 mmol) of L-xylose (2.37) in 4.0 mL of conc HCl was 
added 14.8 mL (12.4 g, 200 mmol) of ethanethiol. The reaction mixture was stirred at 
room temperature until the two-layer mixture gave a homogenous solution (usually after 
15-20 min). The reaction was then diluted with 200 mL of acetone and stirred for 5 h, at 
which time the solution was neutralized with saturated aq NH4OH solution and co-
O
CH(SEt)2
O
O
O
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evaporated with six 20-mL portions of toluene to afford a crude residue. The residue was 
purified by flash chromatography on a silica gel column (25 × 8 cm). Elution with 1:1 
hexanes–ethyl acetate gave 2.38 as a colorless syrup: yield 14.5 g (65%); [𝛼]D + 57.2 (c 
1.8, C6H6), lit.145 [𝛼]D + 51.3 (c 1.8, C6H6); silica gel TLC Rf 0.59 (3:1 ethyl acetate–
hexanes); 1H NMR (CDCl3, 400 MHz) δ 1.26-1.28 (m, 6H), 1.37 (s, 3H), 1.42 (2s, 6H), 
1.46 (s, 3H), 2.74 (m, 4H), 3.92 (m, 2H), 4.04 (m, 1H), 4.13 (m, 1H) and 4.32 (m, 2H); 
13C NMR (CDCl3, 100 MHz) δ 14.26, 14.34, 24.9, 25.3, 25.6, 26.1, 27.1, 27.3, 53.0, 65.9, 
75.2, 78.7, 80.1, 109.5 and 110.0.  
 
2,3,4,5-Di-O-isopropylidene-aldehydo-L-xylose (2.39).124 To a stirred solution 
containing 6.37 g (18.9 mmol) of thioacetal 2.38 in 64 mL of acetone diluted with 6.4 mL 
of water was added 9.44 g (43.6 mmol) of yellow mercury(II) oxide and 9.27 g (34.1 
mmol) of mercury(II) chloride. The reaction mixture was stirred at 55 °C for 2 h and then 
allowed to cool to room temperature. The solvent was filtered through a pad of Celite 
545® and concentrated under diminished pressure to afford a crude residue. The residue 
was suspended in three 100-mL portions of dichloromethane and filtered through a pad of 
Celite 545®. The organic layer was washed with 100 mL of 1 M aq KI, dried (MgSO4), 
filtered and then concentrated under diminished pressure to afford the aldehyde 2.39 as 
O
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oil: yield 2.91 g (67%); silica gel TLC Rf 0.24 (1:1 hexanes–ethyl acetate). The aldehyde 
was used for the next reaction immediately.  
 
2-(Trimethylsilyl)thiazole (2.40).125 A 500-mL four-necked round-bottomed flask was 
equipped with two 100-mL pressure-equalizing dropping funnels and a low temperature 
thermometer. The anhydrous apparatus was kept under argon and cooled to −78 ºC. The 
flask was charged with 98 mL of freshly distilled diethyl ether and 33 mL (83.0 mmol) of 
a 2.5 M solution of n-BuLi in hexane. One of the two dropping funnels was charged with 
6.80 mL (12.4 g, 75.0 mmol) of 2-bromothiazole in 25 mL of diethyl ether and the other 
with 9.60 mL (8.26 g, 75.0 mmol) of chlorotrimethylsilane in 25 mL of diethyl ether. 
While the solution in the flask was stirred, 2-bromothiazole was added dropwise at −78 
ºC over a period of 1 h. After 20 min of additional stirring, chlorotrimethylsilane was 
added dropwise at −78 ºC over a period of 30 min and the stirring was continued for 1 h 
at −78 ºC. The resulting mixture was then allowed to warm to room temperature, 
quenched with 100 mL saturated aq NaHCO3 and extracted with three 200-mL portions 
of diethyl ether. The combined organic layer was dried (Na2SO4), filtered, and 
concentrated under diminished pressure (temperature not exceeding 40 °C). The residue 
was distilled from a 100-mL flask at diminished pressure in a Claisen apparatus at 45 °C. 
The pure product 2.40 was isolated as a clear solution: yield 9.91 g (83%); 1H NMR 
Me3Si
N
S
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(CDCl3, 400 MHz) δ 0.39 (s, 12H), 7.50 (d, 1H, J = 3.0 Hz) and 8.09 (d, 1H, J = 2.9 Hz); 
13C NMR (CDCl3, 100 MHz) δ 1.0, 127.3, 145.6 and 174.2.  
 
1,2,3,4-Bis-O-(1-methylethylidene)-5-C-2-thiazolyl-(5S)-D-xylitol (2.41).124 To a 
stirred solution containing 2.91 g (12.6 mmol) of aldehyde 2.39 in 50 mL of anh 
dichloromethane cooled to −42 °C was added 2.60 mL (16.4 mmol) of 2-
(trimethylsilyl)thiazole (2.40) dropwise over a period of 15 min. The solution was stirred 
at 0 °C for 1 h and then concentrated under diminished pressure to afford a crude residue. 
The residue was dissolved in 50 mL of anh THF and treated with 3.99 g (12.6 mmol) of 
n-Bu4NF•3H2O at 20 °C for 30 min and then concentrated under diminished pressure. 
The residue was diluted by the addition of 250 mL of dichloromethane and washed with 
three 50-mL portions of water, dried (Na2SO4), filtered and then concentrated under 
diminished pressure to yield compound 2.41 as a crude residue. Recrystallization of the 
residue from cyclohexane afforded alcohol 2.41 as a colorless solid: yield 2.39 g (60%); [𝛼]D + 18.2 (c 1.1, CHCl3), lit.124 [𝛼]D + 18.5 (c 1.1, CHCl3); silica gel TLC Rf 0.24 (1:1 
hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 1.28 (s, 3H), 1.36 (s, 6H), 1.40 (s, 
3H), 3.67 (t, 1H, J = 6.6 Hz), 3.82 (m, 2H), 4.12 (dd, 1H, J = 7.2 and 3.6 Hz), 4.32 (m, 
1H), 4.56 (br s, 1H), 5.10 (d, 1H, J = 5.5 Hz), 7.30 (d, 1H, J = 3.2 Hz) and 7.71 (d, 1H, J 
O
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= 3.2 Hz); 13C NMR (CDCl3, 100 MHz) δ 25.6, 26.1, 27.07, 27.13, 65.7, 71.7, 75.5, 77.4, 
79.8, 109.5, 110.2, 119.7, 142.1 and 170.9.  
 
1,2,3,4-Bis-O-(1-methylethylidene)-5-O-(phenylmethyl)-5-C-2-thiazolyl-(5S)-D-
xylitol (2.42).124 To a solution containing 2.11 g (6.69 mmol) of alcohol 2.41 in anh DMF 
cooled to 0 °C was added 0.54 g (60% dispersion in oil, 13.4 mmol) of NaH portionwise 
and the reaction mixture was stirred at 0 °C for 30 min. To this solution was added 1.20 
mL (1.73 g, 9.51 mmol) of benzyl bromide and the reaction mixture was stirred at room 
temperature for 30 min. The reaction mixture was quenched by the addition of 1.2 mL of 
methanol, then stirred for 10 min and diluted with 40 mL of distilled water. The aqueous 
layer was extracted with three 100-mL portions of ether. The combined organic layer was 
dried (MgSO4), filtered and concentrated under diminished pressure to afford a crude 
residue, which was purified by flash chromatography on a silica gel column (25 × 4 cm). 
Elution with 6:1 hexanes–ethyl acetate gave ether 2.42 as a colorless solid: yield 1.40 g 
(60%); [𝛼]D −32.2 (c 1.1, CHCl3), lit.124 [𝛼]D −32.3 (c 1.1, CHCl3); silica gel TLC Rf 0.56 
(1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 1.20 (s, 3H), 1.25 (s, 3H), 
1.29 (s, 3H), 1.33(s, 3H), 3.65 (m, 1H), 3.78 (m, 1H), 3.91 (m, 1H), 3.98 (m, 1H), 4.35 
(dd, 1H, J = 7.3 and 2.5 Hz), 4.44 (d, 1H, J = 12.1 Hz), 4.63 (d, 1H, J = 12.1 Hz), 4.80 (d, 
1H, J = 4.8 Hz), 7.21-7.28 (m, 5H), 7.32 (d, 1H, J = 3.2 Hz) and 7.78 (d, 1H, J = 3.2 Hz); 
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13C NMR (CDCl3, 100 MHz) δ 14.0, 25.5, 26.03, 26.05, 26.7, 27.0, 65.5, 72.2, 75.5, 77.7, 
78.5, 79.4, 109.4, 110.3, 120.1, 127.9, 128.1, 128.3, 136.8, 142.4 and 168.9.  
 
2-O-Benzyl-3,4,5,6-di-O-isopropylidene-aldehydo-L-gulose (2.43). 124 A solution 
containing 4.18 g (10.3 mmol) of O-benzyl ether 2.42 and 20.0 g of activated 4Å 
molecular sieves dissolved in 100 mL of anh acetonitrile was stirred at 20 °C for 10 min 
and then 1.52 mL (2.20 g, 13.4 mmol) of methyl triflate was added dropwise. The 
suspension was stirred at room temperature for 15 min and then concentrated under 
diminished pressure to afford the crude N-methylthiazolium salt. To a stirred solution of 
the crude N-methylthiazolium salt in 100 mL of anh methanol cooled to 0 °C was added 
0.86 g (22.7 mmol) of sodium borohydride. The reaction mixture was stirred at room 
temperature for 5 min and diluted with 10 mL of acetone. The solvent was filtered 
through a pad of Celite 545® and concentrated under diminished pressure to afford a 
crude mixture of thiazolidines. The residue was dissolved in 88 mL of acetonitrile and 8 
mL of water and treated with 6.56 g (82.5 mmol) of CuO and 1.76 g (10.3 mmol) of 
CuCl2•2H2O under vigorous stirring. The reaction mixture was stirred at 20 °C for 15 
min, filtered through a pad of Celite 545® and then concentrated under diminished 
pressure to remove acetonitrile and most of the water (bath temperature not exceeding 40 
°C) to afford a crude residue. The brown residue was triturated with four 100-mL 
portions of ether and the liquid phase was pipetted and filtered through a pad of Florisil® 
O
O
O
O
CHO
OBn
 
 
96 
(60−100 mesh) to afford a colorless solution. After a further washing of Florisil® with 
100 mL of ethyl acetate, the combined organic layer was concentrated under diminished 
pressure to yield the aldehyde 2.43 as a brown syrup; yield 3.40 g (94%); silica gel TLC 
Rf 0.47 (2:1 hexanes–ethyl acetate). The aldehyde was used for the next reaction 
immediately.  
 
1,3,4,6-Tetra-O-acetyl-2-O-benzyl-L-gulopyranose (2.44).124 To 3.40 g (9.70 mmol) of 
aldehyde 2.43 was added 67.4 mL of 4:1 acetic acid-water and stirred at 100 °C for 40 
min. The reaction was cooled and co-evaporation with three 20-mL portions of toluene to 
afford the crude 2-O-benzyl-L-gulose as a mixture of β-pyranose, α-pyranose, and 
furanose forms. To the solution of crude residue in 25 mL of dry pyridine were added 
1.18 g (4.02 mmol) of DMAP and 25 mL of acetic anhydride. The reaction was stirred 
overnight at room temperature. The mixture was concentrated under diminished pressure 
and purified by flash chromatography on a silica gel column (30 × 4 cm). Elution with 
3:1 hexanes–ethyl acetate afforded benzyl ether 2.44 as a yellow oil: yield 2.54 g (60%); 
silica gel TLC Rf 0.44 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.01 (s, 
3H), 2.05 (s, 3H), 2.08 (s, 3H), 2.11 (s, 3H), 3.64 (dd, 1H, J = 8.3 and 4.9 Hz), 4.01 (m, 
2H), 4.28 (m, 1H), 4.49 (d, 1H, J = 11.9 Hz), 4.63 (d, 1H, J = 11.9 Hz), 4.95 (dd, 1H, J = 
3.9 and 2.5 Hz), 5.44 (m, 1H), 5.89 (d, 1H, J =8.3 Hz) and 7.23-7.34 (m, 5H).  
O
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1,3,4,6-Tetra-O-acetyl-L-gulopyranose (2.45).124 To a solution containing 2.15 g (4.90 
mmol) of 2.44 in 30 mL of ethyl acetate was added 1.06 g of 10% Pd/C and the reaction 
mixture was stirred overnight under 1 atm of H2 (g). The solvent was filtered through a 
pad of Celite 545® and concentrated under diminished pressure to afford a crude residue. 
The residue was purified by flash chromatography on a silica gel column (15 × 4 cm). 
Elution with 1:1 hexanes–ethyl acetate afforded 2.45 as a colorless oil: yield 1.67 g 
(98%); silica gel TLC Rf 0.16 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 
1.91 (s, 3H), 2.00 (s, 3H), 2.03 (s, 6H), 3.22-3.52 (br s, 1H), 3.80 (dd, 1H, J = 8.4 and 3.5 
Hz), 3.94 (m, 1H), 4.02 (m, 1H), 4.16 (m, 1H), 4.85 (m, 1H), 5.19 (t, 1H, J = 3.6 Hz) and 
5.70 (d, 1H, J = 8.4 Hz); 13C NMR (CDCl3, 100 MHz) δ 20.4, 20.5, 20.6, 20.8, 61.6, 
66.2, 67.5, 69.5, 70.9, 92.1, 169.4, 169.6, 169.7 and 170.5.  
 
Methyl-4,6-O-benzylidene-α-D-mannopyranoside (2.47).21 To a solution containing 
7.00 g (36.0 mmol) of methyl-α-D-mannopyranoside (2.46) in 85 mL of anh DMF was 
added 5.60 mL (5.68 g, 37.3 mmol) of benzaldehyde dimethyl acetal and a catalytic 
amount of p-TsOH. The reaction mixture was stirred at 60 °C under diminished pressure 
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for 1 h, allowed to cool to room temperature and then poured into a stirring mixture of 
120 mL of ethyl acetate and 100 mL saturated aq NaHCO3. The organic layer was 
washed with three 50-mL portions of brine, dried (MgSO4) and filtered. The solvent was 
concentrated under diminished pressure to afford a crude residue. The residue was 
purified by flash chromatography on a silica gel column (30 × 5 cm). Elution with 4:1 
hexanes–ethyl acetate afforded acetal 2.47 as a colorless solid: yield 7.13 g (70%); silica 
gel TLC Rf 0.31 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 3.38 (s, 3H), 
3.78 (m, 2H), 3.87 (m, 1H), 3.98 (m, 2H), 4.25 (m, 1H), 4.72 (m, 1H), 5.55 (s, 1H), 7.36 
(m, 3H) and 7.47 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 55.2, 63.3, 68.8, 69.0, 71.1, 
79.0, 101.6, 102.4, 126.5, 128.6, 129.5 and 137.4. 
 
Methyl 4,6-O-Benzylidene-3-O-benzyl-α-D-mannopyranoside (2.48).21 To a solution 
of 2.50 g (8.86 mmol) of acetal 2.47 in 76 mL of anh methanol was added 2.42 g (9.71 
mmol) of Bu2SnO and the solution was heated at reflux for 1.5 h to afford a clear 
solution. The solvent was removed under diminished pressure and the resulting solid was 
dried under vacuum overnight to remove traces of methanol. The white residue was 
dissolved in 76 mL of anh DMF, treated with 2.10 mL (17.7 mmol) of BnBr, and warmed 
to 100 °C for 30 min. The cooled reaction mixture was poured into a stirring solution of 
125 mL of ethyl acetate and 75 mL of saturated aq NaHCO3 and the white precipitate of 
tin oxide was filtered off. The aqueous layer was extracted with two 50-mL portions of 
O OMe
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ethyl acetate. The combined organic extract was washed with 50 mL of brine, dried 
(MgSO4), filtered, and concentrated under diminished pressure. The residue was purified 
by flash chromatography on a silica gel column (25 × 4 cm). Elution with 5:1→3:1 
hexanes–ethyl acetate afforded alcohol 2.48 as a colorless oil: yield 2.24 g (68%); silica 
gel TLC Rf 0.30 (3:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 3.38 (s, 3H), 
3.77 (m, 3H), 4.05 (m, 2H), 4.27 (m, 1H), 4.70 (m, 2H), 4.84 (m, 1H), 5.62 (s, 1H) and 
7.28-7.52 (m, 10H); 13C NMR (CDCl3, 100 MHz) δ 54.9, 63.3, 68.8, 69.8, 73.0, 75.7, 
78.8, 101.2, 101.6, 126.1, 127.8, 128.2, 128.4, 128.4, 128.9, 137.6 and 138.0. 
 
1,2,4,6-Tetra-O-acetyl-3-O-benzyl-α-D-mannopyranose (2.49).21 To a solution of 1.60 
g (4.30 mmol) of alcohol 2.48 in 26 mL of acetic anhydride was added 6 drops of 
concentrated H2SO4 and stirred overnight at room temperature. The solution was poured 
into a stirring solution of 100 mL of ethyl acetate and 70 mL of saturated aq NaHCO3. 
The organic layer was washed with 50 mL of brine, dried (MgSO4), filtered, and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (20 × 4 cm). Elution with 4:1→2:1 hexanes–ethyl 
acetate afforded peracetylated benzyl ether 2.49 as a yellow oil: yield 1.60 g (85%); silica 
gel TLC Rf 0.34 (3:1 hexanes–ethyl acetate) and 0.5 (1:1 in hexanes–ethyl acetate); 1H 
NMR (CDCl3, 400 MHz) δ 1.99 (s, 3H), 2.04 (s, 3H), 2.08 (s, 3H), 2.12 (s, 3H), 3.83 (dd, 
1H, J = 9.7 and 3.4 Hz), 3.90 (m, 1H), 4.04 (m, 1H), 4.19 (m, 1H), 4.41 (m, 1H), 4.64 (m, 
1H), 5.25 (m, 1H), 5.34 (dd, 1H, J = 3.4 and 2.1), 6.06 (d, 1H, J = 2.0 Hz) and 7.21-7.33 
O OAc
OAc
OBn
AcO
AcO
 
 
100 
(m, 5H); 13C NMR (CDCl3, 100 MHz) δ 20.79, 20.84, 20.89, 20.94, 62.5, 66.9, 67.1, 
70.9, 71.6, 74.2, 91.1, 127.8, 128.0, 128.5, 137.5, 168.1, 169.6, 170.0 and 170.8. 
 
1,2,4,6-Tetra-O-acetyl-α-D-mannopyranose (2.50).21 To a solution of 1.10 g (2.51 
mmol) of benzyl ether 2.49 in 30 mL of ethyl acetate was added a catalytic amount of 
Pd(OH)2/C and the reaction was placed under 1 atm of H2 (g) overnight. The catalyst was 
removed by filtration through a pad of Celite 545® and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel column (15 × 
3.5 cm). Elution with 2:1→1:1 hexanes–ethyl acetate afforded alcohol 2.50 as a colorless 
oil: yield 856 mg (98%); silica gel TLC Rf 0.13 (1:1 hexanes–ethyl acetate); 1H NMR 
(CDCl3, 400 MHz) δ 2.07 (s, 3H), 2.11 (s, 3H), 2.12 (s, 3H), 2.17 (s, 3H), 2.48 (d, 1H, J 
= 8 Hz), 3.91 (m, 1H), 4.18 (m, 2H), 4.19 (dd, 1H, J = 12.3 and 4.8 Hz), 5.07 (m, 1H), 
5.13 (m, 1H) and 6.10 (d, 1H, J = 1.6 Hz); 13C NMR (CDCl3, 100 MHz) δ 20.8, 20.9, 
20.96, 20.98, 62.3, 68.5, 68.9, 70.4, 71.2, 90.5, 168.2, 170.3, 170.8 and 171.2. 
 
1,2,4,6-Tetra-O-acetyl-3-O-((p-nitrophenyl)carbamoyl)-α-D-mannopyranose (2.51).21 
To a solution of 660 mg (1.89 mmol) of alcohol 2.50 in 7.0 mL of dry pyridine was 
added 926 mg (7.58 mmol) of DMAP and 1.53 g (7.58 mmol) of p-nitrophenyl 
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chloroformate. The reaction was stirred at 40 °C for 2 h at which time it was poured into 
a mixture of 40 mL ethyl acetate and 10 mL of water. The organic layer was washed with 
three 10-mL portions of 1N HCl, 10 mL of saturated aq NaHCO3 and 10 mL of brine. 
The solution was dried (MgSO4), filtered, and concentrated under diminished pressure. 
The residue was purified by flash chromatography on a silica gel column (30 × 3.5 cm). 
Elution with 4:1→1:2 hexanes–ethyl acetate afforded carbonate 2.51 as a light yellow oil: 
yield 788 mg (81%); silica gel TLC Rf 0.53 (1:1 hexanes–ethyl acetate); 1H NMR 
(CDCl3, 400 MHz) δ 2.11 (s, 3H), 2.12 (s, 3H), 2.17 (s, 3H), 2.21 (s, 3H), 4.08 (m, 2H), 
4.25 (m, 1H), 5.15 (m, 1H), 5.42 (m, 2H), 6.11 (s, 1H), 7.34 (d, 2H, J = 9.2 Hz) and 8.23 
(d, 2H, J = 9.2 Hz); 13C NMR (CDCl3, 100 MHz) δ 20.8, 20.86, 20.89, 20.92, 62.1, 65.2, 
67.7, 70.8, 74.4, 90.8, 122.0, 125.5, 125.7, 151.9, 155.4, 168.0, 169.5, 170.1 and 170.7. 
 
1,2,4,6-Tetra-O-acetyl-3-O-carbamoyl-α-D-mannopyranose (4.52).21 To a solution 
of 630 mg (1.22 mmol) of carbonate 4.51 in 33 mL anh dichloromethane was added 16 
mL of anh THF saturated with NH3 (g). The reaction was stirred at room temperature for 
2.5 h at which time the TLC indicated that the reaction was complete. The solution was 
concentrated under diminished pressure and the residue was purified by flash 
chromatography on a silica gel column (24 × 3.5 cm). Elution with 2:1→1:2 hexanes–
ethyl acetate afforded carbamate 4.52 as a colorless oil: yield 450 mg (94%); silica gel 
TLC Rf 0.13 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.03 (s, 3H), 
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2.04 (s, 3H), 2.12 (s, 3H), 2.13 (s, 3H), 4.00-4.10 (m, 2H), 4.24 (dd, 1H, J = 12.6 and 
5.0), 5.00 (br s, 2H), 5.18-5.30 (m, 3H) and 6.04 (d, 1H, J = 1.6 Hz); 13C NMR (CDCl3, 
100 MHz) δ 20.7, 20.78, 20.81, 20.9, 62.1, 65.7, 68.8, 69.7, 70.6, 90.6, 155.4, 168.2, 
169.76, 169.84 and 170.7. 
  
2,4,6-Tri-O-acetyl-3-O carbamoyl-α,β-D-mannopyranose (2.53).21 To a solution of 
369 mg (0.93 mmol) of carbamate 2.52 in 5.7 mL of DMF was added 120 mg (1.32 
mmol) of hydrazine acetate. The solution was stirred at room temperature for 2 h. The 
reaction was diluted with 60 mL of ethyl acetate and washed with 30 mL of brine, dried 
(MgSO4), filtered, and concentrated under diminished pressure. The residue was purified 
by flash chromatography on a silica gel column (20 × 2 cm). Elution with 1:1→1:3 
hexanes–ethyl acetate afforded pyranoside 2.53 as a colorless oil: yield 249 mg (76%); 
silica gel TLC Rf 0.32 (1:3 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.07 (s, 
3H), 2.11 (s, 3H), 2.16 (s, 3H), 4.15 (m, 1H), 4.23 (m, 2H), 4.83 (s, 2H) and 5.25 (m, 
4H); 13C NMR (CDCl3, 100 MHz) δ 20.9, 21.1, 62.7, 66.4, 68.8, 69.8, 70.5, 77.4, 92.4, 
155.3, 170.16, 170.25 and 170.9. 
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2,4,6-Tri-O-acetyl-3-O-carbamoyl-α-D-mannopyranosyl Diphenyl Phosphate 
(2.54).21,126 To a solution of 189 mg (0.54 mmol) of pyranoside 2.53, 84.0 mg (0.69 
mmol) of DMAP and 0.75 mL (5.40 mmol) of dry triethylamine in 2.6 mL of dry 
dichloromethane at 0 °C was added 1.11 mL (5.28 mmol) of diphenyl chlorophosphate 
dropwise. The solution was stirred at 0 °C for 1.5 h and was poured into a mixture of 30 
mL of ethyl acetate and 15 mL of saturated aq NaHCO3. The organic layer was washed 
with two 10-mL portions of brine, dried (MgSO4), filtered and concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica gel 
column (18 × 3 cm). Elution with 2:1→1:3 hexanes–ethyl acetate afforded the phosphate 
ester 2.54 as a colorless oil: yield 288 mg (92%); silica gel TLC Rf 0.51 (1:3 hexanes–
ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 1.98 (s, 3H), 2.06 (s, 3H), 2.16 (s, 3H), 3.92 
(dd, 1H, J = 12.4 and 1.6 Hz), 4.08 (m, 1H), 4.19 (dd, 1H, J = 12.0 and 4.8 Hz), 4.70 (br 
s, 2H), 5.32 (m, 3H), 5.88 (dd, 1H, J = 6.5 and 1.6 Hz), 7.20-7.27 (m, 6H) and 7.34-7.38 
(m, 4H); 13C NMR (CDCl3, 100 MHz) δ 20.7, 20.8, 20.9, 61.8, 65.4, 69.2, 69.3, 70.8, 
96.2, 120.18, 120.24, 120.3, 120.4, 125.9, 126.0, 130.08, 130.13, 155.0, 169.6, 169.9 and 
170.7. 
  
1,3,4,6-Tetra-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-mannopyranosyl)-α-
L-gulopyranoside (2.55).21 To a solution of 147 mg (0.25 mmol) of phosphate ester 2.54 
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and 70.0 mg (0.20 mmol) of gulose alcohol (2.45) in 4.3 mL of anh dichloromethane was 
added 82.0 µL (102 mg, 0.46 mmol) of TMSOTf at 0 °C. The reaction mixture was 
stirred at 0 °C for 20 min, at which time it was poured into a mixture of 50 mL of ethyl 
acetate and 20 mL of saturated aq NaHCO3. The organic layer was washed with two 20-
mL portions of brine, dried (MgSO4), filtered and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel column (25 × 
3 cm). Elution with 1:1→1:3 hexanes–ethyl acetate afforded disaccharide 2.55 as a 
colorless oil: yield 90.0 mg (66%); silica gel TLC Rf 0.27 (1:3 hexanes–ethyl acetate); 1H 
NMR (CDCl3, 400 MHz) δ 2.04 (2s, 6H), 2.11(s, 3H), 2.12 (2s, 6H), 2.14 (s, 3H), 2.18 (s, 
3H), 3.98 (dd, 1H, J = 8.4 and 3.6 Hz), 4.11 (m, 3H), 4.23 (m, 2H), 4.35 (m, 1H), 4.69 (br 
s, 2H), 4.99 (m, 2H), 5.06 (m, 1H), 5.10 (m, 1H), 5.24 (t, 1H, J = 3.6 Hz), 5.43 (t, 1H, J = 
3.6 Hz) and 5.87 (d, 1H, J = 8.4 Hz); 13C NMR (CDCl3, 100 MHz) δ 20.8, 20.81, 20.9, 
20.94, 61.5, 62.2, 65.6, 66.0, 67.80, 69.20, 69.3, 69.8, 69.9, 71.5, 90.8, 95.1, 155.1, 168.8, 
169.37, 169.39, 169.5, 169.9, 170.6 and 170.7. 
  
3,4,6-Tri-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-mannopyranosyl)-α-L-
gulopyranosyl Diphenyl Phosphate (2.56).21 To a solution of 90.0 mg (0.13 mmol) of 
disaccharide 2.55 in 1.4 mL of anh DMF was added 17.0 mg (0.18 mmol) of hydrazine 
acetate. The solution was stirred at room temperature for 2.5 h and diluted with 15 mL of 
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ethyl acetate. The organic solution was washed with 15 mL of brine, dried (MgSO4), 
filtered, and concentrated under diminished pressure to afford the product as a colorless 
oil: yield 72.0 mg; silica gel TLC Rf 0.25 (1:3 hexanes–ethyl acetate). 
To a solution of above residue, 18.0 mg (0.14 mmol) of DMAP and 0.16 mL 
(1.13 mmol) of dry triethylamine in 2.9 mL of anh dichloromethane at 0 °C was added 
0.22 mL (1.08 mmol) of diphenyl chlorophosphate dropwise. The solution was stirred at 
0 °C for 1.5 h and was poured into a mixture of 20 mL of ethyl acetate and saturated 10 
mL of aq NaHCO3. The organic layer was washed with two 10-mL portions of brine, 
dried (MgSO4), filtered and concentrated under diminished pressure. The residue was 
purified by flash chromatography on a silica gel column (22 × 3cm). Elution with 
2:1→1:3 hexanes–ethyl acetate afforded the phosphate ester 2.56 as a colorless oil: yield 
75.0 mg (65% over two steps); silica gel TLC Rf 0.51 (1:3 hexanes–ethyl acetate); 1H 
NMR (CDCl3, 400 MHz) δ 1.70 (s, 3H), 1.97 (s, 3H), 2.05 (s, 3H), 2.11 (s, 3H), 2.13 (s, 
3H), 2.19 (s, 3H), 4.13 (m, 5H), 4.31 (m, 2H), 4.76 (s, 2H), 4.96 (m, 1H), 4.98 (m, 1H), 
5.18 (m, 3H), 5.43 (m, 1H), 5.69 (m, 1H) and 7.25 (m, 10H); 13C NMR (CDCl3, 100 
MHz) δ 20.2, 20.6, 20.7, 61.1, 61.7, 65.3, 65.4, 67.3, 69.0, 69.8, 71.5, 95.3, 96.1, 120.1, 
120.2, 125.5, 129.6, 129.8, 129.9, 155.0, 169.2, 169.3, 169.7, 170.3 and 170.5. 
  
Benzyl 2-(2-Hydroxyethoxy)ethylcarbamate (2.57).18 To a solution containing 1.01 g 
(9.61 mmol) of 2-(2-aminoethoxy)ethanol in 100 mL of anh THF at room temperature 
were added 1.34 mL (9.61 mmol) of dry triethylamine and 1.49 mL (1.78 g, 10.6 mmol) 
of CBzCl. The reaction mixture was stirred for 1 h and was then diluted with 100 mL of 
HO
O
NHCBz
 
 
106 
ethyl acetate. The organic layer was washed with two 50-mL portions of water, 50 mL of 
brine, dried (MgSO4), filtered and concentrated under diminished pressure. The residue 
was purified by flash chromatography on a silica gel column (30 × 4 cm). Elution with 
9:1 hexanes–ethyl acetate afforded alcohol 2.57 as a colorless oil: yield 2.21 g (96%); 
silica gel TLC Rf 0.30 (9:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) 3.30 (m, 
2H), 3.45 (m, 4H), 3.52 (s, 1H), 3.62 (m, 2H), 5.03 (s, 2H), 5.86 (m, 1H) and 7.27 (m, 
5H); 13C NMR (CDCl3, 100 MHz) 40.5, 61.1, 66.3, 69.7, 72.0, 127.72, 127.75, 128.1, 
136.3 and 156.5. 
  
3,4,6-Tri-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-mannopyranosyl)-α-L-
gulopyranosyl Benzyl 2-(2-Ethoxy)ethylcarbamate (2.58).18 To a solution of 40.0 mg 
(0.05 mmol) of phosphate ester 2.56 and 10.0 mg (0.04 mmol) of alcohol 2.57 in 1.1 mL 
of anh dichloromethane was added 15.0 µL (17.8 mg, 0.08 mmol) of TMSOTf at 0 °C. 
The reaction mixture was stirred at 0 °C for 20 min at which time it was poured into a 
mixture of 20 mL of ethyl acetate and 10 mL of saturated aq NaHCO3. The organic layer 
was washed with two 5-mL portions of brine, (MgSO4), filtered and concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica gel 
column (25 × 1.5 cm). Elution with 1:16:16→1:12:24 methanol–hexanes–ethyl acetate 
afforded disaccharide–linker conjugate 2.58 as a colorless oil: yield 26.0 mg (67%); silica 
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gel TLC Rf 0.30 (1:4 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.03 (s, 6H), 
2.07 (s, 3H), 2.09 (s, 3H), 2.11 (s, 3H), 2.12 (s, 3H), 3.54 (m, 8H), 3.83 (m, 1H), 3.96 (m, 
1H), 4.05 (m, 4H), 4.25 (m, 1H), 4.46 (m, 1H), 4.69 (s, 1H), 4.91 (m, 1H), 5.12 (m, 8H), 
5.61 (m, 1H) and 7.34 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ 20.6, 20.7, 20.8, 29.6, 
40.9, 62.1, 62.5, 63.7, 65.5, 66.1, 66.6, 67.6, 68.5, 69.1, 69.6, 69.7, 70.0, 70.3, 70.6, 97.0, 
97.1, 128.1, 128.2, 128.4, 136.5, 156.5, 169.3, 169.5, 169.8 and 170.5; mass spectrum 
(MALDI-TOF), m/z 859.30 (M + H)+, 881.30 (M + Na)+ (theoretical m/z 858.29). 
  
Cy5**succinimidyl ester (2.60).127 To a vial containing 0.50 mg (0.6 µmol) of 
Cy5**COOH were added 5.00 mg (16.0 µmol) of TSTU dissolved in 100 µL of anh 
DMF, followed by 7.50 µL (5.60 mg, 43.0 µmol) of anh DIPEA dissolved in 75 µL of 
anh DMF. The reaction mixture was stirred at room temperature for 3 h and then diluted 
with 3 mL of ethyl acetate. The solution was then centrifuged at 15000 rpm for 15 min. 
The supernatant solution was discarded and the residue was washed with 1 mL of ethyl 
acetate. The residue was then dried under vacuum in the dark for 30 min to afford the 
NHS ester 2.60 as a dark blue solid: yield 0.55 µg (100%); mass spectrum (MALDI-
TOF), m/z 984.55 (M + H)+ (theoretical m/z 984.24). 
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 BLM Disaccharide–Cy5** (2.3).18 To a solution of 8.00 mg (9.30 µmol) of 
disaccharide–linker 2.58 in 2 mL of anh methanol was added 0.2 mL of 25% w/w freshly 
prepared solution of sodium methoxide in methanol. The reaction mixture was allowed to 
stir at room temperature for 2.5 h, and the complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was then 
quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min, filtered and 
concentrated; mass spectrum (MALDI-TOF) m/z 629.40 (M + Na)+ (theoretical m/z 
629.23). To the solution of the crude product in 5 mL of anh methanol was added Pd/C 
and H2 gas was bubbled through for 45 min. The complete consumption of starting 
material was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture 
was filtered through Celite 545® and then concentrated under diminished pressure to 
afford amine 2.59 as a colorless oil: yield 4.78 mg (100%), which was used directly for 
the next reaction; mass spectrum (MALDI-TOF), m/z 473.35 (M + H)+ and 495.32(M + 
Na)+ (theoretical m/z 473.19 and 495.19). 
             To 175 µg (0.37 µmol) of amine 2.59 was added a solution of 110 µg (0.11 µmol) 
of Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the reaction 
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mixture was stirred overnight in the dark. The reaction mixture was purified on an 
Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile) over a period of 28 min at 
a flow rate of 3 mL/min. The fractions containing the desired product eluted at 18.5 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give BLM 
disaccharide–Cy5** (2.3) as a blue solid: yield 63.0 µg (35% over two steps); mass 
spectrum (MALDI-TOF), m/z 1363.50 (M − H + Na )+, 1385.50 (M − 2H + 2Na )+ and 
1407.44 (M − 3H + 3Na )+  (theoretical m/z 1363.38, 1385.36 and 1407.35). 
 
Methyl (S),(R)-2,3,4,6-di-O-benzylidene-α-D-mannopyranoside (2.61a) and 
Methyl(R),(R)-2,3,4,6-di-O-benzylidene-α-D-mannopyranoside (2.61b).128 To a 
solution of 8.00 g (41.2 mmol) of methyl-α-D-mannopyranoside (2.46) in 88 mL of DMF 
were added 16.0 mL (106 mmol) of benzaldehyde dimethylacetal and 120 mg (0.52 
mmol) of camphor sulfonic acid. The reaction was heated at 45 °C under reduced 
pressure in rotatory evaporator for 3 h. To the reaction mixture were then added 8.0 mL 
(53.2 mmol) of benzaldehyde dimethyl acetal and 60.0 mg (0.26 mmol) of camphor 
sulfonic acid and heated at 45 °C for additional 2 h. The solvent was concentrated and the 
residue was co-evaporated with three 20-mL portions of toluene. The residue was 
dissolved in 120 mL of dichloromethane and washed with 60 mL of saturated aq 
O OMe
O
O
O
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NaHCO3, 60 mL of brine (60 mL), dried (MgSO4), filtered, and concentrated under 
diminished pressure. The resulting residue was purified by recrystallization (ethyl 
acetate−methanol) to give the exo-dibenzylidene isomer 2.61a as a white solid: yield 5.20 
g (34%); silica gel TLC Rf 0.80 (3:1 hexanes–ethyl acetate); mp 170-172 °C, lit.145 mp 
176-180 °C; 1H NMR (CDCl3, 400 MHz) δ 3.41 (s, 3H), 3.84 (m, 2H), 3.90 (m, 1H), 4.15 
(d, 1H, J = 5.4 Hz), 4.37 (m, 1H), 4.64 (dd, 1H, J = 7.8 and 5.4 Hz), 5.03 (s, 1H), 5.65 (s, 
1H), 6.30 (s, 1H), 7.33-7.43 (m, 6H), 7.44-7.50 (m, 2H) and 7.51-7.57 (m, 2H); 13C NMR 
(CDCl3, 100 MHz) δ 55.2, 60.3, 68.9, 75.3, 75.5, 77.5, 98.8, 102.0, 103.0, 126.3, 128.2, 
128.3, 129.1, 137.1 and 138.6. The mother liquor was concentrated and recrystallization 
in ethanol to give the endo-dibenzylidene isomer 2.61b as a white solid: yield 5.86 g 
(38%); silica gel TLC Rf 0.80 (3:1 hexanes–ethyl acetate); mp 80-85 °C, lit.145 mp 95-97 
°C; 1H NMR (CDCl3, 400 MHz) δ 3.44 (s, 3H), 3.79 (m, 3H), 4.31 (m, 2H), 4.48 (t, 1H, J 
= 6.7 Hz), 5.09 (s, 1H), 5.54 (s, 1H), 5.98 (s, 1H), 7.34-7.39 (m, 4H), 7.40-7.46 (m, 2H), 
7.49 -7.52 (m, 2H) and 7.53-7.59 (m, 2H). 
 
Methyl 4,6-O-benzylidene-2-O-benzyl-α-D-mannopyranoside (2.62).129 To a stirred 
suspension of 4.22 g endo-dibenzylidene isomer 2.61b (7.69 mmol) in 68 mL of anh 
toluene were added 105 mg of 5 mol% of aluminium chloride and 34.6 mL (34.6 mmol) 
of 1M solution of DIBAL-H in toluene dropwise at 0 °C. The reaction was stirred at 0 °C 
for 1 h and quenched by the addition of 27 mL of methanol. The solution was diluted 
with 300 mL diethyl ether, washed with 120 mL 10% potassium tartarate. The aqueous 
O OMe
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layer was extracted with 400 mL diethyl ether and the combined extract was washed with 
120 mL brine, dried (MgSO4), and concentrated under diminished pressure. The residue 
was purified by flash chromatography on a silica gel column (20 × 6 cm) with 4:1 
hexanes–ethyl acetate to give alcohol 2.62 as colorless oil: yield 4.22 g (72%); silica gel 
TLC Rf 0.52 (2:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 3.36 (s, 3H), 
3.72-3.96 (m, 4H), 4.08 (dd, 1H, J = 9.8 and 3.7 Hz), 4.26 (dd, 1H, J = 9.5 and 4.1 Hz), 
4.72 (m, 3H), 5.58 (s, 1H), 7.27-7.42 (m, 7H) and 7.44-7.53 (m, 2H); 13C NMR (CDCl3, 
100 MHz) δ 55.0, 63.3, 68.7, 68.8, 73.7, 78.4, 79.5, 99.4, 102.13, 102.13, 126.3, 127.9, 
128.2, 129.1 and 137.3; similarly exo-dibenzylidene isomer 2.61a gave alcohol 2.62 in 
65% yield. 
 
1,3,4,6-Tetra-O-acetyl-2-O-benzyl-α-D-mannopyranoside (2.63).147 To a solution of 
2.16 g (11.2 mmol) of alcohol 2.62 in 40 mL of acetic anhydride was added a drop of 
concentrated H2SO4 at 0 °C and stirred overnight at room temperature. The solution was 
poured into a mixture of 200 mL of ethyl acetate and 100 mL of saturated aq NaHCO3. 
The organic layer was washed with 30 mL of brine, dried (MgSO4), filtered, and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (22 × 5 cm). Elution with 4:1→2:1 hexanes–ethyl 
acetate afforded benzyl ether 2.63 as a colorless oil: yield 1.46 g (57%); silica gel TLC Rf 
0.44 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 1.99 (s, 3H). 2.04 (s, 
3H), 2.09 (s, 3H), 2.13 (s, 3H), 3.82 (dd, 1H, J = 3.4 and 2.0 Hz), 3.99-4.03 (m, 1H), 4.12 
O OAc
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(dd, 1H, J = 12.4 and 2.4 Hz), 4.26 (dd, 1H, J = 12.3 and 4.9 Hz), 4.58-4.75 (m, 2H), 
5.19 (dd, 1H, J = 10.1 and 3.3 Hz), 5.48 (t, 1H, J = 10.1 Hz), 6.19 (d, 1H, J = 1.9 Hz) and 
7.28-7.36 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ 20.6, 20.65, 20.69, 20.9, 62.2, 65.8, 
70.5, 70.9, 72.8, 73.8, 91.0, 127.9, 128.0, 128.2, 128.3, 128.4, 137.2, 168.6, 169.4, 170.1 
and 170.6.  
 
3,4,6-Tri-O-acetyl-2-O-benzyl-α-D-mannopyranosyl Diphenyl Phosphate (2.64). To a 
solution of 920 mg (2.10 mmol) of benzyl ether 2.63 in 14.3 mL of anh DMF was added 
271 mg (2.94 mmol) of hydrazine acetate. The solution was stirred at room temperature 
for 2.5 h and diluted with 100 mL of ethyl acetate. The organic solution was washed with 
50 mL of brine, dried (MgSO4), filtered, and concentrated under diminished pressure to 
afford the alcohol as a light yellow oil: crude yield 873 mg (100%), which was used for 
the next reaction; silica gel TLC Rf 0.42 (1:2 hexanes–ethyl acetate). 
To a solution of above residue in 50 mL of anh dichloromethane at 0 °C were 
added 336 mg (2.75 mmol) of DMAP, 3.30 mL (2.42 g, 23.9 mmol) of dry triethylamine, 
and 4.40 mL (5.71 g, 21.2 mmol) of diphenyl phosphoryl chloride. The solution was 
stirred at room temperature for 1.5 h and poured into a mixture of 70 mL of ethyl acetate 
and 35 mL of saturated aq NaHCO3. The organic layer was washed with two 35-mL 
portions of brine, dried (MgSO4), filtered and concentrated under diminished pressure. 
The residue was purified by flash chromatography on a silica gel column (20 × 4 cm). 
Elution with 2:1 hexanes–ethyl acetate afforded phosphate ester 2.64 as a white foam: 
O OP(O)(OPh)2
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yield 730 mg (55% over two steps); silica gel TLC Rf 0.49 (1:2 hexanes–ethyl acetate); 
1H NMR (CDCl3, 400 MHz) δ 1.98 (s, 3H), 1.99 (s, 3H), 2.03 (s, 3H), 3.86 (m, 1H), 3.93 
(dd, 1H, J = 12.3 and 2.3 Hz), 4.00 (ddd, 1H, J = 10.2, 4.7 and 2.2 Hz), 4.17 (dd, 1H, J = 
12.4 and 4.7 Hz), 4.61 (m, 2H), 5.23 (dd, 1H, J = 10.2 and 3.3 Hz), 5.46 (t, 1H, J = 10.1 
Hz), 5.91 (dd, 1H, J = 6.5 and 2.0 Hz), 7.19-7.25 (m, 6H) and 7.28-7.39 (m, 9H); 13C 
NMR (CDCl3, 100 MHz) δ 20.6,  20.7, 61.8, 65.5, 70.0, 70.8, 73.3, 74.6, 74.7, 96.5, 96.6, 
120.1, 120.2, 120.3, 125.7, 125.7, 128.0, 128.1, 128.5, 129.89, 129.92, 136.9, 150.0, 
150.3, 169.4, 170.0 and 170.7; mass spectrum (FAB), m/z 629.1795 (M + H)+ 
(C31H34O12P requires m/z 629.1788). 
 
1,3,4,6-Tetra-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-benzyl-α-D-mannopyranosyl)-β-
L-gulopyranose (2.65). To a solution of 263 mg (0.418 mmol) of phosphate ester 2.64 
and 124 mg (0.36 mmol) of gulose alcohol 2.45 in 5.6 mL of dichloromethane was added 
153 µL (167 mg, 0.75 mmol) of TMSOTf at 0 °C. The reaction was stirred for 15 min at 
which time it was poured into a mixture of 20 mL of ethyl acetate and 10 mL of saturated 
aq NaHCO3. The organic layer was washed with two 10-mL portions of brine, dried 
(MgSO4), filtered, and concentrated under diminished pressure. The residue was purified 
by flash chromatography on a silica gel column (20 × 3.5 cm). Elution with 1:1→1:2  
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hexanes–ethyl acetate afforded disaccharide 2.65 as a white foam: yield 170 mg (56%); 
silica gel TLC Rf 0.28 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 1.90 (s, 
3H), 2.01 (s, 3H), 2.06 (s, 3H), 2.12 (s, 3H), 2.14 (s, 3H), 2.16 (s, 6H), 3.61 (m, 1H), 
3.98-4.24 (m, 5H), 4.36 (m, 1H), 4.53 (m, 1H), 4.70 (m, 2H), 4.97 (dd, 1H, J = 10.2 and 
3.4 Hz), 4.97 (dd, 1H, J = 10.2 and 3.4 Hz), 5.12 (d, 1H, J = 1.6 Hz), 5.39 (m, 1H), 5.48 
(m, 1H), 5.84 (d, 1H, J = 8.8 Hz), 7.28-7.35 (m, 3H) and 7.39-7.42 (m, 2H); 13C NMR 
(CDCl3, 100 MHz) δ 20.65, 20.69, 20.7, 20.8, 61.3, 62.2, 65.4, 65.4, 65.8, 66.1, 67.7, 
68.1, 69.2, 70.5, 71.3, 72.3, 74.0, 77.2, 90.6, 94.3, 127.8, 128.16, 128.19, 137.6, 168.7, 
169.4, 170.1, 170.4 and 170.7; mass spectrum (APCI), m/z 727.2455 (M + H)+ 
(C33H43O18 requires m/z 727.2450). 
 
1,3,4,6-Tetra-O-acetyl-2-O-(3,4,6-tri-O-acetyl-α-D-mannopyranosyl)-β-L-
gulopyranose (2.66). To a solution of 236 mg (0.32 mmol) of disaccharide 2.65 in 4.7 
mL of ethyl acetate was added 117 mg of Pd(OH)2/C and the reaction was placed under 1 
atm of H2 (g) overnight. The catalyst was removed by filtration through a pad of Celite 
545® and concentrated under diminished pressure affording alcohol 2.66 as a white foam: 
yield 203 mg (98%); silica gel TLC Rf 0.13 (1:2 hexanes–ethyl acetate); 1H NMR 
(CDCl3, 400 MHz) δ 2.01 (s, 3H), 2.06 (2s, 6H), 2.11 (s, 3H), 2.15 (s, 6H), 2.16 (s, 3H), 
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3.85 (m, 1H), 4.01 (dd, 1H, J = 8.5 and 3.3 Hz), 4.09 (m, 2H), 4.16 (m, 1H), 4.20 (m, 
1H), 4.27 (m, 1H), 4.36 (ddd, 1H, J = 7.4, 6.0 and 1.5 Hz), 4.99 (dd, 1H, J = 3.8 and 1.4 
Hz), 5.03 (d, 1H, J = 1.8 Hz), 5.07 (dd, 1H, J = 9.8 and 3.2 Hz), 5.35 (t, 1H, J = 10.0 Hz), 
5.45 (t, 1H, J = 3.5 Hz) and 5.87 (d, 1H, J = 8.4 Hz); 13C NMR (CDCl3, 100 MHz) δ 
20.6, 20.7, 20.8, 20.9, 61.3, 61.9, 65.7, 65.8, 67.7, 68.5, 69.9, 69.5, 71.2, 71.3, 77.2, 90.6, 
90.7, 168.7, 169.4, 168.5, 168.6, 169.8, 170.4 and 170.9; mass spectrum (APCI), m/z 
637.1985 (M + H)+ (C26H37O18 requires m/z 637.1980). 
 
1,3,4,6-Tetra-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-((p-nitrophenyl)carbamoyl)-α-D-
mannopyranosyl)-β-L-gulopyranose (2.67). To a solution of 203 mg (0.319 mmol) of 
alcohol 2.66 in 2.1 mL of dry pyridine was added 156 mg (1.276 mmol) of DMAP and 
257 mg (1.28 mmol) of p-nitrophenyl chloroformate. The reaction was stirred overnight 
at 40 °C at which time it was poured into a mixture of 6 mL ethyl acetate and 2.2 mL of 
water. The organic layer was washed with three 3 mL portions of 1N HCl, 3 mL of 
saturated aq NaHCO3 and 3-mL of brine. The solution was dried (MgSO4), filtered, and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (20 × 3 cm). Elution with 1:1 hexanes–ethyl 
acetate affording carbonate 2.67 as a white foam: yield 220 g (86%); silica gel TLC Rf 
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0.46 (1:2 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.01 (s, 3H), 2.06 (2s, 
6H), 2.13 (s, 3H), 2.15 (s, 3H), 2.17 (s, 3H), 2.20 (s, 3H), 4.03 (dd, 1H, J = 8.5 and 3.3 
Hz), 4.08-4.20 (m, 3H), 4.26 (m, 2H), 4.38 (m, 1H), 5.02 (m, 2H), 5.17(m, 1H), 5.23 (dd, 
1H, J = 10.1 and 3.3 Hz), 5.35 (m, 1H), 5.46 (t, 1H, J = 3.5 Hz), 5.90 (d, 1H, J = 8.5 Hz), 
7.41-7.44 (m, 2H) and 8.28-8.32 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 20.6, 20.7, 
20.8, 61.3, 61.8, 62.0, 65.4, 65.6, 65.9, 67.7, 68.7, 69.3, 70.0, 71.3, 73.4, 89.2, 90.5, 94.4, 
121.6, 125.3, 145.5, 151.6, 155.2, 168.6, 169.3, 169.5, 169.6, 169.7, 170.4 and 170.5; 
mass spectrum (APCI), m/z 802.2033 (M + H)+ (C33H40O22 requires m/z 802.2042). 
 
1,3,4,6-Tetra-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-(carbamoyl)-α-D-
mannopyranosyl)-β-L-gulopyranose (2.68). To a solution containing 94.0 mg (0.12 
mmol) of carbonate 2.67 in 5.0 mL of dichloromethane was added 2.2 mL of THF 
saturated with NH3 (g). The reaction mixture was stirred at room temperature for 3 h. The 
solvent was concentrated under diminished pressure to afford a crude residue. The 
residue was purified by flash chromatography on a silica gel column (15 × 2.5 cm). 
Elution with 1:3 hexanes–ethyl acetate afforded carbamate 2.68 as a white foam: yield 
73.0 mg (92%); silica gel TLC Rf  0.13 (1:3 hexanes–ethyl acetate); 1H NMR (CDCl3, 
400 MHz) δ 1.98 (s, 3H), 2.02 (s, 3H), 2.04 (s, 3H), 2.11 (s, 3H), 2.13 (s, 3H), 2.14 (s, 
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3H), 2.18 (s, 3H), 3.98 (dd, 1H, J = 8.4 and 3.3 Hz), 4.08 (m, 2H), 4.15 (m, 1H), 4.18 (m, 
1H), 4.25 (m, 1H), 4.35 (m, 1H), 4.85 (br s, 2H), 4.96 (m, 1H), 5.01 (m, 2H), 5.11 (m, 
1H), 5.25 (m, 1H), 5.44 (t, 1H, J = 3.6 Hz) and 5.89 (d, 1H, J = 8.4 Hz); 13C NMR 
(CDCl3, 100 MHz) δ 20.62, 20.65, 20.68, 20.71, 20.8, 61.4, 62.1, 65.6, 65.7,  67.6, 68.9, 
69.1, 69.4, 69.8, 71.3, 90.7, 95.3, 154.9, 168.7, 169.2, 169.6, 169.9, 170.4 and 170.5; 
mass spectrum (APCI), m/z 680.2026 (M + H)+ (C27H38O19 requires m/z 680.2038). 
 
3,4,6-Tri-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-(carbamoyl)-α-D-mannopyranosyl)-β-
L-gulopyranosyl Diphenyl Phosphate (2.69). To a solution containing 66.0 mg (0.10 
mmol) of disaccharide 2.68 in 1.0 mL of anh DMF was added 13.0 mg (0.14 mmol) of 
hydrazine acetate. The reaction mixture was stirred at room temperature for 3 h and 
diluted by the addition of 20 mL of ethyl acetate. The organic solution was washed with 
10 mL of water, 10 mL of saturated aq NaHCO3, 10 mL of brine. The solvent was dried 
(MgSO4), filtered and concentrated under diminished pressure to afford the crude product 
as a light yellow oil: yield 56.0 mg (90%); silica gel TLC Rf 0.23 (1:4 hexanes–ethyl 
acetate). MALDI, m/z 660.18 for (M + Na)+ (theoretical m/z 660.18); the residue was 
used for next reaction.  
To a stirred solution containing 56.0 mg (0.09 mmol) of the crude residue in 3.3 
mL of anh dichloromethane were added 13.0 mg (0.11 mmol) of DMAP, 133 µL (96.0 
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mg, 0.95 mmol) of dry triethylamine and 176 µL (229 mg, 0.85 mmol) of diphenyl 
chlorophosphate. The reaction mixture was stirred at 0 °C for 2 h and poured into a 
mixture of 5 mL of ethyl acetate and 5 mL of saturated aq NaHCO3. The organic layer 
was washed with 10 mL of brine, dried (MgSO4), filtered and concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica gel 
column (20 × 2 cm). Elution with 1:2 hexanes–ethyl acetate afforded phosphate ester 
2.69 as a colorless oil: yield 36.0 mg (47% over two steps); silica gel TLC Rf 0.18 (1:2 
hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 1.77 (s, 3H), 2.03 (s, 3H), 2.05 (s, 
3H), 2.13 (s, 3H), 2.21 (s, 3H), 2.27 (s, 3H), 4.07 (m, 2H), 4.18 (m, 2H), 4.26 (m, 1H), 
4.39 (m, 2H), 4.87 (br s, 2H), 5.08 (m, 3H), 5.26 (m, 1H), 5.32 (m, 1H), 5.52 (m, 1H), 
5.77 (m, 1H), 7.22-7.28 (m, 2H) and 7.32-7.43 (m, 8H). 13C NMR (CDCl3, 100 MHz) δ 
20.3, 20.63, 20.64, 20.68, 20.71, 61.2, 61.8, 65.3, 65.6, 67.4, 69.0, 69.1, 69.5, 71.1, 71.2, 
71.6, 95.6, 96.17, 96.22, 120.19, 120.24, 125.6, 125.70, 125.71, 129.6, 129.9, 150.0, 
150.1, 154.9, 169.2, 169.6, 169.7, 170.4 and 170.6; mass spectrum (APCI), m/z 870.2224 
(M + H)+ (C37H45 NO21P requires m/z 870.2222). 
 
3,4,6-Tri-O-acetyl-2-O-(3,4,6-tri-O-acetyl-2-O-(carbamoyl)-α-D-mannopyranosyl)-
α,β-L-gulopyranosyl Benzyl 2-(2-Ethoxy)ethylcarbamate (2.70). To a stirred solution 
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containing 31.0 mg (0.04 mmol) of phosphate ester 2.69 in 3.9 mL of anh 
dichloromethane was added a solution of 9.40 mg (0.04 mmol) of CBz linker 2.57 in 4.5 
mL of anh dichloromethane at 0 °C. To the cooled reaction mixture was added 41.0 µL 
(51.0 mg, 0.23 mmol) of TMSOTf. The reaction mixture was stirred at 0 °C for 15 min at 
which time it was poured into a mixture of 20 mL of ethyl acetate and 10 mL of saturated 
aq NaHCO3. The organic layer was washed with 10mL of brine, and dried (MgSO4) and 
filtered. The solvent was concentrated under diminished pressure to afford a crude 
residue. The residue was purified by flash chromatography on a silica gel column (12 × 2 
cm). Elution with 1:3 hexanes–ethyl acetate afforded disaccharide−linker conjugate 2.70 
as a colorless oil: yield 12.0 mg (39%); silica gel TLC Rf 0.12 (1:3 hexanes–ethyl 
acetate); 1H NMR (CDCl3, 400 MHz) δ 1.99 (s, 3H), 2.02 (s, 2H), 2.04 (s, 3H), 2.07 (s, 
3H), 2.09 (s, 3H), 2.12 (s, 3H), 3.37-3.42 (m, 2H), 3.55-3.65 (m, 3H), 3.67-3.69 (m, 2H), 
3.83-3.88 (m, 1H), 3.97 (t, 1H, J = 3.9 Hz), 4.03-4.09 (m, 2H), 4.10-4.15 (m, 1H), 4.28 
(dd, 1H, J = 11.9 and 5.2 Hz), 4.46 (t, 1H, J = 6.6 Hz), 4.77-4.90 (br s, 2H), 4.93 (d, 1H, 
J = 3.9 Hz), 5.03-5.06 (m, 3H), 5.09 (s, 2H), 5.23-5.29 (m, 3H), 5.46-5.48 (m, 1H) and 
7.28-7.37 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ 20.62, 20.65, 20.72, 20.76, 40.9, 62.1, 
62.5, 63.8, 65.8, 66.1, 66.6, 67.6, 68.6, 68.7, 69.0, 70.1, 70.2, 70.3, 71.0, 77.2, 97.0, 97.6, 
128.1, 128.2, 128.5, 136.5, 155.0, 169.3, 169.72, 169.73, 170.0, 170.56 and 170.59; mass 
spectrum (APCI), m/z 859.2987 (M + H)+ (C37H51N2O21 requires m/z 859.2984). 
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Disaccharide−Cy5** Conjugate 2.4. To a solution of 2.20 mg (2.60 µmol) of 
disaccharide−linker 2.70 in 1 mL of anh methanol was added 0.1 mL of a freshly 
prepared 25% w/w solution of sodium methoxide in methanol. The reaction mixture was 
allowed to stir at room temperature for 3 h, and the complete consumption of starting 
material was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture 
was then quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min, 
filtered and concentrated; mass spectrum (MALDI-TOF), m/z 629.64 (M + Na)+ 
(theoretical m/z 629.23). To the solution of the crude product in 5 mL of anh methanol 
was added Pd/C and H2 gas was bubbled through for 1 h. The complete consumption of 
starting material was confirmed by MALDI-TOF mass spectral analysis. The reaction 
mixture was filtered through Celite 545® and the filtrate was concentrated under 
diminished pressure to afford amine 2.71 as a colorless oil: yield 1.32 mg (100%), which 
was used directly for the next reaction; mass spectrum (MALDI-TOF), m/z 495.44 (M + 
Na)+; mass spectrum (APCI), m/z 473.1986 (M + H)+ (C17H33N2O13 requires m/z 
473.1983).  
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         To 101 µg (0.21 µmol) of amine 2.71 was added a solution of 106 µg (0.11 µmol) 
of Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the reaction 
mixture was stirred overnight in the dark. The reaction mixture was purified on an 
Alltech Alltima C18 reversed phase semi-preparative (250 × 10 mm, 5 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile) over a period of 35 min at 
a flow rate of 4 mL/min. The fractions containing the desired product eluted at 23.5 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give disaccharide–
Cy5** conjugate 2.4 as a blue solid: yield 48.0 µg (35% over two steps); mass spectrum 
(APCI), m/z 669.1883 (M − K − 2H)2− (C55H78N4O26S42− requires m/z 669.1899). 
 
4-O-benzyl-α-D-mannopyranoside (2.72).130 To 2.49 g (8.82 mmol) of acetal 2.47 in 50 
mL of anh THF were added 26.5 mL (26.5 mmol) of a 1 M solution of BH3 in THF and 
3.44 g (26.5 mmol) of anh CoCl2 at 0 °C. The reaction mixture was stirred for 3.5 h at 
room temperature and diluted by the addition of 100 mL of ethyl acetate. The solution 
was filtered and the filtrate was treated with 200 mg (5.29 mmol) of NaBH4 in 30 mL of 
water. The solution was again filtered and washed successively with 50 mL of saturated 
aq NaHCO3, 50 mL of brine, and dried (MgSO4) and filtered. The solution was 
concentrated under diminished pressure to afford benzyl ether 2.72 as a colorless oil: 
yield 2.48 g (99%); silica gel TLC Rf 0.27 (1:3 hexanes–ethyl acetate); 1H NMR (CDCl3, 
O OMe
OH
OH
BnO
HO
 
 
122 
400 MHz) δ 3.27 (s, 3H), 3.34 (m, 1H), 3.52 (m, 2H), 3.61 (br s, 1H), 3.78 (m, 2H), 3.87 
(br s, 1H), 3.92-3.95 (m, 1H), 4.45 (br s, 1H), 4.67-4.84 (m, 3H) and 7.22-7.33 (m, 5H).  
 
1,2,3,6-Tetra-O-acetyl-4-O-benzyl-α-D-mannopyranoside (2.73).148 To a solution 
containing 2.49 g (8.44 mmol) of benzyl ether 2.72 in 58 mL of acetic anhydride was 
added a catalytic amount of concentrated H2SO4 at 0 °C. The solution was stirred at room 
temperature for 12 h. The reaction mixture was quenched by the addition of 120 mL of 
ethyl acetate and 80 mL of saturated aq NaHCO3. The organic layer was washed with 50 
mL of brine, dried (MgSO4), filtered and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (30 × 5 cm). Elution 
with 3:1→1:1 hexanes–ethyl acetate afforded peracetylated benzyl ether 2.73 as a 
colorless oil: yield 2.91 g (79%); silica gel TLC Rf 0.5 (1:1 hexanes–ethyl acetate); 1H 
NMR (CDCl3, 400 MHz) δ 2.00 (s, 3H), 2.08 (s, 3H), 2.13 (s, 3H), 2.15 (s, 3H), 3.87 (t, 
1H, J = 9.7 Hz), 3.99 (dt, 1H, J = 9.9 and 3.4 Hz), 4.32 (d, 2H, J = 3.5 Hz), 4.59 (d, 1H, J 
= 11.2 Hz), 4.70 (d, 1H, J = 10.8 Hz), 5.26 (dd, 1H, J = 3.3 and 2.1 Hz), 5.37 (dd, 1H, J = 
9.5 and 3.4 Hz), 6.04 (t, 1H, J = 6.1 Hz) and 7.24-7.38 (m, 5H); 13C NMR (CDCl3, 100 
MHz) δ 20.92, 20.97, 20.99, 21.04, 62.9, 68.9, 71.6, 71.8, 72.6, 75.2, 90.8, 127.9, 128.3, 
128.7, 137.5, 168.4, 169.8, 169.9 and 170.8. 
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1,2,3,6-Tetra-O-acetyl-α-D-mannopyranoside (2.74).149 To a solution of 2.90 g (6.61 
mmol) of benzyl ether 2.73 in 50 mL of ethyl acetate was added 550 mg of Pd(OH)2/C 
and the reaction was stirred under 1 atm of H2 (g) overnight. The catalyst was removed 
by filtration through a pad of Celite 545® and the filtrate was concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica gel 
column (20 × 5 cm). Elution with 2:1 hexanes–ethyl acetate afforded alcohol 2.74 as a 
colorless oil: yield 1.93 g (84%); silica gel TLC Rf 0.25 (1:1 hexanes–ethyl acetate); 1H 
NMR (CDCl3, 400 MHz) δ 2.06 (s, 3H), 2.12 (s, 6H), 2.14 (s, 3H), 2.94 (br s, 1H), 3.88 
(m, 2H), 4.26 (m, 1H), 4.52 (m, 1H), 5.21 (m, 2H) and 6.04 (d, 1H, J = 1.6 Hz). 
 
1,2,3,6-Tetra-O-acetyl-4-O-(p-nitrophenyloxy)carbonyloxy-α-D-mannopyranoside 
(2.75). To a solution of 1.74 g (5.00 mmol) of alcohol 2.74 in 17.8 mL of dry pyridine 
was added 2.44 g (20.0 mmol) of DMAP and 4.03 g (20.0 mmol) of p-nitrophenyl 
chloroformate. The reaction was stirred at 40 °C for 2.5 h at which time it was poured 
into a mixture of 50 mL of ethyl acetate and 19 mL of water. The organic layer was 
washed successively with three 25-mL portions of 1 N HCl, 25 mL of saturated aq 
NaHCO3 and 25 mL of brine. The solution was dried (MgSO4), filtered and concentrated 
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under diminished pressure to afford a crude residue. The residue was purified by flash 
chromatography on a silica gel column (28 × 5 cm). Elution with 2:1 hexanes–ethyl 
acetate afforded carbonate 2.75 as a colorless foam: yield 1.91 g (74%); silica gel TLC Rf  
0.21 (1:2 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.05 (s, 3H), 2.11 (s, 
3H), 2.18 (s, 3H), 2.19 (s, 3H), 4.18 (m, 2H), 4.56 (m, 1H), 5.23 (t, 1H, J = 9.9 Hz), 5.33 
(m, 1H), 5.45 (dd, 1H, J = 10.1 and 3.5 Hz), 6.12 (d, 1H, J = 1.9 Hz), 7.38 (d, 2H, J = 9.2 
Hz) and 8.29 (d, 2H, J = 8.8 Hz); 13C NMR (CDCl3, 100 MHz) δ 20.66, 20.69, 20.8, 
61.6, 68.3, 68.6, 70.1 70.9, 90.4, 121.6, 125.4, 145.7, 151.7, 155.1, 167.9, 169.5, 169.8 
and 170.6; mass spectrum (ESI), m/z 531.1472 (M + NH4)+ (C21H27N2O14 requires m/z 
531.1462). 
 
1,2,3,6-Tetra-O-acetyl-4-O-(carbamoyloxy)-α-D-mannopyranoside (2.76). To a 
solution of 1.90 g (3.70 mmol) of carbonate 2.75 in 100 mL of dichloromethane was 
added a solution of 35 mL of anh THF that had been saturated with NH3 at 0 °C. The 
reaction mixture was allowed to warm to room temperature and then stirred at room 
temperature overnight. The solution was concentrated under diminished pressure and the 
residue was purified by flash chromatography on a silica gel column (15 × 3 cm). Elution 
with 1:1 hexanes–ethyl acetate afforded carbamate 2.76 as a colorless foam: yield 1.25 g 
(87%); silica gel TLC Rf 0.12 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 
2.03 (s, 3H), 2.09 (s, 3H), 2.16 (s, 3H), 2.17 (s, 3H), 4.03 (m, 1H), 4.17 (m, 1H), 4.29 (m, 
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1H), 4.73 (br s, 2H), 5.19 (t, 1H, J = 10.1 Hz), 5.24-5.25 (m, 1H), 5.34-5.37 (m, 1H) and 
6.07 (d, 1H, J = 1.9 Hz); 13C NMR (CDCl3, 100 MHz) δ 20.68, 20.72, 20.76, 20.85, 62.3, 
66.7, 68.4, 68.6, 70.7, 90.6, 154.9, 168.0, 169.8, 170.1 and 170.7; mass spectrum (APCI), 
m/z 392.1203 (M + H)+ (C15H22NO11 requires m/z 392.1193). 
 
2,3,6-Tri-O-acetyl-4-O-(carbamoyloxy)-α-D-mannopyranoside (2.77). To a solution 
containing 553 mg (1.41 mmol) of carbamate 2.76 in 9.2 mL of anh DMF was added 182 
mg (1.98 mmol) of hydrazine acetate. The solution was stirred at 25 °C for 2 h and then 
treated with 120 mL of ethyl acetate. The organic solution was washed successively with 
120 mL of water, 120 mL of saturated aq NaHCO3, 120 mL of brine, dried (MgSO4) and 
filtered. The solvent was concentrated under diminished pressure and co-evaporated with 
three 10-mL portions of toluene to afford pyranoside 2.77 as a colorless foam: yield 501 
mg (100%); silica gel TLC Rf 0.28 (1:3 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 
MHz) δ 2.00 (s, 3H), 2.08 (s, 3H), 2.14 (s, 3H), 4.17-4.24 (m, 3H), 4.58-4.64 (br s, 1H), 
5.10 (t, 1H, J = 9.6 Hz), 5.07-5.15 (br s, 2H), 5.20-5.22 (m, 2H) and 5.37-5.41 (m, 1H); 
mass spectrum (ESI), m/z 348.0932 (M − H)- (C13H18NO10 requires m/z 348.0931). 
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2,3,6-Tri-O-acetyl-4-O-(carbamoyloxy)-α-D-mannopyranosyl Diphenyl Phosphate 
(2.78). To a solution of 496 mg (1.42 mmol) of pyranoside 2.77 in 29 mL of 
dichloromethane at 0 °C were added 217 mg (1.78 mmol) of DMAP, 2.10 mL (15.0 
mmol) of dry triethylamine and 2.80 mL (13.6 mmol) of diphenylphosphoryl chloride. 
The reaction mixture was stirred for 1.5 h and the solution was poured into a mixture of 
40 mL of ethyl acetate and 20 mL of saturated aq NaHCO3. The organic layer was 
washed with two 10-mL portions of brine, dried (MgSO4), filtered and concentrated 
under diminished pressure to afford a crude residue. The residue was purified by flash 
chromatography on a silica gel column (20 × 3 cm). Elution with 2:3 hexanes–ethyl 
acetate afforded phosphate ester 2.78 as a colorless oil: yield 460 mg (56%); silica gel 
TLC Rf 0.33 (1:3 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.06 (s, 3H), 
2.12 (s, 3H), 2.24 (s, 3H), 4.15-4.19 (m, 1H), 4.28-4.32 (m, 1H), 4.37-4.41 (m, 1H), 4.80 
(s, 1H), 4.82-4.90 (br s, 2H), 5.21-5.30 (m, 1H), 5.41-5.50 (m, 1H), 5.95-5.97 (m, 1H), 
7.24-7.36 (m, 6H) and 7.44-7.48 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ 20.56, 20.62, 
20.7, 61.9, 66.3, 68.0, 68.7, 68.8, 70.8, 96.0, 120.01, 120.05, 120.16, 120.21, 125.7, 
125.85, 125.86, 129.93, 129.99, 169.6, 169.9 and 170.6; mass spectrum (APCI), m/z 
582.1387 (M + H)+ (C25H29NO13P requires m/z 582.1377). 
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1,3,4,6-Tetra-O-acetyl-2-O-(2,3,6-tri-O-acetyl-4-O-(carbamoyl)-α-D-
mannopyranosyl)-β-L-gulopyranose (2.79). To a solution of 460 mg (0.79 mmol) of 
phosphate ester 2.78 in 5.1 mL of dichloromethane containing 4Å molecular sieves was 
added 191 mg (0.33 mmol) of gulose alcohol 2.45 in 4.8 mL of dichloromethane. The 
solution was cooled to 0 °C and was then treated with 220 µL (1.22 mmol) of TMSOTf.  
The reaction mixture was stirred for 20 min at which time it was poured into a mixture of 
70 mL of ethyl acetate and 40 mL of saturated aq NaHCO3. The organic layer was 
washed with two 50-mL portions of brine, dried (MgSO4), filtered and concentrated 
under diminished pressure to afford a crude residue. The residue was purified by flash 
chromatography on a silica gel column (25 × 3 cm). Elution with 1:3 hexanes–ethyl 
acetate afforded 2.79 as a colorless oil. The product was isolated as a (5:1) mixture of 
anomers: yield 275 mg (51%); silica gel TLC Rf 0.26 (3:1 hexanes–ethyl acetate); 1H 
NMR (CDCl3, 400 MHz) (major anomer) δ 1.99 (s, 3H), 2.05 (s, 3H), 2.12 (s, 3H), 2.13 
(s, 6H), 2.14 (s, 3H), 2.18 (s, 3H), 3.97-4.00 (m, 1H), 4.03-4.16 (m, 2H), 4.26-4.28 (m, 
1H), 4.33-4.37 (m, 1H), 4.73 (br s, 2H), 4.94-4.97 (m, 1H), 4.99-5.01 (m, 1H), 5.06-5.09 
(m, 2H), 5.13-5.15 (m, 2H), 5.14-5.15 (m, 1H), 5.43 (t, 1H, J = 3.6 Hz) and 5.88 (d, 1H, J 
= 8.3 Hz); 13C NMR (CDCl3, 100 MHz) (mixture of anomers) δ 20.56, 20.63, 20.68, 
20.69, 20.7, 20.8, 20.9, 61.3, 62.2, 65.5, 65.89, 66.9, 67.0, 67.57, 67.60, 68.66, 68.71, 
69.4, 69.8, 71.3, 90.6, 95.1, 155.0, 155.2, 168.7, 169.24, 169.26, 169.5, 170.0, 170.4 and 
170.6; mass spectrum (FAB), m/z 680.2045 (M + H)+ (C27H38NO19 requires m/z 
680.2038).  
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3,4,6-Tri-O-acetyl-2-O-(2,3,6-tri-O-acetyl-4-O-(carbamoyl)-α-D-mannopyranosyl)-β-
L-gulopyranosyl Diphenyl Phosphate (2.80). To a solution containing 62.0 mg (0.09 
mmol) of disaccharide 2.79 in 1.5 mL of anh DMF was added 12.0 mg (0.13 mmol) of 
hydrazine acetate. The reaction mixture was stirred at room temperature for 2.5 h and 
diluted by the addition of 15 mL of ethyl acetate. The organic solution was washed with 
10 mL of brine, dried (MgSO4) and filtered. The solvent was concentrated under 
diminished pressure to afford the product as a yellow oil: yield 51 mg (88%); silica gel 
TLC Rf 0.1 (1:3 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.00 (s, 3H), 2.07 
(s, 3H), 2.12 (s, 3H), 2.13 (s, 3H), 2.14 (s, 3H), 2.17 (s, 3H), 3.74-3.77 (m, 1H), 4.11-4.19 
(m, 2H), 4.23-4.26 (m, 2H), 4.33-4.38 (m, 1H), 4.53-4.56 (br s, 2H), 4.94-4.95 (m, 1H), 
4.97-5.01 (m, 2H), 5.09-5.15 (m, 3H), 5.26-5.30 (m, 1H) and 5.39 (t, 1H, J = 3.6 Hz). 
The crude residue was used directly in the next reaction.  
To a stirred solution containing 51.0 mg (0.10 mmol) of the above residue in 3 
mL of anh dichloromethane was added 15.0 mg (0.12 mmol) of DMAP, 147 µL (106 mg, 
1.04 mmol) of dry triethylamine and 194 µL (252 mg, 0.94 mmol) of diphenylphosphoryl 
chloride. The reaction mixture was stirred at 0 °C for 2 h and was then poured into a 
mixture of 40 mL of ethyl acetate and 20 mL of saturated aq NaHCO3. The organic layer 
was washed successively with 10 mL brine, dried (MgSO4), filtered and concentrated 
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under diminished pressure to afford a crude residue. The residue was purified by flash 
chromatography on a silica gel column (20 × 2 cm). Elution with 1:2 hexanes–ethyl 
acetate afforded the phosphate ester 2.80 as a colorless oil: yield 41.0 mg (52% over two 
steps); silica gel TLC Rf 0.23 (1:3 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 
1.95 (s, 3H), 1.97 (s, 3H), 2.07 (s, 3H), 2.11 (s, 3H), 2.13 (s, 3H), 2.20 (s, 3H), 4.00 (m, 
2H), 4.12 (m, 1H), 4.19 (m, 2H), 4.30 (m, 2H), 4.97 (m, 2H), 5.09 (m, 3H), 5.22 (m, 1H), 
5.40-5.45 (br s, 2H), 5.70 (t, 1H, J = 8.0 Hz), 7.15-7.21 (m, 4H) and 7.28-7.38 (m, 6H); 
13C NMR (CDCl3, 100 MHz) δ 20.6, 20.7, 20.8, 61.1, 62.0, 65.4, 66.4, 67.4, 68.6, 68.9, 
69.2, 71.6, 95.1, 96.2, 120.18, 120.23, 120.4, 120.5, 125.6, 125.7, 129.7, 129.9, 154.9, 
169.3, 169.5, 169.8, 170.4 and 170.6; mass spectrum (APCI), m/z 870.2230 (M + H)+ 
(C37H45NO21P requires m/z 870.2222). 
 
3,4,6-Tri-O-acetyl-2-O-(2,3,6-tri-O-acetyl-4-O-(carbamoyl)-α-D-mannopyranosyl)-
α,β-L-gulopyranosyl Benzyl 2-(2-Ethoxy)ethylcarbamate (2.81). To a stirred solution 
containing 27.0 mg (0.03 mmol) of phosphate ester 2.80 in 3.9 mL of anh 
dichloromethane was added a solution of 8.20 mg (0.03 mmol) of CBz-protected linker 
2.57 in 3.9 mL of anh dichloromethane at 0 °C. To the cooled solution was added 8.20 
µL (10.1 mg, 0.04 mmol) of TMSOTf. The reaction mixture was stirred at 0 °C for 15 
min and then poured into a mixture of 20 mL of ethyl acetate and 4 mL of saturated aq 
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NaHCO3. The organic layer was washed with 10 mL of brine, dried (MgSO4), filtered 
and concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (12 × 2 cm). Elution with 1:3 hexanes−ethyl 
acetate afforded disaccharide–linker conjugate 2.81 as a colorless oil. The product was 
isolated as a mixture of anomers: yield 7.00 mg (26%); silica gel TLC Rf 0.11 (1:4 
hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) (major anomer) δ 1.99 (s, 3H), 2.04 
(s, 3H), 2.09 (s, 3H), 2.10 (s, 3H), 2.12 (s, 3H), 2.13 (s, 3H), 3.33-3.45 (br s, 2H), 3.56-
3.65 (m, 2H), 3.67-3.73 (m, 2H), 3.82-3.88 (m, 1H), 3.96 (t, 1H, J = 4.0 Hz), 4.03-4.11 
(m, 3H), 4.12-4.19 (m, 2H), 4.30 (dd, 1H, J = 12.0 and 5.7 Hz), 4.42 (t, 1H, J = 6.5 Hz), 
4.93-4.98 (m, 3H), 5.00-5.03 (m, 1H), 5.07 (s, 2H), 5.12-5.17 (m, 2H), 5.24-5.30 (m, 3H) 
and 7.30-7.36 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ 20.81, 20.89, 20.90, 20.93, 21.0, 
29.8, 41.2, 62.3, 62.9, 63.8, 65.7, 67.0, 67.1, 68.1, 68.69, 68.72, 69.6, 70.1, 71.1, 77.5, 
97.2, 97.6, 128.32, 128.38, 128.7, 136.5, 155.5, 156.9, 169.5, 169.8, 169.9, 170.2, 170.7 
and 170.8; mass spectrum (APCI), m/z 859.2975 (M + H)+ (C37H51N2O21 requires m/z 
859.2984). 
 
Disaccharide–Cy5** Conjugate 2.5. To a solution containing 2.20 mg (2.56 mmol) of 
disaccharide–linker 2.81 in 1 mL of anh methanol was added 0.1 mL of a freshly 
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prepared 25% w/w solution of sodium methoxide in methanol. The reaction mixture was 
allowed to stir at room temperature for 3 h, and the complete consumption of starting 
material was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture 
was then quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min, 
filtered and concentrated; mass spectrum (MALDI-TOF) m/z 629.30 (M + Na)+ 
(theoretical m/z 629.23). To the solution of the crude product in 5 mL of anh methanol 
was then added a catalytic amount of Pd/C and H2 gas was bubbled through for 1 h. The 
complete consumption of starting material was confirmed by MALDI-TOF mass spectral 
analysis. The reaction mixture was filtered through Celite 545® and the filtrate was 
concentrated under diminished pressure to afford amine 2.82 as a colorless oil: yield 1.32 
mg (100%), which was used directly in the next reaction; mass spectrum (MALDI-TOF) 
m/z 495.44 (M + Na)+; mass spectrum (APCI), m/z 473.1972 (M + H)+ (C17H33N2O13  
requires m/z 473.1983).  
To 101 µg (0.21 µmol) of amine 2.82 was added a solution of 106 µg (0.11 µmol) 
of Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the reaction 
mixture was stirred overnight in the dark. The reaction mixture was purified on an 
Alltech Alltima C18 reversed phase semi-preparative (250 × 10 mm, 5 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile) over a period of 35 min at 
a flow rate of 4 mL/min. The fractions containing the desired product eluted at 23.5 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give disaccharide–
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Cy5** conjugate 2.5 as a blue solid: yield 44.0 µg (32% over two steps); mass spectrum 
(APCI), m/z 669.1880 (M − K − 2H)2− (C55H78N4O26S42− requires m/z 669.1899). 
 
2,4,6-Tri-O-acetyl-3-O-(carbamoyl)-α-D-mannopyranosyl Benzyl 2- 
(Ethoxy)ethylcarbamate (2.83). To a solution of 1.87 g (3.22 mmol) of phosphate ester 
2.54 and 692 mg (2.89 mmol) of CBz-protected linker 2.57 in 50 mL of anh 
dichloromethane was added 1.10 mL (1.29 g, 5.79 mmol) of TMSOTf at 0 °C. The 
reaction mixture was stirred at 0 °C for 20 min at which time it was poured into a mixture 
of 70 mL of ethyl acetate and 28 mL of saturated aq NaHCO3.The organic layer was 
washed with two 30-mL portions of brine, dried (Na2SO4), filtered and concentrated 
under diminished pressure. The residue was purified by flash chromatography on a silica 
gel column (25 × 5 cm). Elution with 1:1→1:2→1:3 hexanes–ethyl acetate afforded 
linker conjugate 2.83 as a colorless oil: yield 1.58 g (96%); silica gel TLC Rf 0.26 (1:3 
hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.02 (s, 3H), 2.08 (s, 3H), 2.12 (s, 
3H), 3.39 (m, 2H), 3.54 (m, 2H), 3.64 (m, 3H), 3.79 (m, 1H), 4.08 (m, 2H), 4.26 (m, 1H), 
4.71 (br s, 2H), 4.91 (s, 1H), 5.10 (s, 2H), 5.25 (m, 3H), 5.37 (br s, 1H) and 7.35 (m, 5H); 
13C NMR (CDCl3, 100 MHz) δ 20.8, 20.9, 21.0, 41.1, 62.7, 66.5, 66.8, 67.3, 68.5, 70.0, 
70.1, 70.3, 70.4, 77.4, 97.6, 128.1, 128.2, 128.6, 136.8, 155.3, 170.1, 170.2 and 170.8; 
mass spectrum (APCI), m/z 571.2141 (M + H)+ (C25H35N2O13 requires m/z 571.2139). 
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BLM Monosaccharide–Cy5** (2.8). To a solution of 4.60 mg (8.06 µmol) of 
monosaccharide–linker 2.83 in 2 mL of anh methanol was added 0.20 mL of a freshly 
prepared 25% w/w solution of sodium methoxide in methanol. The reaction mixture was 
allowed to stir at room temperature for 2.5 h, and the complete consumption of starting 
material was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture 
was then quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min, 
filtered and concentrated; mass spectrum (MALDI-TOF), m/z 467.27 (M + Na)+; mass 
spectrum (APCI), m/z 445.1815 (M + H)+ (C19H29N2O10 requires m/z 445.1822). To the 
solution of the crude product in 5 mL of anh methanol was added Pd/C and H2 gas was 
bubbled through for 45 min. The complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was filtered 
through Celite 545® and the filtrate was concentrated under diminished pressure to afford 
2.84 as a colorless oil: yield 2.50 mg (100%), which was used directly for the next 
reaction; mass spectrum (MALDI-TOF), m/z 333.22 (M + Na)+; mass spectrum (APCI), 
m/z 311.1455 (M + H)+ (C11H23N2O8 requires m/z 311.1454).  
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To 122 µg (0.39 µmol) of 2.84 was added a solution of 110 µg (0.11 µmol) of 
Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the reaction 
mixture was stirred overnight in the dark. The reaction mixture was purified on an 
Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile) over a period of 35 min at 
a flow rate of 4.5 mL/min. The fractions containing the desired product eluted at 22.5 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give BLM 
monosaccharide–Cy5** (2.8) as a blue solid: yield 50.0 µg (36% over two steps); mass 
spectrum (MALDI-TOF), m/z 1201.47 (M − H + Na)+, 1223.47 (M − 2H + 2Na)+, 
1245.45 (M − 3H + 3Na)+ and 1267.43 (M − 4H + 4Na)+; mass spectrum (ESI), m/z 
588.1614 (M − 3H)2− (C49H68N4O21S42− requires m/z 588.1629).  
 
Penta-O-acetyl-α-D-mannopyranose (2.85).131 To a solution containing 1.00 g (5.15 
mmol) of methyl-α-D-mannopyranose (2.46) in 19.0 mL of acetic anhydride was added a 
catalytic amount of concentrated H2SO4, and the solution was stirred at room temperature 
for 12 h. The reaction mixture was poured into a stirred mixture of 150 mL of ethyl 
acetate and 80 mL of saturated aq NaHCO3. The organic layer was washed with 40 mL of 
saturated aq NaHCO3, 30 mL of brine, then dried (Na2SO4) and concentrated under 
diminished pressure. The residue was purified by flash chromatography on a silica gel 
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column (18 × 5 cm). Elution with 5:1→3:1 hexanes–ethyl acetate afforded mannose 2.85 
as a colorless oil: yield 1.97 g (98%); silica gel TLC Rf 0.60 (1:2 hexanes–ethyl acetate); 
1H NMR (CDCl3, 400 MHz) δ 1.86 (s, 3H), 1.91 (s, 3H), 1.95 (m, 3H), 2.04 (m, 6H), 
3.94 (m, 2H), 4.13 (m, 1H), 5.12 (s, 1H), 5.20 (m, 2H) and 5.94 (s, 1H); 13C NMR 
(CDCl3, 100 MHz) δ 20.40, 20.43, 20.47, 20.53, 20.6, 61.9, 65.3, 68.1, 68.6, 70.4, 76.8, 
77.2, 77.5, 167.8, 169.3, 169.5, 169.7 and 170.3.  
 
2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl Diphenyl Phosphate (2.86).132 To a 
solution of 525 mg (1.34 mmol) of mannose 2.85 in 8.1 mL of dry DMF was added 170 
mg (1.88 mmol) of hydrazine acetate. The reaction was stirred at room temperature for 2 
h until analysis by silica gel TLC indicated it was complete. The reaction mixture was 
diluted with 50 mL of ethyl acetate and washed with three 20-mL portions of brine. The 
aqueous layer was re-extracted with three 30-mL portions of ethyl acetate. The combined 
organic layer was dried (Na2SO4), filtered and concentrated under diminished pressure to 
afford the pyranoside as a colorless oil; silica gel TLC Rf 0.39 (3:1 hexanes–ethyl 
acetate). 
 To the solution of 397 mg (1.14 mmol) of the above residue alcohol in 16.5 mL 
of dry dichloromethane was added 180 mg (1.47 mmol) of DMAP and 1.6 mL (11.4 
mmol) of dry triethylamine. The reaction mixture was stirred for 10 min, followed by the 
addition of 2.30 mL (10.9 mmol) of diphenyl chlorophosphate dropwise at 0 °C. The 
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solution was stirred at 0 °C for 1.5 h and was poured into a mixture of 100 mL of ethyl 
acetate and 50 mL of saturated aq NaHCO3 soln. The organic layer was washed with two 
30-mL portions of brine, dried (Na2SO4), filtered, and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel column (18 × 
5 cm). Elution with 3:1→2:1 hexanes–ethyl acetate afforded phosphate ester 2.86 as a 
colorless oil: yield 424 mg (54% over two steps); silica gel TLC Rf 0.54 (3:1 hexanes–
ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.04 (s, 3H), 2.06 (s, 3H), 2.10 (s, 3H), 2.22 
(s, 3H), 3.98 (dd, 1H, J = 12.4 and 2.0 Hz), 4.14 (m, 1H), 4.25 (dd, 1H, J = 12.4 and 4.8 
Hz), 5.40 (m, 3H), 5.92 (dd, 1H, J = 6.8 and 1.6 Hz), 7.28-7.33 (m, 6H) and 7.40-7.45 
(m, 4H); 13C NMR (CDCl3, 100 MHz) δ 20.70, 20.72, 20.78, 20.84, 61.8, 65.2, 68.3, 
68.7, 68.8, 70.9, 96.17, 96.22, 120.18, 120.22, 120.3, 120.4, 125.90, 125.91, 126.0, 130.1, 
130.2, 169.6, 169.9 and 170.7.  
 
2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyl Benzyl 2-(2-Ethoxy)ethylcarbamate 
(2.87). To a solution of 300 mg (0.52 mmol) of phosphate ester 2.86 and 111 mg (0.46 
mmol) of the CBz-protected linker 2.57 in 5.5 mL of anhydrous dichloromethane was 
added 168 µL (207 mg, 0.93 mmol) of TMSOTf at 0 °C. The reaction was stirred at 0 °C 
for 18 min and was then poured into a mixture of 100 mL of ethyl acetate and 40 mL of 
saturated aq NaHCO3. The organic layer was washed with two 40-mL portions of brine, 
dried (Na2SO4), filtered and concentrated under diminished pressure. The residue was 
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purified by flash chromatography on a silica gel column (25 × 2.5 cm). Elution with 
2:1→1:2 hexanes–ethyl acetate afforded linker conjugate 2.87 as a colorless oil: yield 
110 mg (37%); silica gel TLC Rf 0.35 (1:3 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 
MHz) δ 1.98 (s, 3H), 2.00 (s, 3H), 2.08 (s, 3H), 2.13 (s, 3H), 3.40 (m, 2H), 3.53 (m, 2H), 
3.62 (m, 3H), 3.77 (m, 1H), 4.06 (m, 1H), 4.11 (m, 1H), 4.24 (m, 1H), 4.87 (br s, 1H), 
5.08 (s, 2H), 5.24 (m, 2H), 5.35 (m, 2H) and 7.26-7.34 (m, 5H); 13C NMR (CDCl3, 100 
MHz) δ 20.80, 20.82, 20.9, 21.0, 39.4, 41.1, 62.7, 66.4, 66.8, 67.2, 68.6, 69.1, 69.8, 70.1, 
70.4, 97.7, 128.2, 128.6, 136.8, 169.9, 170.0, 170.3, 170.8 and 170.9; mass spectrum 
(MALDI-TOF), m/z 592.34 (M + Na)+; mass spectrum (APCI), m/z 570.2182 (M + H)+ 
(C26H36NO13 requires m/z 570.2187).  
 
Decarbamoyl BLM Monosaccharide–Cy5** (2.9). To a solution of 8.90 mg (15.6 
µmol) of linker 2.87 in 2.00 mL of anh methanol was added 0.20 mL of a freshly 
prepared 25% w/w solution of sodium methoxide in methanol. The reaction mixture was 
allowed to stir at room temperature for 2.5 h, and the complete consumption of starting 
material was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture 
was then quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min, 
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filtered and concentrated; mass spectrum (MALDI-TOF) m/z 424.24 (M + Na)+; mass 
spectrum (APCI), m/z 402.1759 (M + H)+ (C18H28NO9 requires m/z 402.1764). To a 
solution of the crude product in 5 mL of anh methanol was added Pd/C and H2 gas was 
bubbled through for 45 min. The complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was filtered 
through Celite 545® and then concentrated under diminished pressure to afford amine 
2.88 as a colorless oil: yield 4.17 mg (100%), which was used for the next reaction; mass 
spectrum (MALDI-TOF), m/z 268.25 (M + H)+ and 290.25 (M + Na)+; mass spectrum 
(APCI), m/z 268.1391 (M + H)+ (C10H22NO7 requires m/z 268.1396).  
To 152 µg (0.57 µmol) of amine 2.88 was added a solution of 110 µg (0.11 µmol) 
of Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the reaction 
mixture was stirred overnight in the dark. The reaction mixture was purified on an 
Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile) over a period of 35 min at 
a flow rate of 4.5 mL/min. The fractions containing the desired product eluted at 19.5 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give decarbamoyl 
BLM monosaccharide–Cy5** (2.9) as a blue solid: yield 39.0 µg (30% over two steps); 
mass spectrum (MALDI-TOF), m/z 1158.40 (M − H + Na)+ and 1180.47 (M − 2H + 
2Na)+; mass spectrum (ESI), m/z 1136.3409 (M)+ (C48H70N3O20S4 requires m/z 
1136.3435). 
 
 
139 
 
BLM Monosaccharide Trimer (2.91). H2 gas was bubbled through a mixture containing 
36.0 mg (21.0 µmol) of monosaccharide–linker 2.83 and a catalytic amount of Pd/C in 6 
mL of dry THF for 45 min. The reaction mixture was filtered through a pad of Celite 
545® and the filtrate was concentrated under diminished pressure to obtain amine 2.89 as 
a colorless oil, which was used immediately in the next step: crude yield 27.0 mg (99%); 
silica gel TLC Rf 0.29 (1:3 hexanes–ethyl acetate); mass spectrum (MALDI-TOF), m/z 
459.26 (M + Na)+; mass spectrum (APCI), m/z 437.1768 (M + H)+ (C17H29N2O11 requires 
m/z 437.1772).  
To a solution containing 27.0 mg (61.8 µmol) of amine 2.89 in 0.53 mL of dry 
DMF were added 13.0 µL (0.09 mmol) of dry triethylamine and 15.2 mg (20.4 µmol) of 
NHS ester of the trimeric linker 2.90130 and the reaction mixture was stirred at room 
temperature for 24 h. The reaction mixture was concentrated under diminished pressure. 
The residue was purified by flash chromatography on a silica gel column (15 × 1.5 cm). 
Elution with 16:12:1→11:12:1 chloroform–acetone–methanol afforded BLM 
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monosaccharide trimer−linker conjugate 2.91 as a colorless oil: yield 15.0 mg (43%); 
silica gel TLC Rf 0.56 (4:4:1 chloroform–acetone–methanol); mass spectrum (MALDI-
TOF), m/z 1730.76 (M + Na)+; mass spectrum (ESI), m/z 854.3351 (M + 2H)2+ 
(C72H108N8O39 requires m/z 854.3357).  
 
BLM Monosaccharide–Cy5** Trimer (2.10). To a solution of 4.20 mg (2.46 µmol) of 
linker 2.91 in 2 mL of anh methanol was added 200 µL of a freshly prepared 25% w/w 
solution of sodium methoxide in methanol. The reaction mixture was allowed to stir at 
room temperature for 2.5 h, and the complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was then 
quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min, filtered and 
concentrated; mass spectrum (MALDI-TOF), m/z 1351.40 (M + Na)+ (theoretical m/z 
1328.56). To the solution of the crude product in 5 mL of anh methanol was added Pd/C 
and H2 gas was bubbled through for 45 min. The complete consumption of starting 
material was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture 
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was filtered through Celite 545® and then concentrated under diminished pressure to 
afford amine 2.92 as a colorless oil: yield 2.90 mg (100%), which was used directly for 
the next reaction; mass spectrum (MALDI-TOF), m/z 1217.62 (M + Na)+; mass spectrum 
(ESI), m/z 1229.4961 (M + Cl)- (C46H82N8O28Cl requires m/z 1229.4927).  
To 540 µg (0.448 µmol) of amine 2.92 was added a solution of 110 µg (0.11 
µmol) of Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the 
reaction mixture was stirred overnight in the dark. The reaction mixture was purified on 
an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile) over a period of 28 min at 
a flow rate of 4.5 mL/min. The fractions containing the desired product eluted at 21.0 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give BLM 
monosaccharide–Cy5** trimer 2.10 as a blue solid: yield 77.0 µg (33%); mass spectrum 
(MALDI-TOF), m/z 2085.85 (M + Na − H)+ and 2107.85 (M + 2Na − 2H)+; mass 
spectrum (ESI), m/z 686.6584 (M − 4H)3− (C84H127N10O41S4 requires m/z 686.5679). 
 
2-(2-(2-Hydroxyethoxy)ethyl)isoindoline-1,3-dione (2.93).133 To a solution of 2.10 g 
(19.9 mmol) of 2-(2-aminoethyl)-ethanol in 90 mL dry toluene was added 2.95 g (19.9 
mmol) of phthalic anhydride. The resulting solution was then heated under reflux for 6 h 
with Dean-Stark apparatus. The reaction mixture was allowed to cool, dried (MgSO4), 
filtered, and concentrated under diminished pressure to afford protected linker 2.93 as a 
OHO N
O
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white solid: yield 4.67 g (99%); silica gel TLC Rf 0.35 (1:2 hexanes–ethyl acetate); 1H 
NMR (CDCl3, 400 MHz) δ 3.61 (m, 2H), 3.69 (m, 2H), 3.75 (t, 2H, J = 5.3 Hz), 3.91 (t, 
2H, J = 5.3 Hz), 7.73 (m, 2H) and 7.85 (m, 2H). 
 
3,4,6-Tri-O-acetyl-2-O-benzyl-α-D-mannopyranosyl 2-(2-(Ethoxy)ethyl)isoindoline-
1,3-dione (2.94). To a solution of 1.11 g (1.77 mmol) of phosphate ester 2.64 and 374 mg 
(1.59 mmol) of the alcohol 2.93 in 30 mL of anh dichloromethane was added 0.58 mL 
(707 mg, 3.18 mmol) of TMSOTf at 0 °C. The reaction was stirred at 0 °C for 20 min and 
was then poured into a mixture of 150 mL of ethyl acetate and 60 mL of saturated aq 
NaHCO3. The organic layer was washed with two 20-mL portions of brine, dried 
(MgSO4), filtered and concentrated under diminished pressure. The residue was purified 
by flash chromatography on a silica gel column (22 × 5 cm).  Elution with 4:1→1:1 
hexanes–ethyl acetate afforded monosaccharide 2.94 as a colorless oil: yield 860 mg 
(79%); silica gel TLC Rf 0.41 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 
1.91 (s, 3H), 1.96 (s, 3H), 2.00 (s, 3H), 3.54 (m, 3H), 3.67 (m, 3H), 3.78 (m, 1H), 3.82 
(m, 1H), 3.88 (m, 1H), 4.00 (m, 1H), 4.16 (m, 1H), 4.57 (q, 2H, J = 12.0 Hz), 4.82 (d, 
1H, J = 1.2 Hz), 5.16 (m, 1H), 5.32 (t, 1H, J = 10.0 Hz), 7.22-7.30 (m, 5H), 7.63 (m, 2H) 
and 7.76 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 20.83, 20.85, 20.9, 37.3, 62.8, 66.7, 
67.0, 68.1, 68.6, 69.6, 71.3, 73.1, 75.5, 98.0, 123.3, 127.9, 127.9, 128.4, 132.2, 133.0, 
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137.9, 168.3, 169.8, 170.2 and 170.9; mass spectrum (ESI), m/z 636.2040 (M + Na)+ 
(C31H35NO12Na requires m/z 636.2057). 
 
3,4,6-Tri-O-acetyl-α-D-mannopyranosyl 2-(2-(Ethoxy)ethyl)isoindoline-1,3-dione 
(2.95). To a solution of 860 mg (1.40 mmol) of monosaccharide 2.94 in 23 mL of ethyl 
acetate was added 420 mg of Pd(OH)2/C and the reaction was placed under 1 atm of H2 
(g) overnight. The catalyst was removed by filtration through a pad of Celite 545® and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (18 × 3.5 cm). Elution with 3:1→1:1 hexanes–
ethyl acetate afforded alcohol 2.95 as a colorless foam: yield 601 mg (82%); silica gel 
TLC Rf 0.13 (1:1 hexanes–ethyl acetate). 1H NMR (CDCl3, 400 MHz) δ 1.97 (s, 3H), 
2.01 (2s, 6H), 2.94 (br s, 1H), 3.60 (m, 3H), 3.69 (m, 3H), 3.84 (m, 2H), 3.94 (m, 1H), 
4.00 (m, 2H), 4.20 (m, 1H), 4.84 (d, 1H, J = 2.0 Hz), 5.17 (m, 1H), 5.28 (t, 1H, J = 10.0 
Hz), 7.67 (m, 2H) and 7.80 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 20.73, 20.77, 20.9, 
37.4, 62.6, 66.3, 67.0, 68.1, 68.3, 69.1, 69.7, 71.6, 99.9, 123.3, 132.0, 134.0, 168.3, 169.9, 
170.0 and 170.9; mass spectrum (ESI), m/z 546.1596 (M + Na)+ (C24H29NO12Na requires 
m/z 546.1588). 
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3,4,6-Tri-O-acetyl-2-O-((p-nitrophenyl)carbamoyl)-α-D-mannopyranosyl 2-(2-
(Ethoxy)ethyl)isoindoline-1,3-dione (2.96). To a solution of 461 mg (0.88 mmol) of 
alcohol 2.95 in 4.8 mL of dry pyridine was added 430 mg (3.52 mmol) of DMAP and 710 
mg (3.52 mmol) of p-nitrophenyl chloroformate. The reaction was stirred at 40 °C 
overnight until the analysis by silica gel TLC indicated it was complete. The solution was 
cooled and poured into a mixture of 20 mL ethyl acetate and 5 mL of water. The organic 
layer was washed successively with three 10-mL portions of 1N HCl, 5 mL of saturated 
aq NaHCO3 and 5 mL of brine. The solution was dried (MgSO4), filtered, and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (30 × 2.5 cm). Elution with 4:1→1:1 hexanes–
ethyl acetate afforded carbonate 2.96 as a white foam: yield 443 mg (73%); silica gel 
TLC Rf 0.55 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.02 (s, 3H), 
2.05 (s, 3H), 2.07 (s, 3H), 3.66 (m, 2H), 3.72 (m, 3H), 3.79 (m, 1H), 3.89 (m, 2H), 4.06 
(m, 2H), 4.17 (m, 1H), 5.08 (m, 1H), 5.18 (m, 1H), 5.30 (t, 1H, J = 10.0 Hz), 5.41 (m, 
1H), 7.44 (d, 2H, J = 9.2 Hz), 7.70 (m, 2H) 7.84 (m, 2H) and 8.29 (d, 2H, J = 9.2 Hz); 
13C NMR (CDCl3, 100 MHz) δ 20.83, 20.85, 20.86, 37.5, 62.4, 66.0, 67.3, 68.4, 68.6, 
69.1, 69.8, 74.5, 97.2, 121.9, 123.4, 125.5, 132.2, 134.1, 145.7, 152.1, 155.5, 168.4, 169.8 
and 170.8; mass spectrum (APCI), m/z 689.1817 (M + H)+ (C31H33N2O16 requires m/z 
689.1830). 
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3,4,6-Tri-O-acetyl-2-O-(methylcarbamoyl)-α-D-mannopyranosyl 2-(2-
(Ethoxy)ethyl)isoindoline-1,3-dione (2.97). To a solution containing 166 mg (0.24 
mmol) of carbamate 2.96 in 7.6 mL of anh THF was added 0.12 mL (0.24 mmol) of 2 M 
solution of methylamine in THF dropwise at 0 °C. The reaction mixture was allowed to 
warm to room temperature and then stirred overnight at room temperature. The solvent 
was concentrated under diminished pressure and was purified by flash chromatography 
on a silica gel column (18 × 2.5 cm). Elution with 3:1→1:2 hexanes–ethyl acetate 
afforded monosaccharide 2.97 as a colorless foam: yield 125 mg (89%); silica gel TLC Rf 
0.11 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 1.96 (s, 3H), 2.01 (s, 
3H), 2.04 (s, 3H), 2.77 (d, 3H, J = 4.8 Hz), 3.62 (m, 3H), 3.71 (m, 3H), 3.89 (m, 2H), 
4.01 (m, 2H), 4.27 (m, 1H), 4.85 (s, 1H), 4.89 (q, 1H, J = 4.8 Hz), 5.11 (m, 1H), 5.21 (m, 
1H), 5.28 (m, 1H), 7.68 (m, 2H) and 7.82 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 20.80, 
20.85, 27.6, 37.3, 62.6, 64.4, 66.2, 67.2, 68.1, 68.3, 69.4, 70.1, 77.4, 98.1, 123.4, 132.2, 
134.0, 155.8, 168.2, 169.9, 169.9 and 170.8; mass spectrum (ESI), m/z 603.1797 (M + 
Na)+ (C26H32N2O13Na requires m/z 603.1802). 
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3,4,6-Tri-O-acetyl-2-O-(dimethylcarbamoyl)-α-D-mannopyranosyl 2-(2-
(Ethoxy)ethyl)isoindoline-1,3-dione (2.98).  To a solution containing 180 mg (0.26 
mmol) of carbamate 2.96 in 8.2 mL of anh THF was added 0.13 mL (0.26 mmol) of 2 M 
solution of dimethylamine in THF dropwise at 0 °C. The reaction mixture was allowed to 
warm to room temperature and then stirred overnight at room temperature. The solvent 
was concentrated under diminished pressure and was purified by flash chromatography 
on a silica gel column (18 × 2.5 cm). Elution with 3:1→1:2 hexanes–ethyl acetate 
afforded monosaccharide 2.98 as a colorless foam: yield 125 mg (80%); silica gel TLC Rf 
0.15 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 1.95 (s, 3H), 2.01 (2s, 
6H), 2.88 (s, 3H), 2.96 (s, 3H), 3.61 (m, 3H), 3.72 (m, 3H), 3.86 (m, 2H), 4.02 (m, 2H), 
4.25 (m, 1H), 4.85 (d, 1H, J = 1.6 Hz), 5.08 (m, 1H), 5.28 (m, 2H), 7.68 (m, 2H) and 7.81 
(m, 2H); 13C NMR (CDCl3, 100 MHz) δ 20.7, 20.80, 20.84, 36.0, 36.6, 37.3, 62.5, 66.2, 
67.3, 68.1, 68.4, 69.39, 69.41, 70.6, 97.9, 123.3, 132.2, 134.0, 155.2, 168.2, 169.87, 
169.92 and 170.6; mass spectrum (ESI), m/z 617.1963 (M + Na)+ (C27H34N2O13Na 
requires m/z 617.1959). 
 
3,4,6-Tri-O-acetyl-2-O-(butylcarbamoyl)-α-D-mannopyranosyl 2-(2-
(Ethoxy)ethyl)isoindoline-1,3-dione (2.99). To a solution containing 41.0 mg (0.06 
mmol) of carbamate 2.96 in 1.9 mL of anh THF was added 30.0 µL (0.06 mmol) of 2 M 
solution of butylamine in THF dropwise at 0 °C. The reaction mixture was allowed to 
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warm to room temperature and then stirred overnight at room temperature. The solvent 
was concentrated under diminished pressure and was purified by flash chromatography 
on a silica gel column (18 × 2 cm). Elution with 3:1→1:2 hexanes–ethyl acetate afforded 
monosaccharide 2.99 as a colorless foam: yield 27.0 mg (73%); silica gel TLC Rf 0.17 
(1:1 hexanes–ethyl acetate); 1H (CDCl3, 400 MHz) δ 0.91 (t, 3H, J = 7.2 Hz), 1.35 (m, 
2H), 1.48 (m, 2H), 1.98 (s, 3H), 2.03 (s, 3H), 2.06 (s, 3H), 3.16 (q, 2H, J = 6.8 Hz), 3.63 
(m, 3H), 3.75 (m, 3H), 3.89 (m, 2H), 4.04 (m, 2H), 4.30 (m, 1H), 4.87 (s, 2H), 5.13 (br s, 
1H), 5.27 (m, 2H), 7.70 (m, 2H) and 7.84 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 13.8, 
20.0, 20.8, 20.87, 20.92, 29.8, 32.0, 37.3, 41.0, 62.7, 66.4, 67.3, 68.2, 68.4, 69.4, 69.5, 
70.0, 98.2, 123.4, 132.2, 134.0, 155.3, 168.3, 170.0 and 170.8; mass spectrum (ESI), m/z 
645.2278 (M + Na)+ (C29H38N2O13Na requires m/z 645.2272). 
 
3,4,6-Tri-O-acetyl-2-O-(pyrrolidinylcarbamoyl)-α-D-mannopyranosyl 2-(2-
(Ethoxy)ethyl)isoindoline-1,3-dione (2.100). To a solution containing 80.0 mg (0.12 
mmol) of carbamate 2.96 in 3.7 mL of anh THF was added 10.0 µL (0.12 mmol) of 
pyrrolidine at 0 °C. The reaction mixture was allowed to warm to room temperature and 
then stirred overnight at room temperature. The solvent was concentrated under 
diminished pressure and was purified by flash chromatography on a silica gel column (18 
× 2.5 cm). Elution with 3:1→1:2 hexanes–ethyl acetate afforded monosaccharide 2.100 
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as a colorless foam: yield 69.0 mg (96%); silica gel TLC Rf 0.19 (1:1 hexane–ethyl 
acetate); 1H NMR (CDCl3, 400 MHz) δ 1.88 (m, 4H), 1.96 (s, 3H), 2.01 (s, 3H), 2.03 (s, 
3H), 3.35 (m, 2H), 3.45 (s, 2H), 3.62 (m, 3H), 3.71 (m, 3H), 3.89 (m, 2H), 4.04 (m, 2H), 
4.26 (m, 1H), 4.87 (s, 1H), 5.11 (m, 1H), 5.31 (m, 2H), 7.68 (m, 2H) and 7.82 (m, 2H); 
13C NMR (CDCl3, 100 MHz) δ 20.75, 20.83, 20.9, 25.0, 25.7, 37.3, 46.0, 46.3, 62.6, 66.3, 
67.3, 68.1, 68.4, 69.41, 69.45, 70.2, 98.0, 123.4, 132.2, 134.0, 153.6, 168.3, 169.95, 
169.98 and 170.7; mass spectrum (ESI), m/z 643.2123 (M + Na)+ (C29H36N2O13Na 
requires m/z 643.2115). 
 
3,4,6-Tri-O-acetyl-2-O-(hexylcarbamoyl)-α-D-mannopyranosyl 2-(2-
(Ethoxy)ethyl)isoindoline-1,3-dione (2.101). To a solution containing 43.0 mg (0.06 
mmol) of carbamate 2.96 in 2 mL of anh THF was added 31.0 µL (0.06 mmol) of 2 M 
solution of hexylamine in THF dropwise at 0 °C. The reaction mixture was allowed to 
warm to room temperature and then stirred overnight at room temperature. The solvent 
was concentrated under diminished pressure and was purified by flash chromatography 
on a silica gel column (18 × 2 cm). Elution with 3:1→1:2 hexanes–ethyl acetate afforded 
monosaccharide 2.101 as a colorless oil: yield 25.0 mg (62%); silica gel TLC Rf 0.23 (1:1 
hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 0.88 (m, 3H), 1.24-1.35 (m, 7H), 
1.99 (s, 3H), 2.04 (s, 3H), 2.07 (s, 3H), 2.39 (m, 1H), 3.15 (m, 2H), 3.64 (m, 3H), 3.73 
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(m, 3H), 3.90 (m, 2H), 4.05 (m, 2H), 4.30 (m, 1H), 4.88 (m, 2H), 5.14 (s, 1H), 5.27 (m, 
2H), 7.71 (m, 2H) and 7.85 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 14.1, 20.88, 20.89, 
20.93, 22.7, 26.5, 29.9, 31.6, 37.35, 37.40, 41.4, 62.7, 66.4, 67.3, 68.2, 68.3, 68.4, 69.46, 
69.51, 69.6, 70.0, 98.2, 123.4, 132.3, 134.1, 155.28, 168.3, 170.0 and 170.9; mass 
spectrum (APCI), m/z 651.2771 (M + H)+ (C31H43N2O13 requires m/z 651.2765). 
 
Monosaccharide–Cy5** Conjugate 2.11. To a solution of 9.00 mg (15.5 µmol) of 
compound 2.97 in 2 mL of anh methanol was added 0.2 mL of 25% w/w freshly prepared 
solution of sodium methoxide in methanol. The reaction mixture was allowed to stir at 
room temperature for 2.5 h, and the complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was then 
quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min, filtered and 
concentrated; mass spectrum (MALDI-TOF), m/z 477.33 (M + Na)+; mass spectrum 
(APCI), m/z 445.1661 (M + H)+ (C20H27N2O10 requires m/z 445.1665). To the solution of 
the crude product in 0.2 mL of ethanol was added 0.48 µL (15.5 µmol) of hydrazine 
hydrate and stirred at 60 °C overnight. The complete consumption of starting material 
was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was filtered 
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and concentrated under diminished pressure to afford 2.102 as a colorless oil: yield 4.90 
mg (100%), which was used for the next reaction; mass spectrum (MALDI-TOF), m/z 
347.12 (M + Na)+. 
To 191 µg (0.59 µmol) of 2.102 was added a solution of 110 µg (0.11 µmol) of 
Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the reaction 
mixture was stirred overnight in the dark. The reaction mixture was purified on an 
Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile) over a period of 28 min at 
a flow rate of 4.5 mL/min. The fractions containing the desired product eluted at 19.4 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give 
monosaccharide–Cy5** conjugate 2.11 as a blue solid: yield 34.0 µg (25%); mass 
spectrum (MALDI), m/z 1193.34 (M)+ and 1215.33 (M − H + Na)+; mass spectrum (ESI), 
m/z 396.4448 (M − 3H)3− (C50H72N4O21S43− requires m/z 396.4446). 
 
Monosaccharide–Cy5** Conjugate 2.12. To a solution of 9.00 mg (15.1 µmol) of 
compound 2.98 in 2 mL of anh methanol was added 0.2 mL of 25% w/w freshly prepared 
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solution of sodium methoxide in methanol. The reaction mixture was allowed to stir at 
room temperature for 2.5 h, and the complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was then 
quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min, filtered and 
concentrated; mass spectrum (MALDI-TOF), m/z 491.32 (M + Na)+; mass spectrum 
(APCI), m/z 491.1639 (M + Na)+ (C21H28N2O10Na requires m/z 491.1642). To the 
solution of the crude product in 0.2 mL of ethanol was added 0.48 µL (15.1 µmol) of 
hydrazine hydrate and stirred at 60 °C overnight. The complete consumption of starting 
material was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture 
was filtered and concentrated under diminished pressure to afford 2.103 as a colorless oil: 
yield 5.00 mg (100%), which was used for the next reaction; mass spectrum (MALDI-
TOF), m/z 339.22 (M + H)+; mass spectrum (APCI), m/z 339.1773 (M + H)+ (C13H27N2O8 
requires m/z 339.1767). 
To 192 µg (0.57 µmol) of 2.103 was added a solution of 110 µg (0.11 µmol) of 
Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the reaction 
mixture was stirred overnight in the dark. The reaction mixture was purified on an 
Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile) over a period of 28 min at 
a flow rate of 4.5 mL/min. The fractions containing the desired product eluted at 21.0 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give 
monosaccharide–Cy5** conjugate 2.12 as a blue solid: yield 30.0 µg (22%); mass 
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spectrum (MALDI), m/z 1208.36 (M)+ and 1246.34 (M − H + K)+; mass spectrum (ESI), 
m/z 401.1162 (M − 3H)3− (C51H74N4O21S43− requires m/z 401.1165). 
 
Monosaccharide–Cy5** Conjugate 2.13. To a solution of 10.0 mg (16.1 µmol) of 
compound 2.99 in 2 mL of anh methanol was added 0.2 mL of 25% w/w freshly prepared 
solution of sodium methoxide in methanol. The reaction mixture was allowed to stir at 
room temperature for 2.5 h, and the complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was then 
quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min, filtered and 
concentrated; mass spectrum (MALDI-TOF), m/z 519.40 (M + Na)+; mass spectrum 
(ESI), m/z 519.1958 (M + Na)+ (C23H32N2O10Na requires m/z 519.1954). To the solution 
of the crude product in 0.5 mL of ethanol was added 0.50 µL (16.0 µmol) of hydrazine 
hydrate and stirred at 60 °C overnight. The complete consumption of starting material 
was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was filtered 
and concentrated under diminished pressure to afford 2.104 as a colorless oil: yield 5.10 
mg (98%), which was used for the next reaction; mass spectrum (APCI), m/z 367.2078 
(M + H)+ (C15H31N2O8 requires m/z 367.2080). 
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To 221 µg (0.60 µmol) of 2.104 was added a solution of 110 µg (0.11 µmol) of 
Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer and the reaction mixture was 
stirred overnight in the dark. The reaction mixture was purified on an Econosil C18 
reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column using aq 0.1% 
TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 0.1% aq 
TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile) over a period of 28 min at a flow 
rate of 4.5 mL/min. The fractions containing the desired product eluted at 19.3 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give 
monosaccharide–Cy5** 2.13 as a blue solid: yield 73.0 µg (52%); mass spectrum 
(MALDI-TOF), m/z 1235.45 (M)+; mass spectrum (ESI), m/z 1279.3722 (M − 2H + 
2Na)+ (C53H77N4O21S4Na2 requires m/z 1279.3753).  
 
Monosaccharide–Cy5** Conjugate 2.14. To a solution of 18.0 mg (29.0 µmol) of 
compound 2.100 in 4 mL of anh methanol was added 0.4 mL of 25% w/w freshly 
prepared solution of sodium methoxide in methanol. The reaction mixture was allowed to 
stir at room temperature for 2.5 h, and the complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was then 
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quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min, filtered and 
concentrated; mass spectrum (ESI), m/z 517.1808 (M + Na)+ (C23H30N2O10Na requires 
m/z 517.1798). To the solution of the crude product in 0.4 mL of ethanol was added 0.90 
µL (29.0 µmol) of hydrazine hydrate and stirred at 60 °C overnight. The complete 
consumption of starting material was confirmed by MALDI-TOF mass spectral analysis. 
The reaction mixture was filtered and concentrated under diminished pressure to afford 
2.105 as a colorless oil: yield 10.0 mg (95%), which was used for the next reaction; mass 
spectrum (APCI), m/z 365.1926 (M + H)+ (C15H29N2O8 requires m/z 365.1924). 
To 220 µg (0.60 µmol) of 2.105 was added a solution of 110 µg (0.11 µmol) of 
Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the reaction 
mixture was stirred overnight in the dark. The reaction mixture was purified on an 
Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile) over a period of 35 min at 
a flow rate of 4.5 mL/min. The fractions containing the desired product eluted at 20.7 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give 2.14 as a blue 
solid: yield 75.0 µg (54%); mass spectrum (MALDI-TOF), m/z 1255.47 (M − H + Na)+, 
1277.55 (M − 2H + 2Na)+ and 1299.49 (M − 3H + 3Na)+; mass spectrum (ESI), m/z 
1233.4021 (M)+ (C53H77N4O21S4 requires m/z 1233.3958). 
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Monosaccharide–Cy5** Conjugate 2.15. To a solution of 3.70 mg (5.69 µmol) of 
compound 2.101 in 1 mL of anh methanol was added 0.1 mL of 25% w/w freshly 
prepared solution of sodium methoxide in methanol. The reaction mixture was allowed to 
stir at room temperature for 2.5 h, and the complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was then 
quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min, filtered and 
concentrated; mass spectrum (MALDI-TOF), m/z 547.57 (M + Na)+; mass spectrum 
(APCI), m/z 525.2447 (M + H)+ (C25H37N2O10 requires m/z 525.2448). To the solution of 
the crude product in 0.2 mL of ethanol was added 0.18 µL (5.70 µmol) of hydrazine 
hydrate and stirred at 60 °C overnight. The complete consumption of starting material 
was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was filtered 
and concentrated under diminished pressure to afford 2.106 as a colorless oil: yield 2.24 
mg (99%), which was used for the next reaction; mass spectrum (MALDI-TOF), m/z 
395.30 (M + H)+; mass spectrum (APCI), m/z 395.2402 (M + H)+ (C17H35N2O8 requires 
m/z 395.2393). 
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To 220 µg (0.57 µmol) of 2.106 was added a solution of 110 µg (0.11 µmol) of 
Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the reaction 
mixture was stirred overnight in the dark. The reaction mixture was purified on an 
Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile) over a period of 28 min at 
a flow rate of 4.5 mL/min. The fractions containing the desired product eluted at 21.0 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give 
monosaccharide–Cy5** conjugate 2.15 as a blue solid: yield 30.0 µg (21%); mass 
spectrum (MALDI-TOF), m/z 1263.55 (M)+ and 1285.43 (M − H + Na)+ (theoretical m/z 
1263.44 and 1307.44). 
 
2,4,6-Tri-O-acetyl-3-O-benzyl-α-D-mannopyranosyl Diphenyl Phosphate (2.107).114 
To a solution of 910 mg (2.07 mmol) of benzyl ether 2.49 in 14 mL of anh DMF was 
added 262 mg (2.91 mmol) of hydrazine acetate. The solution was stirred at room 
temperature for 2.5 h and diluted with 100 mL of ethyl acetate. The organic solution was 
washed with 50 mL of brine, dried (MgSO4), filtered, and concentrated under diminished 
pressure to afford the alcohol as a light yellow oil: crude yield 820 mg (100%), which 
was used for the next reaction; silica gel TLC Rf 0.40 (1:1 hexanes–ethyl acetate). 
O OP(O)(OPh)2
OAc
OBn
AcO
AcO
 
 
157 
To a solution of above residue in 32 mL of anh dichloromethane at 0 °C were 
added 326 mg (2.67 mmol) of DMAP, 2.90 mL (2.01 g, 20.7 mmol) of dry triethylamine, 
and 4.10 mL (5.32 g, 19.8 mmol) of diphenyl phosphoryl chloride. The solution was 
stirred at room temperature for 1.5 h and poured into a mixture of 70 mL of ethyl acetate 
and 35 mL of saturated aq NaHCO3. The organic layer was washed with two 35-mL 
portions of brine, dried (MgSO4), filtered and concentrated under diminished pressure. 
The residue was purified by flash chromatography on a silica gel column (20 × 4 cm). 
Elution with 2:1 hexanes–ethyl acetate afforded phosphate ester 2.107 as a colorless oil: 
yield 550 mg (42% over two steps); silica gel TLC Rf 0.38 (1:1 hexanes–ethyl acetate); 
1H NMR (CDCl3, 400 MHz) δ 2.01 (s, 3H), 2.08 (s, 3H), 2.15 (s, 3H), 3.94 (dd, 1H, J = 
6.0 and 3.6 Hz), 4.11 (m, 1H), 4.14 (m, 1H), 4.19 (m, 1H), 4.55 (ABq, 2H, J = 12.4 Hz), 
5.26 (m, 2H), 5.37 (m, 1H), 7.14-7.18 (m, 5H) and 7.26-7.36 (m, 10H); 13C NMR 
(CDCl3, 100 MHz) δ 20.9, 21.0, 21.2, 63.0, 67.6, 68.6, 69.0, 71.6, 74.1, 92.7, 120.3, 
120.4, 125.5, 127.9, 128.0, 128.5, 128.8, 129.9, 137.8, 150.6, 169.9, 170.6 and 171.0. 
 
2,4,6-Tri-O-acetyl-3-O-benzyl-α-D-mannopyranosyl 2-(2-(Ethoxy)ethyl)isoindoline-
1,3-dione (2.108). To a solution of 550 mg (0.87 mmol) of phosphate ester 2.107 and 185 
mg (0.79 mmol) of the alcohol 2.57 in 15 mL of anh dichloromethane was added 0.29 
mL (350 mg, 1.58 mmol) of TMSOTf at 0 °C. The reaction was stirred at 0 °C for 20 min 
and was then poured into a mixture of 75 mL of ethyl acetate and 30 mL of saturated aq 
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NaHCO3. The organic layer was washed with two 20-mL portions of brine, dried 
(MgSO4), filtered and concentrated under diminished pressure. The residue was purified 
by flash chromatography on a silica gel column (22 × 4 cm).  Elution with 4:1→1:1 
hexanes–ethyl acetate afforded monosaccharide 2.108 as a colorless oil: yield 290 mg 
(60%); silica gel TLC Rf 0.40 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 
2.00 (s, 3H), 2.06 (s, 3H), 2.13 (s, 3H), 3.64 (m, 3H), 3.73 (m, 3H), 3.84-3.94 (m, 4H), 
4.05 (m, 1H), 4.23 (m, 1H), 4.52 (ABq, 2H, J = 12.0 Hz), 4.86 (s, 1H), 5.22 (t, 1H, J = 
10.0 Hz), 5.37 (d, 1H, J = 0.8 Hz), 7.22-7.34 (m, 5H), 7.70 (m, 2H) and 7.84 (m, 2H); 13C 
NMR (CDCl3, 100 MHz) δ 20.7, 20.8, 21.0, 37.2, 62.7, 67.0, 67.4, 68.0, 68.2, 68.6, 69.3, 
71.4, 74.7, 97.8, 123.3, 127.6, 127.7, 128.3, 132.0, 134.0, 137.9, 168.2, 169.7, 170.2 and 
170.7; mass spectrum (APCI), m/z 614.2237 (M + H)+ (C31H36NO12 requires m/z 
614.2238). 
 
2,4,6-Tri-O-acetyl-α-D-mannopyranosyl 2-(2-(Ethoxy)ethyl)isoindoline-1,3-dione 
(2.109). To a solution of 275 mg (0.45 mmol) of monosaccharide 2.108 in 10 mL of ethyl 
acetate was added 135 mg of Pd(OH)2/C and the reaction was placed under 1 atm of H2 
(g) overnight. The catalyst was removed by filtration through a pad of Celite 545® and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (18 × 3 cm). Elution with 3:1→1:1 hexanes–ethyl 
acetate afforded alcohol 2.109 as a colorless foam: yield 142 mg (61%); silica gel TLC Rf 
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0.21 (1:2 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.07 (s, 3H), 2.12 (s, 
3H), 2.15 (s, 3H), 2.22 (m, 1H), 3.59 (m, 1H), 3.65 (m, 2H), 3.75 (m, 3H), 3.89 (m, 2H), 
3.95 (m, 1H), 4.07 (m, 2H), 4.29 (m, 1H), 4.88 (d, 1H, J = 1.2 Hz), 5.05 (m, 2H) 
7.71 (m, 2H) and 7.85 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 20.7, 20.9, 21.0, 37.1, 
62.5, 67.1, 68.0, 68.1, 68.5, 69.2, 69.3, 72.3, 97.3, 123.3, 132.0, 134.0, 168.2, 170.4, 
170.7 and 171.2; mass spectrum (APCI), m/z 524.1764 (M + H)+ (C24H30NO12 requires 
m/z 524.1768). 
 
2,4,6-Tri-O-acetyl-2-O-((p-nitrophenyl)carbamoyl)-α-D-mannopyranosyl 2-(2-
(Ethoxy)ethyl)isoindoline-1,3-dione (2.110). To a solution of 39.0 mg (0.07 mmol) of 
2.109 in 0.42 mL of dry pyridine were added 3.00 mg (0.30 mmol) of DMAP and 60.0 
mg (0.30 mmol) of p-nitrophenyl chloroformate. The reaction was stirred at 40 °C 
overnight until the analysis by silica gel TLC indicated it was complete. The solution was 
cooled and poured into a mixture of 15 mL ethyl acetate and 5 mL of water. The organic 
layer was washed successively with three 5-mL portions of 1 N HCl, 5 mL of saturated 
aq NaHCO3 and 5 mL of brine. The solution was dried (MgSO4), filtered, and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (30 × 1.5 cm). Elution with 4:1→1:1 hexanes–
ethyl acetate afforded carbonate 2.110 as a white foam: yield 45.0 mg (88%); silica gel 
TLC Rf 0.55 (1:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.08 (s, 3H), 
O
OAc
OCOOC6H4NO2
AcO
AcO O O N
O
O
 
 
160 
2.10 (s, 3H), 2.17 (s, 3H), 3.64 (m, 3H), 3.72 (m, 2H), 3.77 (m, 1H), 3.89 (m, 2H), 4.08 
(m, 2H), 4.30 (m, 1H), 4.92 (s, 1H), 5.21 (s, 1H), 5.36 (t, 1H, J = 10.0 Hz), 5.47 (m, 1H), 
7.38 (d, 2H, J = 9.2 Hz), 7.69 (m, 2H), 7.83 (m, 2H) and 8.26 (d, 2H, J = 9.2 Hz); 13C 
NMR (CDCl3, 100 MHz) δ 20.8, 20.9, 21.0, 37.3, 62.4, 65.8, 67.3, 68.3, 68.5, 68.8, 69.6, 
74.8, 97.7, 122.0, 123.4, 125.4, 132.2, 134.1, 145.7, 151.7, 155.5, 168.3, 169.8, 170.3 and 
170.8; mass spectrum (APCI), m/z 689.1839 (M + H)+ (C31H33N2O16 requires m/z 
689.1830). 
  
2,4,6-Tri-O-acetyl-2-O-(methylcarbamoyl)-α-D-mannopyranosyl 2-(2-
(Ethoxy)ethyl)isoindoline-1,3-dione (2.111). To a solution containing 21.0 mg (0.03 
mmol) of carbamate 2.110 in 1 mL of anh THF was added 15.0 µL (0.03 mmol) of 2 M 
solution of methylamine in THF dropwise at 0 °C. The reaction mixture was allowed to 
warm to room temperature and then stirred overnight at room temperature. The solvent 
was concentrated under diminished pressure and was purified by flash chromatography 
on a silica gel column (18 × 1.5 cm). Elution with 3:1→1:2 hexanes–ethyl acetate 
afforded monosaccharide 2.111 as a colorless foam: yield 15.0 mg (85%); silica gel TLC 
Rf 0.21 (1:2 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 2.04 (s, 3H), 2.07 (s, 
3H), 2.13 (s, 3H), 2.76 (d, 3H, J = 4.8 Hz), 3.63 (m, 3H), 3.72 (m, 3H), 3.88 (m, 2H), 
4.04 (m, 2H), 4.28 (m, 1H), 4.61 (d, 1H, J = 4.8 Hz), 4.85 (s, 1H), 5.25 (m, 3H), 7.70 (m, 
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2H) and 7.85 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 20.89, 20.94, 21.1, 27.7, 29.8, 
37.4, 62.7, 66.5, 67.3, 68.3, 68.5, 69.6, 69.9, 70.3, 97.8, 123.4, 132.3, 134.0, 155.7, 168.4, 
170.1 and 170.8; mass spectrum (APCI), m/z 581.1983 (M + H)+ (C26H33O13N2 requires 
m/z 581.1983). 
 
Monosaccharide–Cy5** Conjugate 2.16. To a solution of 3.70 mg (6.37 µmol) of 
compound 2.111 in 1 mL of anh methanol was added 0.1 mL of 25% w/w freshly 
prepared solution of sodium methoxide in methanol. The reaction mixture was allowed to 
stir at room temperature for 2.5 h, and the complete consumption of starting material was 
confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was then 
quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 min, filtered and 
concentrated; mass spectrum (MALDI-TOF), m/z 477.46 (M + Na)+; mass spectrum 
(ESI), m/z 445.1484 (M + Na)+ (C20H26N2O10Na requires m/z 445.1485). To the solution 
of the crude product in 0.2 mL of ethanol was added 0.48 µL (15.5 µmol) of hydrazine 
hydrate and stirred at 60 °C overnight. The complete consumption of starting material 
was confirmed by MALDI-TOF mass spectral analysis. The reaction mixture was filtered 
and concentrated under diminished pressure to afford 2.112 as a colorless oil: yield 1.50 
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mg (73%), which was used for the next reaction; mass spectrum (MALDI-TOF), m/z 
347.36 (M + Na)+; mass spectrum (APCI), m/z 325.1612 (M + H)+ (C12H25N2O8 requires 
m/z 325.1611). 
To 185 µg (0.57 µmol) of 2.112 was added a solution of 110 µg (0.11 µmol) of 
Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the reaction 
mixture was stirred overnight in the dark. The reaction mixture was purified on an 
Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile) over a period of 28 min at 
a flow rate of 4.5 mL/min. The fractions containing the desired product eluted at 19.4 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give 
monosaccharide–Cy5** conjugate 2.16 as a blue solid: yield 40.0 µg (30%); mass 
spectrum (MALDI-TOF), m/z 1215.71 (M − H + Na)+, 1237.73 (M − 2H + 2Na)+ and 
1259.74 (M − 3H + 3Na)+; mass spectrum (ESI), m/z 396.4445 (M − 3H)3− 
(C50H72N4O21S43− requires m/z 396.4446). 
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BLM Monosaccharide–sulphoCy5 (2.17). To 251 µg (0.81 µmol) of amine 2.84 was 
added a solution of 114 µg (0.15 µmol) of sulphoCy5COOSu (2.113) in 100 µL of 0.2 M 
phosphate buffer (pH 8.0) and the reaction mixture was stirred overnight in the dark. The 
reaction mixture was purified on an Econosil C18 reversed phase semi-preparative (250 × 
10 mm, 10 µm) HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–
acetonitrile) over a period of 28 min at a flow rate of 4.5 mL/min. The fractions 
containing the desired product eluted at 25.3 min (monitoring at 650 nm) and were 
collected, frozen and lyophilized to give BLM monosaccharide–sulphoCy5 conjugate 
(2.17) as a blue solid: yield 14.0 µg (10%); mass spectrum (MALDI-TOF), m/z 957.62 
(M + Na − H)+ and 979.59 (M + 2Na − 2H)+; mass spectrum (ESI), m/z 933.3231 (M)+ 
(C43H57N4O15S2+ requires m/z 933.3262). 
 
BLM Monosaccharide–Cy5 (2.18). To 1.40 mg (4.38 µmol) of amine 2.84 was added a 
solution of 500 µg (0.81 µmol) of Cy5COOSu (2.114) in 500 µL of 0.2 M phosphate 
buffer (pH 8.0) and 100 µL of DMSO. The reaction mixture was stirred overnight in the 
dark and purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 
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µm) HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient 
was employed (99:1 0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile→ 
0:100 0.1% aq TFA–acetonitrile) over a period of 10 min and 5 min, respectively, at a 
flow rate of 4.5 mL/min. The fractions containing the desired product eluted at 15.6 min 
(monitoring at 650 nm) and were collected, frozen and lyophilized to give BLM 
monosaccharide–Cy5 conjugate (2.18) as a blue solid: yield 185 µg (30%); mass 
spectrum (MALDI-TOF), m/z 775.57 (M)+ and 776.67 (M + H)+; mass spectrum (ESI), 
m/z 775.4278 (M)+ (C43H59N4O9 requires m/z 775.4277).  
 
BLM Monosaccharide–Cy7 (2.19). To 284 µg (0.92 µmol) of amine 2.84 was added a 
solution of 116 µg (0.17 µmol) of Cy7COOSu (2.115) in 100 µL of 0.2 M phosphate 
buffer (pH 8.0) and 20 µL of DMSO. The reaction mixture was stirred overnight in the 
dark and purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 
µm) HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient 
was employed (99:1 0.1% aq TFA–acetonitrile→0:100 0.1% aq TFA–acetonitrile→ 
0:100 0.1% aq TFA–acetonitrile) over a period of 12 min and 13 min, respectively, at a 
flow rate of 4.5 mL/min. The fractions containing the desired product eluted at 16.0 min 
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(monitoring at 750 nm) and were collected, frozen and lyophilized to give BLM 
monosaccharide–Cy7 conjugate (2.19) as a blue solid: yield 27.0 µg (19%); mass 
spectrum (MALDI-TOF), m/z 842.73 (M)+; mass spectrum (ESI), m/z 841.4730 (M)+ 
(C48H65N4O9+ requires m/z 841.4746). 
 
BLM Monosaccharide–Alexa Fluor 647 (2.20). To 134 µg (0.43 µmol) of amine 2.84 
was added a solution of 100 µg (0.08 µmol) of Alexa-Fluor647COOSu (2.116) in 100 µL 
of 0.2 M phosphate buffer and the reaction mixture was stirred overnight in the dark. The 
reaction mixture was purified on an Econosil C18 reversed phase semi-preparative (250 × 
10 mm, 10 µm) HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–
acetonitrile) over a period of 25 min at a flow rate of 4.5 mL/min. The fractions 
containing the desired product eluted at 17.4 min (monitoring at 650 nm) and were 
collected, frozen and lyophilized to give BLM monosaccharide–Alexa Fluor 647 
conjugate (2.20) as a blue solid: yield 56.0 µg (48%); mass spectrum (MALDI-TOF), m/z 
1369.32 (M)+, (theoretical m/z 1369; the structure of Alexa Fluor 647 fluorophore has not 
been reported).  
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BLM Monosaccharide–Cy5GE (2.21). To 211 µg (0.68 µmol) of amine 2.84 was added 
a solution of 100 µg (0.13 µmol) of Cy5GECOOSu (2.117) in 100 µL of 0.2 M phosphate 
buffer and 20 µL DMSO. The reaction mixture was stirred overnight in the dark and was 
purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) 
HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was 
employed (99:1 0.1% aq TFA–acetonitrile→0:100 0.1% aq TFA–acetonitrile) over a 
period of 12 min at a flow rate of 4.5 mL/min. The fractions containing the desired 
product eluted at 6.9 min (monitoring at 650 nm) and were collected, frozen and 
lyophilized to give BLM monosaccharide–Cy5GE conjugate (2.21) as a blue solid: yield 
86.0 µg (72%); mass spectrum (MALDI-TOF), m/z 949.48 (M)+ and 971.49 (M + Na)+; 
mass spectrum (ESI), m/z 949.3538 (M)+ (C44H61N4O15S2+ requires m/z 949.3575).  
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BLM Monosaccharide–Cy5.5GE (2.22). To 148 µg (0.48 µmol) of amine 2.84 was 
added a solution of 100 µg (0.09 µmol) of Cy5.5GECOOSu (2.118) in 100 µL of 0.2 M 
phosphate buffer and 20 µL DMSO. The reaction mixture was stirred overnight in the 
dark and was purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 
10 µm) HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A linear 
gradient was employed (99:1 0.1% aq TFA–acetonitrile→70:30 0.1% aq TFA–
acetonitrile) over a period of 18 min at a flow rate of 4.5 mL/min. The fractions 
containing the desired product eluted at 16.5 min (monitoring at 675 nm) and were 
collected, frozen and lyophilized to give BLM monosaccharide–Cy5.5GE (2.22) as a blue 
solid: yield 47.0 µg (44%); mass spectrum (MALDI-TOF), m/z 1231.55 (M − H + Na)+, 
1247.57 (M − H + K)+, 1253.55 (M − 2H + 2Na)+, 1269.57 (M − 2H + Na + K)+ and 
1275.55 (M − 3H + 3Na)+ (theoretical m/z 1231.38, 1247.26, 1253.27, 1269.24 and 
1275.25). 
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Decarbamoyl BLM Monosaccharide–Cy5 (2.23). To 1.80 mg (4.38 µmol) of amine 
2.88 was added a solution of 500 µg (0.81 µmol) of Cy5COOSu (2.114) in 500 µL of 0.2 
M phosphate buffer and the reaction mixture was stirred overnight in the dark. The 
reaction mixture was purified on an Econosil C18 reversed phase semi-preparative (250 × 
10 mm, 10 µm) HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–
acetonitrile→0:100 0.1% aq TFA–acetonitrile) over a period of 10 and 5 min, 
respectively, at a flow rate of 4.5 mL/min. The fractions containing the desired product 
eluted at 15.7 min (monitoring at 650 nm) and were collected, frozen and lyophilized to 
give decarbamoyl BLM monosaccharide–Cy5 (2.23) as a blue solid: yield 169 µg (23%); 
mass spectrum (ESI), m/z 732.4219 (M)+ (C42H58N3O8+ requires m/z 732.4218).  
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BLM Disaccharide–Cy5 (2.24). To 1.90 mg (4.02 µmol) of amine 2.59 was added a 
solution of 500 µg (0.81 µmol) of Cy5COOSu (2.114) in 500 µL of 0.2 M phosphate 
buffer and 100 µL of DMSO. The reaction mixture was stirred overnight in the dark and 
purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) 
HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was 
employed (99:1 0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile→0:100 
0.1% aq TFA–acetonitrile) over a period of 10 min and 5 min, respectively, at a flow rate 
of 4.5 mL/min. The fractions containing the desired product eluted at 15.0 min 
(monitoring at 650 nm) and were collected, frozen and lyophilized to give BLM 
disaccharide–Cy5 (2.24) as a blue solid: yield 235 µg (31%); mass spectrum (MALDI-
TOF), m/z 937.65 (M)+; mass spectrum (ESI), m/z 937.4803 (M)+ (C49H69N4O14+ requires 
m/z 937.4805). 
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BLM Disaccharide–Cy5GE (2.25).115 To 322 µg (0.68 µmol) of amine 2.59 was added a 
solution of 100 µg (0.13 µmol) of Cy5GECOOSu (2.114) in 100 µL of 0.2 M phosphate 
buffer and 20 µL DMSO. The reaction mixture was stirred overnight in the dark and was 
purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) 
HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was 
employed (99:1 0.1% aq TFA–acetonitrile→0:100 0.1% aq TFA–acetonitrile) over a 
period of 12 min at a flow rate of 4.5 mL/min. The fractions containing the desired 
product eluted at 6.7 min (monitoring at 650 nm) and were collected, frozen and 
lyophilized to give BLM disaccharide–Cy5GE (2.25) as a blue solid: yield 38.0 µg (27%); 
mass spectrum (MALDI-TOF), m/z 1111.41 (M)+ (theoretical m/z 1111.41). 
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1,3,4,6-Tetra-O-acetyl-2-O-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-α-L-
gulopyranoside (2.119).150 To a solution of 300 mg (0.52 mmol) of phosphate ester 2.86 
and 144 mg (0.41 mmol) of gulose alcohol 2.45 in 8.6 mL of anh dichloromethane at 0 
°C was added 0.17 mL (207 mg, 0.93 mmol) of TMSOTf dropwise. The reaction mixture 
was stirred at 0 °C for 18 min at which time it was poured into a mixture of 60 mL of 
ethyl acetate and 30 mL of saturated aq NaHCO3. The organic layer was washed with two 
20-mL portions of brine, dried (Na2SO4), filtered and concentrated under diminished 
pressure. The residue was purified by flash chromatography on a silica gel column (22 × 
3 cm). Elution with 3:1→1:1 hexanes–ethyl acetate afforded disaccharide 2.119 as a 
colorless oil: yield 150 mg (53%); silica gel TLC Rf 0.36 (1:2 hexanes–ethyl acetate); 1H 
NMR (CDCl3, 400 MHz) δ 1.96 (s, 3H), 2.02 (s, 3H), 2.05 (s, 3H), 2.12 (s, 3H), 2.13 (2s, 
6H), 2.15 (s, 3H), 2.18 (s, 3H), 3.98 (dd, 1H, J = 4.8 and 3.6 Hz), 4.05-4.18 (m, 4H), 4.22 
(m, 2H), 4.36 (m, 1H), 4.97 (d, 1H, J = 1.6 Hz), 5.00 (m, 1H), 5.09 (m, 1H), 5.14 (m, 
1H), 5.26 (m, 1H), 5.43 (t, 1H, J = 3.6 Hz) and 5.89 (d, 1H, J = 8.4 Hz); 13C NMR 
(CDCl3, 100 MHz) δ 20.78, 20.81, 20.88, 20.94, 61.5, 62.2, 65.6, 65.9, 67.8, 68.7, 68.8, 
68.9, 69.3, 69.8, 71.5, 90.8, 95.1, 168.8, 169.38, 169.42, 169.6, 169.7, 170.0, 170.6 and 
170.7. 
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3,4,6-Tri-O-acetyl-2-O-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-α-L-
gulopyranosyl Diphenyl Phosphate (2.120).118 To a solution of 150 mg (0.22 mmol) of 
disaccharide 2.119 in 1.9 mL of anh DMF was added 28.0 mg (0.31 mmol) of hydrazine 
acetate salt and the reaction mixture was stirred for 2.5 h at room temperature. The 
solution was diluted with 50 mL of ethyl acetate and washed with three 20-mL portions 
of brine, dried (Na2SO4), filtered and concentrated under diminished pressure. The 
residue was co-evaporated with toluene to give the product as a colorless oil: yield 140 
mg (99%); silica gel TLC Rf 0.25 (1:2 hexanes–ethyl acetate). 
To the solution of 140 mg of the residue in 5.5 mL of anh dichloromethane were 
added 35.0 mg (0.28 mmol) of DMAP, 0.31 mL (222 mg, 2.20 mmol) of dry 
triethylamine and 0.44 mL (564 mg, 2.10 mmol) of diphenyl chlorophosphate at 0 °C. 
The solution was stirred at 0 °C for 1.5 h and was then poured into a mixture of 50 mL of 
ethyl acetate and 20 mL of saturated aq NaHCO3. The organic layer was washed with 15 
mL of brine, dried (Na2SO4), filtered and concentrated under diminished pressure. The 
residue was purified by flash chromatography on a silica gel column (25 × 2.5 cm). 
Elution with 2:1→1:1 hexanes–ethyl acetate afforded phosphate ester 2.120 as a colorless 
oil: yield 108 mg (56% over two steps); silica gel TLC Rf 0.28 (1:2 hexanes–ethyl 
acetate). 1H NMR (CDCl3, 400 MHz) δ 1.70 (s, 3H), 1.94 (s, 3H), 1.99 (s, 3H), 2.08 (s, 
3H), 2.13 (s, 3H), 2.15 (s, 3H), 2.21 (s, 3H), 4.00 (m, 3H), 4.13 (m, 2H), 4.33 (dd, 2H, J 
= 15.5 and 8.8 Hz), 4.99 (m, 2H), 5.14 (m, 1H), 5.24 (m, 2H), 5.44 (s, 1H), 5.71 (t, 1H, J 
= 7.3 Hz) and 7.28 (m, 10H); 13C NMR (CDCl3, 100 MHz) δ 20.2, 20.60, 20.61, 20.65, 
20.7, 61.1, 61.8, 65.3, 65.5, 67.4, 68.6, 69.0, 69.1, 71.0, 71.6, 95.4, 96.1, 120.2, 120.2, 
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125.6, 125.7, 129.6, 129.9, 150.0, 150.3, 169.2, 169.3, 169.4, 169.5, 169.6, 170.3 and 
170.5. 
  
3,4,6-Tri-O-acetyl-2-O-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-α,β-L-
gulopyranosyl Benzyl 2-(2-ethoxy)ethylcarbamate (2.121).118 To a solution of 26.0 mg 
(30.0 µmol) of phosphate ester 2.120 and 6.50 mg (27.0 µmol) of CBz-protected linker 
2.57 in 1.2 mL of anh dichloromethane was added 10.0 µL (12.3 mg, 54.0 µmol) of 
TMSOTf at 0 °C. The reaction was stirred at 0 °C for 17 min and was then poured into a 
mixture of 25 mL of ethyl acetate and 10 mL of saturated aq NaHCO3. The organic layer 
was washed with two 5-mL portions of brine, dried (Na2SO4), filtered and concentrated 
under diminished pressure. The residue was purified by flash chromatography on a silica 
gel column (25 × 2 cm).  Elution with 32:16:1→12:12:1 hexanes–ethyl acetate–methanol 
afforded compound 2.121 as a colorless oil: yield 18.0 mg (70%); silica gel TLC Rf 0.80 
(12:12:1 hexanes–ethyl acetate–methanol); 1H NMR (CDCl3, 400 MHz) δ 1.98 (s, 3H), 
2.02 (s, 3H), 2.04 (s, 3H), 2.08 (s, 3H), 2.10 (s, 3H), 2.12 (s, 3H), 2.14 (s, 3H), 3.40 (m, 
2H), 3.61 (m, 3H), 3.68 (m, 2H), 3.85 (m, 1H), 3.97 (m, 1H), 4.18 (m, 5H), 4.27 (m, 4H), 
4.47 (t, 1H, J = 6.4 Hz), 4.92 (d, 1H, J = 3.7 Hz), 5.01 (m, 2H), 5.09 (m, 2H), 5.15 (s, 
1H), 5.45 (s, 1H) and 7.33 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ 20.61, 20.62, 20.70, 
20.75, 20.8, 29.7, 40.9, 62.1, 62.5, 63.7, 65.5, 66.6, 68.61, 68.62, 69.1, 69.2, 70.1, 70.3, 
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70.6, 97.0, 97.1, 128.05, 128.15, 128.5, 136.5, 156.4, 169.3, 169.5, 169.6, 169.8, 169.9, 
170.52 and 170.53. 
 
Decarbamoyl BLM Disaccharide–Cy5 (2.26). To a solution of 12.0 mg (14.0 mmol) of 
decarbamoyl disaccharide CBz protected linker 2.121 in 3 mL of anh methanol was 
added 0.3 mL of 25% w/w freshly prepared solution of sodium methoxide in methanol. 
The reaction mixture was allowed to stir at room temperature for 2.5 h, and the complete 
consumption of starting material was confirmed by MALDI-TOF mass spectral analysis. 
The reaction mixture was then quenched by the addition of 500 mg of Dowex 50x resin, 
shaken for 15 min, filtered and concentrated; mass spectrum (MALDI-TOF), m/z 586.34 
(M + Na)+ (theoretical m/z 563.22). To the solution of the crude product in 5 mL of anh 
methanol was added Pd/C and H2 gas was bubbled through for 45 min. The complete 
consumption of starting material was confirmed by MALDI-TOF mass spectral analysis. 
The reaction mixture was filtered through Celite 545® and then concentrated under 
diminished pressure to afford amine 2.122 as a colorless oil: yield 6.00 mg (100%), 
which was used for the next reaction; mass spectrum (MALDI-TOF), m/z 430.32 (M + 
Na)+. 
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To 1.80 mg (4.38 µmol) of amine 2.122 was added a solution of 500 µg (0.81 
µmol) of Cy5COOSu (2.114) in 500 µL of 0.2 M phosphate buffer (pH 8.0) and the 
reaction mixture was stirred overnight in the dark. The reaction mixture was purified on 
an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→69:31 0.1% aq TFA–acetonitrile→0:100 0.1% aq TFA–
acetonitrile) over a period of 10 min and 5 min, respectively, at a flow rate of 4.5 
mL/min. The fractions containing the desired product eluted at 14.9 min (monitoring at 
650 nm) and were collected, frozen and lyophilized to give decarbamoyl BLM 
disaccharide–Cy5 2.26 as a blue solid: yield 169 µg (23%); mass spectrum (MALDI-
TOF), m/z 894.53 (M)+; mass spectrum (ESI), m/z 894.4737 (M)+ (C48H68N3O13+ requires 
m/z 894.4747).  
 
Decarbamoyl BLM Disaccharide–Cy5GE (2.27). To 293 µg (0.68 µmol) of amine 2.122 
was added a solution of 100 µg (0.13 µmol) of Cy5GECOOSu (2.117) in 100 µL of 0.2 M 
phosphate buffer (pH 8.0) and 20 µL DMSO. The reaction mixture was stirred overnight 
in the dark and was purified on an Econosil C18 reversed phase semi-preparative (250 × 
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10 mm, 10 µm) HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→0:100 0.1% aq TFA–
acetonitrile) over a period of 12 min at a flow rate of 4.5 mL/min. The fractions 
containing the desired product eluted at 6.6 min (monitoring at 650 nm) and were 
collected, frozen and lyophilized to give decarbamoyl BLM disaccharide–Cy5GE (2.27) as 
a blue solid: yield 59.0 µg (44%); mass spectrum (ESI), m/z 1066.3878 (M – 2H)− 
(C49H68N3O19S2 requires m/z 1066.3888). 
 
Cu(II)•Bleomycin–Cy5GE (2.124).115 To 912 µg (0.61 µmol) of 
Cu(II)•deglycobleomycin A5 (2.123) was added a solution of 200 µg (0.25 µmol) of 
Cy5GECOOSu (2.117) in 200 µL of 0.2 M phosphate buffer (pH 8.0) and the reaction 
mixture was stirred overnight in the dark. The reaction mixture was purified on an 
Econosil C18 reversed phase semi-preparative (250 ×10 mm, 10 µm) HPLC column using 
aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 0.1% 
aq TFA–acetonitrile→0:100 0.1% aq TFA–acetonitrile) over a period of 12 min at a flow 
rate of 4.5 mL/min. The fractions containing the desired product eluted at 6.9 min 
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(monitoring at 650 nm) and were collected, frozen and lyophilized to give 
Cu(II)•bleomycin–Cy5GE (2.124) as a blue solid: yield 120 µg (22%); mass spectrum 
(MALDI-TOF), m/z 2079.55 (M + H)+ (theoretical m/z 2079.82). 
 
Bleomycin–Cy5GE (2.28).115 To 120 µg (0.06 µmol) of 2.124 was added 150 µL of 15% 
EDTA and 20 µL of DMSO. The reaction mixture was stirred overnight in the dark and 
was purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) 
HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was 
employed (99:1 0.1% aq TFA–acetonitrile→0:100 0.1% aq TFA–acetonitrile) over a 
period of 12 min at a flow rate of 4.5 mL/min. The fractions containing the desired 
product eluted at 6.9 min (monitoring at 650 nm) and were collected, frozen and 
lyophilized to give bleomycin–Cy5GE (2.28) as a blue solid: yield 110 µg (94%); mass 
spectrum (MALDI-TOF), m/z 2079.55 (M + H)+ (theoretical m/z 2079.82). 
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1-O-[(p-Nitrophenyl)oxycarbonyl]-3,4,6-tri-O-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-
carbamoyl-α-D-mannopyranosyl)-α,β-L-gulopyranoside (2.125).118 To a solution of 
7.00 mg (0.01 mmol) of disaccharide 2.55 in 0.2 mL of anh DMF was added 1.30 mg 
(0.01 mmol) of hydrazine acetate. The solution was stirred at room temperature for 2.5 h 
and diluted with 15 mL of ethyl acetate. The organic solution was washed with 5 mL of 
brine, dried (MgSO4), filtered, and concentrated under diminished pressure to afford the 
product as a colorless oil: yield 6.50 mg; silica gel TLC Rf 0.25 (1:3 hexanes–ethyl 
acetate). 
To a solution of 6.50 mg (0.01 mmol) of the above residue in 1.1 mL of dry 
acetonitrile were added 1.90 mg (15.3 µmol) of DMAP and a solution containing 3.10 mg 
(15.3 µmol) of p-nitrophenyl chloroformate in 100 µL of acetonitrile. The reaction 
mixture was stirred at room temperature for 2 h, at which time silica gel TLC analysis 
showed complete consumption of the starting material. The reaction mixture was 
concentrated under diminished pressure, dissolved in 10 mL of ethyl acetate, and then 
washed successively with 5 mL of water, 5 mL of 1 N aqueous HCl and 5 mL of brine. 
The solution was dried (Na2SO4), filtered, and concentrated under diminished pressure. 
The residue was purified by flash chromatography on a silica gel column (15 × 1.5 cm). 
Elution with 1:1→1:2 hexanes–ethyl acetate afforded the carbonate 2.125 as a colorless 
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oil: yield 6.00 mg (73%); silica gel TLC Rf 0.38 (2:3 hexanes–ethyl acetate); 1H NMR 
(CDCl3, 400 MHz) δ 1.94 (s, 3H), 2.06 (s, 3H), 2.10 (s, 3H), 2.15 (s, 3H), 2.16 (s, 3H), 
2.21 (s, 3H), 4.11 (m, 6H), 4.41 (m, 1H), 4.69 (br s, 2H), 5.04 (m, 2H), 5.16 (m, 2H), 
5.29 (m, 1H), 5.48 (m, 1H) 5.83 (d, 1H, J = 8.4 Hz), 7.47 (dd, 1H, J = 6.8 and 2 Hz) and 
8.31 (dd, 1H, J = 6.8 and 2 Hz); 13C NMR (CDCl3, 100 MHz) δ 20.78, 20.84, 20.95, 
61.4, 62.0, 65.6, 65.9, 67.5, 69.2, 69.7, 69.8, 70.0, 72.0, 95.3, 95.5, 122.1, 125.6, 146.0, 
151.1, 155.1, 155.2, 169.3, 169.3, 169.6, 169.8, 170.5 and 170.7. 
 
Cu(II)•Deglycobleomycin–Disaccharide Conjugate 2.126.118 To a solution containing 
2.00 mg (2.40 µmol) of carbamate 2.125 and 2.00 mg (1.80 µmol) of 
Cu(II)•deglycobleomycin A5 (2.123) in 1 mL of anhydrous DMF was added 10.0 µL 
(7.40 mg; 72.0 µmol) of dry triethylamine and shaken at room temperature for 3 h. The 
reaction mixture was treated with 100 µL (102 mg; 3.20 mmol) of hydrazine and was 
shaken at room temperature for additional 1 h. The reaction mixture was then 
concentrated under diminished pressure and purified on an Econosil C18 reversed phase 
semi-preparative (250 × 10 mm, 10 µm) HPLC column using aq 0.1% TFA and 
acetonitrile mobile phases. A linear gradient was employed (99:1 0.1% aq TFA–
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acetonitrile→50:50 0.1% aq TFA–acetonitrile) over a period of 28 min at a flow rate of 
4.5 mL/min. The fractions containing the desired product eluted at 11.0 min (monitoring 
at 292 nm) and were collected, frozen and lyophilized to give conjugate 2.126 as a light 
blue solid: yield 843 µg (31%); mass spectrum (MALDI-TOF), m/z 1546.8 (M)+ 
(theoretical m/z 1546.5); mass spectrum (ESI), m/z 773.2547 (M + 2H)2+ 
(C58H87N19O23S2Cu requires m/z 773.2558).  
 
Deglycobleomycin–Disaccharide Conjugate 2.29. To 0.83 mg (0.54 µmol) of 
Cu(II)•deglycoBLM–disaccharide 2.126 was added 0.8 mL of 15% EDTA solution and 
the reaction mixture was shaken at room temperature for overnight. The reaction mixture 
was purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) 
HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was 
employed (99:1 0.1% aq TFA–acetonitrile→50:50 0.1% aq TFA–acetonitrile) over a 
period of 18 min at a flow rate of 4.5 mL/min. The fractions containing the desired 
product eluted at 3.2 min (monitoring at 292 nm) and were collected, frozen, and 
lyophilized to give conjugate 2.29 as white solid: yield 0.31 mg (40%); mass spectrum 
(MALDI-TOF), m/z 1484.9 (M + H)+ (theoretical m/z 1483.6); mass spectrum (ESI), m/z 
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742.7975 (M + 2H)2+ (C58H89N19O23S2 requires m/z 742.7988). 
 
Cu(II)•Deglycobleomycin–Linker Conjugate 2.128. To a solution containing 4.00 mg 
(8.50 µmol) of lysine linker 2.127 in 1.1 mL anh dichloromethane were added 1.20 mg 
(10.0 µmol) of N-hydroxysuccinimide and 3.10 µL (2.52 mg, 20 µmol) of N,N′-
diisopropylcarbodiimide. The reaction mixture was stirred overnight at room 
temperature. The reaction mixture was concentrated to give the activated acid as a 
colorless solid: yield 4.80 mg (99%); mass spectrum (MALDI-TOF), m/z 588.31 (M + 
Na)+ (theoretical m/z 588.23). 
To a solution containing 2.40 mg (4.20 µmol) of compound the activated acid and 
5.00 mg (4.40 µmol) of Cu(II)•deglycobleomycin A5 (2.123) in 0.9 mL of anhydrous 
DMF was added 6.00 µL (4.40 mg, 40.0 µmol) of dry triethylamine and the reaction 
mixture was shaken overnight at room temperature. The reaction mixture was 
concentrated under diminished pressure and purified on an Econosil C18 reversed phase 
semi-preparative (250 × 10 mm, 10 µm) HPLC column using aq 0.1% TFA and 
acetonitrile mobile phases. A linear gradient was employed (99:1 0.1% aq TFA–
acetonitrile→50:50 0.1% aq TFA–acetonitrile→0:100 0.1% aq TFA–acetonitrile) over a 
period of 16 min and 4 min, respectively, at a flow rate of 4.5 mL/min. The fractions 
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containing the desired product eluted at 22.8 min (monitoring at 292 nm) and were 
collected, frozen, and lyophilized to give linker 2.128 as a light blue solid: yield 1.04 mg 
(15% over two steps); mass spectrum (MALDI-TOF), m/z 1545.79 (M − Cu + Na)+ 
(theoretical m/z 1545.69). 
 
 
Cu(II)•Deglycobleomycin–Linker–Disaccharide Conjugate 2.129. To 1.03 mg (0.65 
µmol) of linker 2.128 was added 0.24 mL of 20% piperidine in DMF and the reaction 
mixture was stirred for 1.5 h. The reaction mixture was frozen and lyophilized to give the 
crude amine as a white solid: yield 844 µg (95%); mass spectrum (MALDI-TOF), m/z 
1300.81 (M − Cu)+ (theoretical m/z 1300.63).  
To a solution containing 0.84 mg (0.62 µmol) of the crude amine and 0.84 mg 
(0.86 µmol) of carbonate 2.125 in 0.5 mL of anh DMF was added 10.0 µL (7.40 mg; 72.0 
µmol) of dry triethylamine and the reaction mixture was shaken overnight at room 
temperature. Fifty µL (51.0 µg; 1.60 mmol) of hydrazine was added and the reaction 
mixture was shaken at room temperature for 1 h and then concentrated under diminished 
pressure. The reaction mixture was purified on an Econosil C18 reversed phase semi-
preparative (250 × 10 mm, 10 µm) HPLC column using aq 0.1% TFA and acetonitrile 
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mobile phases. A linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→50:50 
0.1% aq TFA–acetonitrile→0:100 0.1% aq TFA–acetonitrile) over a period of 16 min 
and 4 min, respectively, at a flow rate of 4.5 mL/min. The fractions containing the 
desired product eluted 10.4 min (monitoring at 292 nm) and were collected, frozen, and 
lyophilized to give Cu(II)•deglycoBLM–linker–disaccharide 2.129 as a light blue solid: 
yield 367 µg (32%); mass spectrum (MALDI-TOF), m/z 1712.52 (M – Cu + H)+ 
(theoretical m/z 1712.74). 
  
Cu(II)•Deglycobleomycin–Linker–Disaccharide–Cy5** Conjugate 2.130. To 363 µg 
(0.20 µmol) of linker 2.129 was added 0.3 mL of 60% TFA and the reaction mixture was 
stirred for 2 h. The reaction mixture was frozen and lyophilized to give the free amine as 
a light blue solid: yield 342 µg (100%); mass spectrum (MALDI-TOF), m/z 1613.94 (M 
− Cu + 2H)+ (theoretical m/z 1613.69).  
To 341 µg (0.20 µmol) of the free amine was added a solution of 110 µg (0.11 
µmol) of Cy5**COOSu (2.60) in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the 
reaction mixture was stirred overnight in the dark. The reaction mixture was purified on 
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an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→50:50 0.1% aq TFA–acetonitrile→0:100 0.1% aq TFA–
acetonitrile) over a period of 16 min and 4 min, respectively, at a flow rate of 4.5 
mL/min. The fractions containing the desired product eluted at 10.1 min (monitoring at 
651 nm) and were collected, frozen and lyophilized to give Cy5** conjugate 2.130 as a 
blue solid: yield 47.0 µg (17%); mass spectrum (MALDI-TOF), m/z 2480.66 (M − Cu)+ 
and 2585.02 (M + 3Na + K − 3H)+, (theoretical m/z 2480.89 and 2585.80). 
 
Deglycobleomycin–Linker–Disaccharide–Cy5** Conjugate 2.30. To 46.0 µg (0.02 
µmol) of Cy5** conjugate 2.130 was added 100 µL of 15% EDTA and the reaction 
mixture was stirred at room temperature overnight in the dark. The reaction mixture was 
purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 10 µm) 
HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was 
employed (99:1 0.1% aq TFA–acetonitrile→50:50 0.1% aq TFA–acetonitrile→0:100 
0.1% aq TFA–acetonitrile) over a period of 16 min and 4 min, respectively, at a flow rate 
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of 4.5 mL/min. The fractions containing the desired product eluted at 10.1 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give Cy5** 
conjugate 2.30 as a blue solid: yield 18.0 µg (40%); mass spectrum (MALDI-TOF), m/z 
2480.66 (M)+, 2556.46 (M − 2H + 2K)+, 2564.08 (M + 2Na + K − H)+ and 2586.87 (M + 
3Na + K − 2H)+, (theoretical m/z 2480.89, 2556.80, 2564.82 and 2586.81). 
 
Cu(II)•Deglycobleomycin–Cy5** Conjugate 2.131. To 400 µg (0.27 µmol) of modified 
BLM 2.31 was added 200 µL of a 2.94 mM aq CuCl2 solution and the reaction mixture 
was stirred overnight in the dark. The reaction mixture was frozen and lyophilized to give 
the metallated BLM as a light blue solid: yield 417 µg (100%); mass spectrum (MALDI-
TOF), m/z 1543.45 (M)+ and 1481.53 (M – Cu + H)+, (theoretical m/z 1543.58 and 
1481.66).  
To 417 µg (0.27 µmol) of the metallated BLM was added a solution of 110 µg 
(0.11 µmol) of Cy5**COOSu in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the 
reaction mixture was stirred overnight in the dark. The reaction mixture was purified on 
an Econosil C18 reversed phase semi-preparative (250 ×10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
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0.1% aq TFA–acetonitrile→75:25 0.1% aq TFA–acetonitrile) over a period of 23 min at 
a flow rate of 4.5 mL/min. The fractions containing the desired product eluted at 21.1 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give Cy5** 
conjugate 2.131 as a blue solid: yield 100 µg (37%); mass spectrum (MALDI-TOF), m/z 
2388.36 (M − Cu + K)+ (theoretical m/z 2388.83). 
 
 
Deglycobleomycin–Cy5** Conjugate 2.33. To 98.0 µg (0.04 µmol) of Cy5** conjugate 
2.131 was added 100 µL of 15% EDTA and the reaction mixture was stirred overnight in 
the dark. The reaction mixture was purified on an Econosil C18 reversed phase semi-
preparative (250 × 10 mm, 10 µm) HPLC column using aq 0.1% TFA and acetonitrile 
mobile phases. A linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→0:100 
0.1% aq TFA–acetonitrile) over a period of 15 min at a flow rate of 4.5 mL/min. The 
fractions containing the desired product eluted at 6.6 min (monitoring at 651 nm) and 
were collected, frozen and lyophilized to give Cy5** conjugate 2.33 as a blue solid: yield 
64.0 µg (67%); mass spectrum (MALDI-TOF), m/z 2388.51 (M + K)+ (theoretical m/z 
2388.83). 
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Cu(II)•Deglycobleomycin–Cy5** Conjugate 2.132. To 200 µg (0.14 µmol) of modified 
BLM 2.32 was added 150 µL of a 2.94 mM aq CuCl2 solution and the reaction mixture 
was stirred overnight in the dark. The reaction mixture was frozen and lyophilized to give 
the metallated BLM as a light blue solid: yield 208 µg (100%); mass spectrum (MALDI-
TOF), m/z 1543.53 (M)+, 1481.61 (M − Cu + H)+, (theoretical m/z 1543.58, 1481.66).  
To 208 µg (0.13 µmol) of the metallated BLM was added a solution of 110 µg 
(0.11 µmol) of Cy5**COOSu in 100 µL of 0.2 M phosphate buffer (pH 8.0) and the 
reaction mixture was stirred overnight in the dark. The reaction mixture was purified on 
an Econosil C18 reversed phase semi-preparative (250 ×10 mm, 10 µm) HPLC column 
using aq 0.1% TFA and acetonitrile mobile phases. A linear gradient was employed (99:1 
0.1% aq TFA–acetonitrile→75:25 0.1% aq TFA–acetonitrile) over a period of 23 min at 
a flow rate of 4.5 mL/min. The fractions containing the desired product eluted at 21.2 min 
(monitoring at 651 nm) and were collected, frozen and lyophilized to give Cy5** 
conjugate 2.132 as a blue solid: yield 97.0 µg (36%); mass spectrum (MALDI-TOF), m/z 
2388.11 (M − Cu + K)+ (theoretical m/z 2388.83). 
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Deglycobleomycin–Cy5** Conjugate 2.34. To 95.0 µg (0.04 µmol) of Cy5** conjugate 
2.132 was added 100 µL of 15% EDTA and the reaction mixture was stirred overnight in 
the dark. The reaction mixture was purified on an Econosil C18 reversed phase semi-
preparative (250 × 10 mm, 10 µm) HPLC column using aq 0.1% TFA and acetonitrile 
mobile phases. A linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→0:100 
0.1% aq TFA–acetonitrile) over a period of 15 min at a flow rate of 4.5 mL/min. The 
fractions containing the desired product eluted at 6.6 min (monitoring at 651 nm) and 
were collected, frozen and lyophilized to give Cy5** conjugate 2.34 as a blue solid: yield 
39.0 µg (42%); mass spectrum (MALDI-TOF), m/z 2388.01 (M + K)+, (theoretical m/z 
2388.83). 
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3,4,6-Tri-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-mannopyranosyl)-α-L-
gulopyranosyl 2-(Benzyloxy)ethane (2.134).  To a solution of 63.0 mg (0.07 mmol) of 
phosphate ester 2.56 and 9.20 µL (9.13 mg, 0.06 mmol) of 2-(benzyloxy)ethanol (2.133) 
in 1.8 mL of anh dichloromethane was added 24.0 µL (29.0 mg, 0.13 mmol) of TMSOTf 
at 0 °C. The reaction mixture was stirred at 0 °C for 18 min at which time it was poured 
into a mixture of 30 mL of ethyl acetate and 15 mL of saturated aq NaHCO3. The organic 
layer was washed with two 10-mL portions of brine, dried (Na2SO4), filtered and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (25 × 1.5 cm). Elution with 1:1→1:3 hexanes–
ethyl acetate afforded disaccharide 2.134 as a colorless oil: yield 34.0 mg (68%); silica 
gel TLC Rf 0.41 (1:3 hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 1.98-2.14 
(m, 18H), 3.69 (m, 3H), 3.81 (m, 2H), 4.19 (m, 4H), 4.26 (m, 2H), 4.57 (m, 3H), 4.75 (m, 
1H), 4.91 (m, 2H), 5.35 (m, 3H) and 7.27-7.31 (m, 5H); mass spectrum (APCI), m/z 
772.2665 (M + H)+ (C34H46NO19 requires m/z 772.2664). 
 
3,4,6-Tri-acetyl-2-O-(2,4,6-tri-O-acetyl-3-O-carbamoyl-α-D-mannopyranosyl)-α-L-
gulopyranosyl 2-(Fluoro)ethane (2.135).134 To a solution of 20.0 mg (0.03 mmol) of 
disaccharide 2.134 in 3 mL of anh methanol was added a catalytic amount of Pd/C and 
the reaction was placed under 1 atm of H2 (g) overnight. The catalyst was removed by 
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filtration through a pad of Celite 545® and concentrated under diminished pressure to 
give the alcohol as a colorless oil: yield 19.0 mg (100%); silica gel TLC Rf 0.08 (1:3 
hexanes–ethyl acetate).   
To the solution of 19.0 mg (0.3 mmol) of the alcohol in 0.3 mL of anh 
dichloromethane at −78 °C were added 6.2 µL (6.09 mg, 0.04 mmol) of DBU and 10.0 
mg (0.04 mmol) of XtalFluor-E and stirred for 30 min. The reaction mixture was then 
allowed to warm to room temperature and stirred for 24 h at room temperature. The 
solution was poured into a mixture of 10 mL of ethyl acetate and 5 mL of saturated aq 
NaHCO3. The organic layer was washed with 5 mL portions of brine, dried (Na2SO4), 
filtered and concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (25 × 1.5 cm). Elution with 1:1→1:3 hexanes–
ethyl acetate afforded compound peracetylated fluoro BLM disaccharide (2.135) as a 
colorless oil: yield 9.00 mg (54% over two steps); silica gel TLC Rf 0.34 (1:3 hexanes–
ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 1.99-2.17 (m, 18H), 3.41 (m, 3H), 4.17 (m, 
3H), 4.28 (m, 2H), 4.52 (m, 2H), 4.64 (br s, 2H), 4.71 (m, 2H), 4.91 (m, 1H), 5.08 (m, 
2H) and 5.29 (m, 3H); 19F NMR (CDCl3, 376 MHz) δ −223.1 (m), −223.9 (m); m/z 
722.43 (M + K)+; mass spectrum (APCI), m/z 684.2151 (M + H)+ (C27H39FNaO18 
requires m/z 684.2151). 
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Fluoro BLM Disaccharide (3.35). To a solution of 1.00 mg (1.5 µmol) of peracetylated 
fluoro BLM disaccharide (2.135) in 1.1 mL of anh methanol was added 0.11 mL of 25% 
w/w freshly prepared solution of sodium methoxide in methanol. The reaction mixture 
was allowed to stir at room temperature for 2.5 h and the complete consumption of 
starting material was confirmed by MALDI-TOF mass spectral analysis. The reaction 
mixture was then quenched by the addition of 500 mg of Dowex 50x resin, shaken for 15 
min, filtered, concentrated and lyophilized to afford fluoro BLM disaccharide (2.35) as a 
white solid: yield 0.70 mg (100%); mass spectrum (MALDI-TOF), m/z 454.33 (M + Na)+ 
(theoretical m/z 454.13). 
 
3,4,6-Tri-acetyl-2-O-(2,3,4,6-tri-O-acetyl-α-D-mannopyranosyl)-α-L-gulopyranosyl 
2-(Benzyloxy)ethane (2.136).  To a solution of 108 mg (0.12 mmol) of phosphate ester 
2.120 and 16.0 µL (18.3 mg, 0.12 mmol) of 2-(benzyloxy)ethanol (2.133) in 3.5 mL of 
anh dichloromethane was added 40.0 µL (48.9 mg, 0.22 mmol) of TMSOTf at 0 °C. The 
reaction mixture was stirred at 0 °C for 20 min at which time it was poured into a mixture 
of 30 mL of ethyl acetate and 15 mL of saturated aq NaHCO3. The organic layer was 
washed with two 15-mL portions of brine, dried (Na2SO4), filtered and concentrated 
under diminished pressure. The residue was purified by flash chromatography on a silica 
gel column (25 × 2.5 cm). Elution with 3:1→1:1 hexanes–ethyl acetate afforded 
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disaccharide 2.136 as a colorless oil: yield 60.0 mg (69%); silica gel TLC Rf 0.51 (1:1 
hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 1.97-2.15 (m, 21H), 3.67 (m, 3H), 
3.84 (m, 2H), 4.09 (m, 4H), 4.25 (m, 2H), 4.55 (m, 3H), 4.76 (m, 1H), 4.95 (m, 2H), 5.32 
(m, 3H) and 7.33 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ 20.77, 20.83, 20.90, 20.92, 
21.0, 21.1, 62.6, 66.2, 66.4, 67.5, 68.0, 68.5, 68.9, 69.0, 69.3, 69.4, 70.2, 70.2, 71.5, 
73.36, 73.40, 97.8, 127.6, 127.81, 127.84, 128.6, 138.2, 155.3, 169.8, 170.1 and 170.8; 
mass spectrum (ESI), m/z 793.2529 (M + Na)+ (C35H46O19Na requires m/z 793.2531 ). 
 
3,4,6-Tri-acetyl-2-O-(2,3,4,6-tri-O-acetyl-α-D-mannopyranosyl)-α-L-gulopyranosyl 
2-(Fluoro)ethane (2.137).134 To a solution of 60.0 mg (0.08 mmol) of disaccharide 2.136 
in 8.2 mL of anh methanol was added a catalytic amount of Pd/C and the reaction was 
placed under 1 atm of H2 (g) overnight. The catalyst was removed by filtration through a 
pad of Celite 545® and concentrated under diminished pressure to give the alcohol as a 
colorless oil: yield 45.0 mg (85%); silica gel TLC Rf 0.08 (1:1 hexanes–ethyl acetate).   
To the solution of 45.0 mg (0.06 mmol) of the alcohol in 0.3 mL of anh 
dichloromethane at −78 °C were added 15.0 µL (15.2 mg, 0.10 mmol) of DBU and 23 mg 
(0.10 mmol) of XtalFluor-E were added and stirred for 30 min. The reaction mixture was 
then allowed to warm to room temperature and stirred for 24 h at room temperature. The 
solution was poured into a mixture of 15 mL of ethyl acetate and 7.5 mL of saturated aq 
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NaHCO3. The organic layer was washed with 7.5 mL of brine, dried (Na2SO4), filtered 
and concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (25 × 1.5 cm). Elution with 3:1→1:2 hexanes–
ethyl acetate afforded compound peracetylated fluoro decarbamoyl BLM disaccharide 
(2.137) as a colorless oil: yield 20.0 mg (38% over two steps); silica gel TLC Rf 0.37 (1:1 
hexanes–ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 1.98-2.18 (m, 21H), 3.40 (m, 1H), 
4.07 (m, 2H), 4.14 (m, 3H), 4.27 (m, 2H), 4.52 (m, 1H), 4.64 (m, 1H), 4.71 (m, 2H), 4.89 
(m, 1H), 5.01 (m, 2H) and 5.29 (m, 3H); 13C NMR (CDCl3, 100 MHz) δ 11.2, 20.77, 
20.82, 20.88, 20.91, 20.96, 20.98, 21.1, 62.6, 62.7, 66.2, 66.3, 67.4, 67.6, 68.7, 68.8, 68.8, 
70.0, 70.1, 70.1, 81.5, 83.2, 97.9, 98.7, 155.3, 170.1 and 170.8; 19F NMR (CDCl3, 376 
MHz) δ -224.43 (m); mass spectrum (MALDI-TOF), m/z 705.46 (M + Na)+; mass 
spectrum (ESI), m/z 705.2027 (M + Na)+ (C28H39FNaO18 requires m/z 705.2018). 
 
Decarbamoyl Fluoro BLM Disaccharide (3.36). To a solution of 7.00 mg (10.2 mmol) 
of peracetylated fluoro decarbamoyl BLM disaccharide (2.137) in 2.2 mL of anh 
methanol was added 0.22 mL of 25% w/w freshly prepared solution of sodium methoxide 
in methanol. The reaction mixture was allowed to stir at room temperature for 2.5 h and 
the complete consumption of starting material was confirmed by MALDI-TOF mass 
spectral analysis. The reaction mixture was then quenched by the addition of 500 mg of 
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Dowex 50x resin, shaken for 15 min, filtered, concentrated, and lyophilized to afford 
fluoro decarbamoyl BLM disaccharide (2.36) as a light yellowish solid: yield 3.60 mg 
(90%); mass spectrum (MALDI-TOF), m/z 411.31 (M + Na)+; mass spectrum (ESI), m/z 
411.1280 (M + Na)+ (C14H25FNaO11 requires m/z 411.1279).  
 
Cell Growth Conditions.  
MCF-7 cells (ATCC HBT-22), A498 cells (ATCC HTB-41), A549 cells (ATCC CCL-
185) and BT474 cells (ATCC HTB-20) were grown in RPMI 1640 (Gibco, Grand Island, 
NY) supplemented with 10% fetal bovine serum (HyClone, South Logan, UT) and 1% 
penicillin–streptomycin mix antibiotic supplement (Cellgro, Manassas, VA). MCF-10A 
cells (ATCC CRL-10317) were grown in MEGM (Invitrogen, Grand Island, NY) 
supplemented with 100 ng/mL cholera toxin (Sigma-Aldrich) and 1% penicillin-
streptomycin mix antibiotic supplement. DU-145 (ATCC HTB-81) prostate cells, BxPC-
3 (ATCC CRL-1687) pancreas cells, SVR A221a (CRL-2386) pancreatic normal cells, 
PZ-HPV-7 (ATCC CRL-2221) prostate normal cells, WI-38 (ATCC CCL-75) lung 
normal cells and CCD-1105 KIDTr (CRL-2305) kidney normal cells were grown in 
MEM (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (HyClone) 
and 1% penicillin–streptomycin mix antibiotic supplement. Cell lines were maintained at 
37 °C under a humidified atmosphere of 5% CO2 and 95% air. 
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Fluorescence microscopy.  
The fluorescent images were obtained using a Zeiss Axiovert 200M inverted fluorescence 
microscope fitted with an AxioCam MRm camera equipped with a 300-w xenon lamp 
(Sutter, Novato, CA) and a Cy5 cyanine filter (Chroma, Bellows Falls, VT). The cells 
were grown on 16-well Lab-Tek glass chamber slides at a cell density of 5000 cells/well 
(Thermo Scientific, Waltham, MA) at 37 °C for 48 h. When the cell confluency reached 
about 70%, the cells were rinsed twice with phosphate buffered saline (PBS), and the old 
medium was replaced with RPMI 1640 (no phenol red). Subsequently, the dye-labeled 
conjugates were added to the final desired concentrations and incubation of the cells was 
carried out at 37 °C for 1 h. Thereafter, the cells were washed with PBS, and fixed with 
4% paraformaldehyde at 37 °C for 5 min. Finally, the slide was mounted with Prolong 
Antifade Gold reagent with DAPI (Invitrogen). The cells were imaged using a Zeiss EC 
Plan Neofluor 40x/1.3 DIC M27 oil objective and the target cells were counted for 
quantification. For comparative studies, the exposure time and source intensity were kept 
identical for accurate measurements. Three different viewing fields each containing at 
least 10 individual cells were analyzed from each experiment. The mean pixel intensities 
[per unit area of the cells] in the viewing fields were measured to give the normalized 
fluorescence and quantification values were generated by using AxioVision 4 v 4.7.1.0 
software in conjunction with the interactive measurement tool. 
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CHAPTER 3 
SYNTHESIS OF SACCHARIDE–DRUG CONJUGATES FOR TARGETED 
DELIVERY TO CANCER CELLS 
3.1. Introduction 
A major problem associated with conventional chemotherapy is the lack of 
specificity of the drug for the cancer cells, resulting in high cytotoxicity towards normal 
cells. This type of treatment results in side effects, disease relapse and poor quality of life 
after treatment for many patients. However, more recently chemotherapy has focused not 
only in finding the correct drug molecule with optimized pharmacokinetic properties but 
also in finding a way to improve its selectivity towards cancer cells. One such approach is 
the identification of therapeutic targets with over-expressed receptors or antigens.  
The conjugation of drugs to the monoclonal antibodies that can precisely deliver 
drugs to cancer cells with overexpressed antigens has been a very promising area of 
development.151 The linkers that attach the cytotoxic agent to the antibody are designed in 
such a way that they are stable in the circulatory system and release the cytotoxic drug 
inside the targeted cells (Figure 3.1).142,152,153 
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Figure 3.1. Elements of an Antibody–Drug Conjugate (ADC).142  
 
The use of antibody drug conjugates (ADC) in cancer therapy has led to increased 
therapeutic efficacy for many drugs (Figure 3.2). However, the development of ADCs 
requires the optimization of several parameters, including immunogenicity associated 
with the conjugate, stability of the conjugate, pharmacokinetics, retention of immugenic 
response and proper release of the drug at the target site.154,155 The proposed mechanism 
of internalization of ADCs is illustrated in Figure 3.3. 
 
Figure 3.2. Structure of Antibody–Drug Conjugate: Trastuzumab-DM1 (recently 
approved by FDA). 
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Figure 3.3. Proposed Mechanism of Targeted Delivery of a Cytotoxic Agent by 
Antibody–Drug Conjugates (ADCs) (adapted from ref. 142). 
 
Another approach has involved utilization of an overexpressed receptor on the 
cancerous cell to guide the toxin to tumor cells. As described earlier, the BLM saccharide 
is responsible for tumor targeting ability possessed by BLM18 and hence, it seems 
possible that BLM saccharides might be able to serve the role of delivering the toxins 
selectively to the cancer cells. 
Camptothecin (CPT) is a naturally occurring pentacyclic alkaloid isolated from 
Camptotheca acuminate exhibiting antitumor activity towards solid tumors.156 It inhibits 
the action of DNA topoisomerase I (type I inhibitor) and causes programmed cell 
death.157 Due to high cell toxicity, it has been a very interesting lead compound for 
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cancer chemotherapy for decades. But the clinical utility of CPT was restricted due to 
poor solubility in water, which was addressed by utilization of the sodium salt of the ring-
opened compound in the earliest clinical trials, the latter of which proved to be inactive. 
Later, the limitation associated with water solubility was resolved by the discovery of its 
more water soluble congeners topotecan and irinotecan (Figure 3.4), which are now used 
clinically for the treatment of ovarian and colon cancers.158-160  
 
 
Figure 3.4. Structures of CPT Congeners: Topotecan and Irinotecan. 
 
Base treatment of 3.1 opens the lactone ring to form the inactive water-soluble 
carboxylate 3.4 (Figure 3.5). This occurs to some extent under physiological conditions 
in human blood circulation. Hence, the prodrug approach by esterification of 20-OH may 
be useful in the development of a better therapeutic form of CPT.161 In an effort to design 
and develop a more selective CPT pro-drug, a series of CPT–saccharide carbamates were 
synthesized and their cytoxicities were evaluated (Figure 3.6). 
  
Figure 3.5. Equilibrium Between the Closed and Open Lactone Ring of CPT. 
 
N
N
O
O
O
HO
N
N
O
O
O
HO
NMe2
HO
O
O
N
N
N
N
O
O
O
HO
CPT (3.1) Topotecan (3.2) Irinotecan (3.3)
N
N
O
O
O
HO
N
N
O
O-Na+
O
HO
OH
CPT (3.1) 3.4
 
 
200 
 
Figure 3.6. Series of CPT–saccharide Carbamates Synthesized and Evaluated. 
 
Later, a series of CPT–saccharide esters and CPT–bis-saccharide esters were also 
synthesized to study the effect of the increase in the number of conjugated sugars to the 
cytoxicity of the drug (Figures 3.7 and 3.8). 
 
Figure 3.7. CPT–saccharide Esters Synthesized and Evaluated. 
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Figure 3.8. CPT–bis-saccharide Esters Synthesized and Evaluated. 
 
 
3.2. Results 
The synthesis of the CPT–saccharide carbamate conjugates started with the 
activation of the 20-OH group of CPT as the p-nitrophenyl carbonate (3.13) in 73% yield 
(Scheme 3.1).161 Carbonate 3.13 was coupled with BLM monosaccharide linker 2.84, 
BLM disaccharide linker 2.59, BLM monosaccharide trimer linker 2.92 and decarbamoyl 
BLM monosaccharide linker 2.88 to give CPT–BLM monosaccharide carbamate 3.5, 
CPT–BLM disaccharide carbamate 3.6, CPT–BLM monosaccharide trimer carbamate 3.7 
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and CPT–decarbamoyl BLM monosaccharide carbamate 3.8 in 22%, 30%, 20% and 29% 
yields, respectively.  
 
Scheme 3.1. Synthesis of CPT–saccharide Carbamate Conjugates 3.5–3.8. 
 
CPT–saccharide ester conjugates were synthesized to afford easily hydrolyzable 
saccharide prodrugs of CPT. The synthesis of CPT–saccharide esters began with the 
esterification of 20-OH group of CPT with mono protected succinic acid ester (3.14) to 
form CPT ester linker 3.15 in 86% yield (Scheme 3.2).162 The tert-butyl ester of 
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compound 3.15 was cleaved with TFA to afford CPT acid linker 3.16 in 78% yield. CPT 
acid linker 3.16 was activated as the NHS ester and coupled with BLM monosaccharide 
linker 2.84 and BLM disaccharide linker 2.59 to afford CPT–BLM monosaccharide ester 
conjugate 3.9 and CPT–BLM disaccharide ester conjugate 3.10 in 17% and 21% yields, 
respectively, over two steps.  
 
Scheme 3.2. Synthesis of CPT–saccharide Ester Conjugates 3.9 and 3.10. 
 
To further study the effect of increasing the number of sugar moieties attached to 
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synthesis of bis-saccharide conjugates started with the coupling of the NHS ester of CPT 
acid linker acid 3.16 with the amine of di-tert-butyl ester of glutamic acid (3.17) to form 
CPT bis-ester linker 3.18 in quantitative yield (Scheme 3.3). The tert-butyl ester of 
compound 3.18 was cleaved with TFA to give CPT bis-acid linker 3.19 in 47% yield. 
Linker 3.19 was then activated as the bis-NHS ester and coupled with BLM 
monosaccharide linker 2.84 and BLM disaccharide linker 2.59 to afford CPT–bis-
monosaccharide ester 3.11 and CPT ester–bis-disaccharide ester 3.12 in 27% and 6% 
yields, respectively, over two steps.  
 
Scheme 3.3. Synthesis of CPT–bis-saccharide Ester Conjugates 3.11 and 3.12. 
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3.3. Discussion 
The cytotoxic drug camptothecin (CPT) was modified with different BLM 
saccharides as 20-OH prodrugs to promote targeted delivery to tumor cells. The 20-OH 
p-nitrophenyl carbonate of CPT (3.13) was synthesized from CPT (3.1) by following 
reported procedures (Scheme 3.1).21,161 Carbonate prodrugs 3.5–3.8 were then prepared 
by coupling the free amine of BLM monosaccharide linker 2.84, BLM disaccharide 
linker 2.59, trimer BLM monosaccharide linker 2.92 and decarbamoyl BLM 
monosaccharide linker 2.88, respectively with carbonate 3.13. 
The easily hydrolyzable ester prodrugs of CPT were also prepared to ensure 
complete release of the drug after saccharide–mediated internalization. The 20-OH CPT 
ester 3.15 was synthesized from CPT (3.1) by following reported procedures (Scheme 
3.2).162 The tert-butyl ester of 3.15 was cleaved using TFA and the resulting free acid of 
CPT linker 3.16 activated as the NHS ester, was condensed with the free amine of BLM 
monosaccharide linker 2.84 and BLM disaccharide linker 2.59 to afford CPT esters 3.9 
and 3.10.  
Later, the bis-sugar ester prodrugs of CPT were synthesized to facilitate 
polyvalent interaction with the cell surface receptor. CPT free acid 3.16, activated as the 
NHS ester, was coupled with linker amine 3.17 to give the tert-butyl ester 3.18 (Scheme 
3.3). Hydrolysis of the tert-butyl ester, followed by subsequent coupling of the NHS ester 
of the bis-acid 3.19 with BLM monosaccharide linker 2.84 and BLM disaccharide linker 
2.59 afforded CPT esters 3.11 and 3.12. The biological evaluation of these analogues is in 
progress. 
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3.4. Experimental Procedures 
Materials. The chemicals used were purchased from Aldrich Chemical Co., Sigma 
Chemical Co. or Combi-Blocks and were used without further purification. Anhydrous 
methanol, DMSO and pyridine were used as purchased. Dichloromethane was distilled 
from calcium hydride.  
General Experimental Procedures. Flash column chromatography was carried out 
using silica gel (Silicycle R10030B, 60 particle size, 230-400 mesh), applying a low-
pressure stream of nitrogen or dry air. Analytical thin layer chromatographic separations 
were carried out on glass plates coated with silica gel (60 particle size F254, Silicycle 
TLG-R10011B-323) and the developed chromatogram was observed under UV light.  
Instrumentation. HPLC was performed using an Agilent 1100 series instrument. High 
resolution mass spectrometric data were obtained at the Arizona State University CLAS 
High Resolution Mass Spectrometry Facility or the Michigan State Mass Spectrometry 
Facility. 1H and 13C NMR spectra were recorded on Varian Inova 400 MHz and 100 
MHz, respectively, using CDCl3 as solvent and internal standard with a residual peak at 
7.26 ppm and 77.16 ppm, respectively. Splitting patterns are designated as s, singlet; br s, 
broad singlet; d, doublet; dd, doublet of doublets; dt, doublet of triplets; m, multiplet and 
q, quartet.  
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CPT 20-(p-nitrophenyl)carbonate (3.13).21,161 To a solution of 40.0 mg (0.11 mmol) of 
CPT (3.1) in 0.42 mL of dry pyridine were added 56.0 mg (0.46 mmol) of DMAP and 
92.0 mg (0.46 mmol) of p-nitrophenyl chloroformate and was stirred at 40 °C overnight. 
The solution was cooled and poured into a mixture of 20 mL ethyl acetate and 5 mL of 
water. The organic layer was washed with three 5-mL portions of 1N HCl, 5 mL of 
saturated aq NaHCO3 and 5 mL of brine. The solution was dried (MgSO4), filtered, and 
concentrated under diminished pressure. The residue was purified by flash 
chromatography on a silica gel column (20 × 2.5 cm). Elution with 15:1→8:1 
chloroform–methanol afforded carbonate 3.13 as a light yellow solid: yield 43.0 mg 
(73%); silica gel TLC Rf 0.30 (7:1 hexanes–ethyl acetate); 1H NMR (CDCl3, 500 MHz) δ 
1.07 (m, 3H), 2.25 (m, 1H), 2.37 (m, 1H), 5.31 (m, 2H), 5.42 (d, 1H, J = 16.5 Hz),  5.72 
(d, 1H, J = 17.0 Hz), 7.40 (m, 2H), 7.70 (m, 1H), 7.86 (m, 1H),  7.96 (d, 1H, J = 7.5 Hz), 
8.23 (m, 3H) and 8.42 (s, 1H).    
  
CPT 20-(BLM Monosaccharide)carbamoyl Conjugate (3.5) To 6.00 mg (19.5 µmol) 
of amine 2.84 in 1.75 mL of 2:4:1 THF–methanol–DMSO was added 5.00 mg (9.74 
µmol) of carbamate 3.13 and the reaction mixture was stirred overnight. The crude 
reaction mixture was purified on an Econosil C18 reversed phase semi-preparative (250 × 
10 mm, 10 µm) HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A 
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linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→60:40 0.1% aq TFA–
acetonitrile) over a period of 18 min at a flow rate of 4.5 mL/min. The fractions 
containing the desired product eluted at 15.9 min (monitoring at 364 nm) and were 
collected, frozen and lyophilized to give CPT carbamate conjugate 3.5 as a light yellow 
solid: yield 1.50 mg (22%); mass spectrum (MALDI-TOF), m/z 685.72 (M + H)+; mass 
spectrum (ESI), m/z 683.2197 (M − H)− (C32H35N4O13 requires m/z 683.2201). 
  
CPT 20-(BLM Disaccharide)carbamoyl Conjugate (3.6). To 6.60 mg (14.0 µmol) of 
amine 2.59 in 1.8 mL of 2:1 THF–methanol was added 3.60 mg (7.01 µmol) of 
carbamate 3.13 and the reaction mixture was stirred overnight. The crude reaction 
mixture was purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 
10 µm) HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A linear 
gradient was employed (99:1 0.1% aq TFA–acetonitrile→60:40 0.1% aq TFA–
acetonitrile) over a period of 18 min at a flow rate of 4.5 mL/min. The fractions 
containing the desired product eluted at 13.8 min (monitoring at 364 nm) and were 
collected, frozen and lyophilized to give CPT carbamate conjugate 3.6 as a white solid: 
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yield 1.80 mg (30%); mass spectrum (MALDI-TOF), m/z 869.43 (M + Na)+; mass 
spectrum (ESI), m/z 869.2706 (M + Na)+ (C38H46N4O18Na requires m/z 869.2705). 
 
CPT 20-(BLM Monosaccharide Trimer)carbamoyl Conjugate (3.7). To 9.30 mg 
(7.78 µmol) amine 2.92 in 1.5 mL of 2:4:1 THF–methanol–DMSO was added 2.00 mg 
(3.90 µmol) of carbamate 3.13 and the reaction mixture was stirred overnight. The crude 
reaction mixture was purified on an Econosil C18 reversed phase semi-preparative (250 × 
10 mm, 10 µm) HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→60:40 0.1% aq TFA–
acetonitrile) over a period of 18 min at a flow rate of 4.5 mL/min. The fractions 
containing the desired product eluted at 16.5 min (monitoring at 364 nm) and were 
collected, frozen and lyophilized to give CPT carbamate conjugate 3.7 as a light yellow 
solid: yield 1.20 mg (20%); mass spectrum (MALDI-TOF), m/z 1591.89 (M + Na)+ and 
1607.61 (M + K)+ (theoretical m/z 1591.61 and 1607.61). 
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CPT 20-(Decarbamoyl BLM Monosaccharide)carbamoyl Conjugate (3.8). To 5.20 
mg (19.5 µmol) of amine 2.88 in 1.5 mL of 2:1 THF–MeOH was added 5.00 mg (9.74 
µmol) of carbamate 3.13 and the reaction mixture was stirred overnight. The crude 
reaction mixture was purified on an Econosil C18 reversed phase semi-preparative (250 × 
10 mm, 10 µm) HPLC column using aq 0.1% TFA and acetonitrile mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→60:40 0.1% aq TFA–
acetonitrile) over a period of 18 min at a flow rate of 4.5 mL/min. The fractions 
containing the desired product eluted at 15.2 min (monitoring at 364 nm) and were 
collected, frozen and lyophilized to give CPT carbamate conjugate 3.8 as a white solid: 
yield 1.80 mg (29%); mass spectrum (APCI), m/z 642.2280 (M + H)+  (C31H36N3O12 
requires m/z 642.2299).  
  
tert-Butyl CPT 20-Succinate Ester (3.15).162 To a solution of 198 mg (1.13 mmol) of 
acid 3.14 in 12 mL of dry dichloromethane were added 93.0 mg (0.76 mmol) of DMAP, 
0.18 mL (145 mg, 1.15 mmol) of diisopropylcarbodiimide (DIC) and 200 mg (0.57 
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mmol) of CPT (3.1). The reaction was stirred at room temperature overnight and diluted 
with 10 mL dichloromethane. The solution was washed with 3 mL of 0.1 N HCl, dried 
(MgSO4), filtered and concentrated under diminished pressure. The residue was 
crystallized from methanol, filtered and dried to afford 3.15 as a yellow solid: yield 170 
mg (56%); silica gel TLC Rf 0.30 (12:1 chloroform–methanol); 1H NMR (CDCl3, 
400 MHz) δ 0.99 (t, 3H, J = 7.2 Hz), 1.36 (s, 9H), 2.15 (m, 1H), 2.26 (m, 1H), 2.56 (m, 
2H), 2.78 (m, 2H), 5.26 (d, 2H, J = 3.2 Hz), 5.38 (d, 1H, J = 17.2 Hz), 5.68 (d, 1H, J = 
17.2 Hz), 7.31 (s, 1H), 7.66 (m, 1H), 7.82 (m, 1H), 7.92 (d, 1H, J = 8.4 Hz), 8.22 (d, 1H, 
J = 8.4 Hz) and 8.37 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 7.8, 28.1, 29.3, 30.2, 31.9, 
50.0, 67.2, 76.3, 81.1, 96.6, 120.2, 128.1, 128.3, 128.3, 128.6, 129.9, 130.7, 131.2, 146.2, 
146.3, 149.0, 152.6, 157.5, 167.6, 171.2 and 171.6. 
  
CPT 20-Succinate Acid (3.16).162 To 134 mg (0.27 mmol) of ester 3.15 in 1.5 mL of 
dichloromethane was added 0.6 mL of TFA and the reaction mixture was stirred for 5 h 
at room temperature. The reaction mixture was concentrated under diminished pressure, 
crystallized from methanol and dried to afford acid 3.16 as a pale yellow solid: yield 98.0 
mg (82%); silica gel TLC Rf 0.29 (12:1 chloroform–methanol); 1H NMR (DMSO-d6, 
400 MHz) δ 1.05 (m, 3H), 2.29 (m, 2H), 2.61 (m, 2H), 2.90 (m, 2H), 5.41 (d, 2H, J = 1.2 
Hz), 5.62 (s, 2H), 7.26 (s, 1H), 7.84 (t, 1H, J = 7.2 Hz), 8.00 (m, 1H), 8.25 (d, 1H, J = 8.0 
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Hz), 8.30 (d, 1H, J = 8.4 Hz) and 8.80 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 7.5, 
28.4, 28.6, 30.4, 50.2, 66.3, 75.9, 95.1, 118.9, 127.7, 128.0, 128.5, 129.0, 129.8, 130.4, 
131.5, 145.2, 145.9, 145.9, 152.4, 156.5, 167.2, 171.3 and 173.0. 
 
BLM Monosaccharide CPT 20-Succinate Ester Conjugate (3.9). To 5.00 mg (11.0 
µmol) of acid 3.16 in 0.15 mL of DMSO were added 1.50 mg (13.0 µmol) of N-
hydroxysuccinimide and 1.70 µL (1.40 mg, 11 µmol) of diisopropylcarbodiimide and the 
reaction mixture was stirred at room temperature for 24 h. To the activated acid solution 
was added 3.50 mg (11.0 µmol) of amine 2.84 in 0.5 mL of 1:1 0.2 M aq sodium 
phosphate buffer (pH 8.0)–DMSO. The reaction mixture was stirred overnight at room 
temperature and purified on an Econosil C18 reversed phase semi-preparative HPLC 
column (250 × 10 mm, 10 µm) using aq 0.1% TFA and acetonitrile mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→60:40 0.1% aq TFA–
acetonitrile) over a period of 18 min at a flow rate of 4.5 mL/min. The fractions 
containing the desired product eluted at 18.8 min (monitoring at 364 nm) and were 
collected, frozen and lyophilized to give CPT ester conjugate 3.9 as a light yellow solid: 
yield 1.40 mg (17% over two steps); mass spectrum (MALDI-TOF), m/z 779.68 (M + 
K)+ (theoretical requires m/z 779.22). 
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BLM Disaccharide CPT 20-Succinate Ester Conjugate (3.10). To 2.00 mg (4.50 
µmol) of acid 3.16 in 0.15 mL of DMSO were added 1.00 mg (8.90 µmol) N-
hydroxysuccinimide and 1.40 µL (1.10 mg, 8.90 µmol) of diisopropylcarbodiimide and 
the reaction mixture was stirred at room temperature for 24 h. To the activated acid 
solution was added 3.20 mg (6.77 µmol) of amine 2.59 in 0.4 mL of 1:1 0.2 M aq sodium 
phosphate buffer (pH 8.0)–DMSO. The reaction mixture was stirred overnight at room 
temperature and purified on an Econosil C18 reversed phase semi-preparative HPLC 
column (250 × 10 mm, 10 µm) using aq 0.1% TFA and CH3CN mobile phases. A linear 
gradient was employed (99:1 0.1% aq TFA–acetonitrile→60:40 0.1% aq TFA–
acetonitrile) over a period of 18 min at a flow rate of 4.5 mL/min. The fractions 
containing the desired product eluted at 17.9 min (monitoring at 364 nm) and were 
collected, frozen and lyophilized to give CPT ester conjugate 3.10 as a light yellow solid: 
yield 2.08 mg (21% over two steps); mass spectrum (MALDI-TOF), m/z 925.22 (M + 
Na)+; mass spectrum (ESI), m/z 903.3157 (M + H)+  (C41H51N4O19 requires m/z 
903.3148). 
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L-Glutamic Acid CPT 20-Succinate (3.19). To a solution of 174 mg (0.39 mmol) of 
acid 3.16 in 5 mL of dry DMSO were added 89.0 mg (0.78 mmol) N-hydroxysuccinimide 
and 0.12 mL (98.0 mg, 0.78 mmol) of diisopropylcarbodiimide (DIC) and the reaction 
mixture was stirred at room temperature for 24 h. To the activated acid solution were 
added 92.0 mg (0.31 mmol) of amine 3.17 and 43.0 µL of dry triethylamine (31.3 mg, 
0.31 mmol) in 3 mL of dry DMSO and stirred at room temperature overnight. The 
mixture was then diluted with 20 mL dichloromethane and washed with 5 mL of 0.1 N 
HCl, then dried (MgSO4), filtered, and concentrated under diminished pressure. The 
residue was crystallized from methanol, filtered and dried to afford bis-ester 3.18 as a 
yellow solid: yield 280 mg (100%); silica gel TLC Rf 0.35 (12:1 chloroform–methanol).  
To 280 mg (0.41 mmol) bis-ester 3.18 in 3.1 mL of dichloromethane was added 
1.3 mL of TFA and the reaction mixture was stirred for 5 h. The reaction mixture was 
concentrated under diminished pressure and crystallized from methanol, filtered and 
dried to afford bis-acid 3.19 as a pale yellow solid: yield 110 mg (47%); silica gel TLC Rf 
0.25 (12:1 chloroform–methanol); 1H NMR (CDCl3, 400 MHz) δ 0.93 (t, 3H, J = 7.6 Hz), 
1.79 (m, 1H), 1.99 (m, 1H), 2.13 (m, 2H), 2.29 (m, 2H), 2.41 (m, 1H), 2.56 (m, 1H), 2.73 
(m, 2H), 4.40 (m, 1H), 5.26 (s, 2H), 5.48 (s, 2H), 7.12 (s, 1H), 7.70 (t, 1H, J = 7.2 Hz), 
7.84 (t, 1H, J = 7.4 Hz), 8.11 (d, 1H, J = 8.0 Hz), 8.22 (dd, 2H, J = 8.4 and 4.8 Hz) and 
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8.66 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 7.6, 26.5, 29.0, 29.4, 30.1, 30.3, 50.2, 51.1, 
66.2, 75.8, 95.3, 118.7, 127.7, 127.9, 128.5, 129.0, 129.7, 130.3, 131.5, 145.5, 145.9, 
147.9, 152.4, 156.5, 167.2, 170.5, 171.2, 173.3 and 173.7; mass spectrum (APCI), m/z 
578.1774 (M + H)+ (C29H28N3O10 requires m/z 578.1774). 
  
 
(Bis-BLM Monosaccharide)-L-Glutamate CPT 20-Succinate Ester Conjugate (3.11). 
To 3.00 mg (5.20 µmol) of bis-acid 3.19 in 0.2 mL of DMSO were added 2.20 mg (18.7 
µmol) N-hydroxysuccinimide and 2.40 µL (2.0 mg, 15.6 µmol) of 
diisopropylcarbodiimide (DIC) and the reaction mixture was stirred at room temperature 
for 24 h. To the activated acid solution was added 3.30 mg (10.5 µmol) of amine 2.84 in 
0.3 mL of 0.2 M sodium phosphate buffer (pH 8.0). The reaction mixture was stirred 
overnight at room temperature and purified on an Econosil C18 reversed phase semi-
preparative HPLC column (250 × 10 mm, 10 µm) using aq 0.1% TFA and acetonitrile 
mobile phases. A linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→70:30 
0.1% aq TFA–acetonitrile→50:50 0.1% aq TFA acetonitrile) over a period of 8 min and 
12 min, respectively, at a flow rate of 4.5 mL/min. The fractions containing the desired 
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product eluted at 11.7 min (monitoring at 364 nm) and were collected, frozen and 
lyophilized to give CPT ester conjugate 3.11 as a light yellow solid: yield 1.60 mg (27% 
over two steps); mass spectrum (ESI), m/z 1162.4308 (M)+ (C51H68N7O24 requires m/z 
1162.4316). 
  
 
(Bis-BLM Monosaccharide)-L-Glutamate CPT 20-Succinate Ester Conjugate (3.12). 
To 3.00 mg (5.20 µmol) of bis-acid 3.19 in 0.2 mL of DMSO were added 2.20 mg (18.7 
µmol) N-hydroxysuccinimide and 2.40 µL (2.00 mg, 15.6 µmol) of 
diisopropylcarbodiimide and the reaction mixture was stirred at room temperature for 24 
h. To the activated acid solution was added 5.00 mg (10.5 µmol) of amine 2.59 in 0.3 mL 
of 0.2 M sodium phosphate buffer (pH 8.0). The reaction mixture was stirred overnight at 
room temperature and purified on an Econosil C18 reversed phase semi-preparative HPLC 
column (250 × 10 mm, 10 µm) using aq 0.1% TFA and acetonitrile mobile phases. A 
linear gradient was employed (99:1 0.1% aq TFA–acetonitrile→70:30 0.1% aq TFA–
acetonitrile→50:50 0.1% aq TFA–acetonitrile) over a period of 8 min and 12 min, 
respectively, at a flow rate of 4.5 mL/min. The fractions containing the desired product 
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eluted at 10.8 min (monitoring at 364 nm) and were collected, frozen and lyophilized to 
give CPT ester conjugate 3.12 as a light yellow solid: yield 0.44 mg (6% over two steps); 
mass spectrum (MALDI-TOF), m/z 1508.43 (M + Na)+; mass spectrum (ESI), m/z 
1508.5216 (M + Na)+ (C63H87N7O34Na requires m/z 1508.5192). 
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CHAPTER 4 
SYNTHESIS OF LYSINE ANALOGUES FOR MODIFICATION OF HUMAN DNA 
POLYMERASE BETA 
4.1. Introduction 
A variety of chemical, biochemical and physical events can lead to alteration or 
deletion of nucleotide bases in cellular genomic DNA. Such damage in DNA repair genes 
or cell cycle regulation genes may prove lethal. Hence, the cell maintains genomic 
stability by using a set of DNA repair pathways, which include base excision repair 
(BER), DNA mismatch repair (MMR) and nucleotide excision repair (NER).163,164 Base 
excision repair (BER) is the major pathway among these and protects the cell mainly 
against single base damage. BER is a sequential multistep process involving a cascade of 
events including (i) recognition and removal of the altered base, resulting in the 
generation of an apurinic/apyrimidinic (AP) site by DNA glycosylase, (ii) cleavage of the 
phosphodiester bond 5ʹ- to the lesion by AP endonuclease, (iii) removal of the remaining 
sugar by polymerase beta, (iv) addition of the missing nucleotide by DNA polymerase 
beta, and (v) sealing of the nick by DNA ligase.165 DNA polymerase beta is very 
important for BER as it is involved in both removal of the sugar residue and addition of 
the missing nucleotide. 
DNA polymerase beta is a multifunctional enzyme comprised of two domains 
including a 31 kDa C-terminal polymerase and an 8 kDa N-terminal dRP lyase separated 
by a protease sensitive linker.166 In solution it exists as a monomeric polypeptide of 335 
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amino acids167 (Figure 4.1) and has the lowest fidelity of all DNA polymerases on the 
order of 1error/1500 bases.168  
 
 
Figure 4.1. Amino Acid Sequence of Human DNA Polymerase Beta, Highlighted Red 
Letters Include the Residues Present in the Active Site of dRP Lyase Domain. 
 
Polymerase beta contains a ‘helix-hairpin-helix’ (HhH) motif in both the domains 
which is similar to those found in other DNA repair enzymes.169,170 The dRP lyase 
domain of polymerase mediates excision of the dRP group of the AP lesion by 
elimination, as suggested by Matsumoto and Kim.171 Later, Pierson et al. demostrated 
that β-elimination involves the formation of a Schiff base between the enzyme and dRP-
containing DNA (Figure 4.2).172 Although the active site of dRP domain is Lys-rich 
(Figure 4.3), it was shown by site-directed mutagenesis that Nε of Lys72 is the atom 
involved in Schiff base formation.173,174 
1   MSKRKAPQET LNGGITDMLT ELANFEKNVS QAIHKYNAYR KAASVIAKYP HKIKSGAEAK        
61  KLPGVGTKIA EKIDEFLATG KLRKLEKIRQ DDTSSSINFL TRVSGIGPSA ARKFVDEGIK       
121 TLEDLRKNED KLNHHQRIGL KYFGDFEKRI PREEMLQMQD IVLNEVKKVD SEYIATVCGS       
181 FRRGAESSGD MDVLLTHPSF TSESTKQPKL LHQVVEQLQK VHFITDTLSK GETKFMGVCQ       
241 LPSKNDEKEY PHRRIDIRLI PKDQYYCGVL YFTGSDIFNK NMRAHALEKG FTINEYTIRP       
301 LGVTGVAGEP LPVDSEKDIF DYIQWKYREP KDRSE 
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Figure 4.2. Proposed Mechanism of dRP Excision.175 
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Figure 4.3. Active Site of dRP Lyase Domain of Human DNA Polymerase Beta 
Including Lys35, Tyr39, Lys60, Lys68, Lys72 And Lys84. (PBD ID of human DNA 
polymerase beta used is 3C2K).  
 
To gain a better understanding of the mechanism involved in the excision of dRP, 
our laboratory decided to modify position 72 of rat DNA polymerase beta with a number 
of unnatural synthesized amino acids by site directed mutagenesis (Fig 4.4) and studied 
their effect on the dRP lyase activity of the enzyme.176 
 
Figure 4.4. Amino Acids Used for Modification of Lys72 of Rat DNA Polymerase 
Beta.176 
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It was concluded from the study of dRP excision activity of the modified proteins 
that nature has already optimized the required nucleophile for the excision reaction. The 
modified protein obtained by site-directed mutagenesis of Lys 72 with Nε-methyllysine 
(4.6) retained 86% of the activity of wild type (Figure 4.5), and is thought to stabilize the 
Schiff base compared to wild type making the adjacent C-2 proton of the sugar less acidic 
(Figure 4.2). The lower activity of modified protein obtained by site-directed mutagenesis 
of Lys 72 with analogue 4.9 implied that the distance between the Nε and α-C of amino 
acid is critical as it helps in proper positioning of the nucleophile to attack the dRP DNA 
bound in the catalytic pocket.176 
 
Figure 4.5. Summary of dRP Excision Activity of Rat Polymerases Beta Modified at 
Position 72 With Lysine Analogues.176 
 
As the rat and human polymerase beta have 95.5% sequence homology (Figure 
4.6), the conclusions drawn from the modification of rat polymerase beta can presumably 
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be reasonably extended to human polymerase beta. Hence, the ideal amino acid required 
to substitute at position 72 should be an amino acid with nucleophile at the ε–position of 
the side chain and will be able to stabilize the formed Schiff base without making the 
adjacent C-2 proton more acidic. Thus, in the quest for exploring a better nucleophile for 
DNA excision of human polymerase beta, a series of unnatural aminoacyl–pdCpA 
derivatives were designed and synthesized for site-specific incorporation in human DNA 
polymerase beta (Figure 4.7). 
 
 
Figure 4.6 Amino Acid Sequence of Rat DNA Polymerase Beta. (The modification at 15 
positions of rat enzyme sequence will result into the human enzyme sequence; V20T, 
T104S, L114F, E144G, L169V, P171S, N119S, S205T, R113Q, R222H, R228L, E244K, 
N248K, Q317K, and R326K). 
1   MSKRKAPQET LNGGITDMLV ELANFEKNVS QAIHKYNAYR KAASVIAKYP HKIKSGAEAK        
61  KLPGVGTKIA EKIDEFLATG KLRKLEKIRQ DDTSSSINFL TRVTGIGPSA ARKLVDEGIK       
121 TLEDLRKNED KLNHHQRIGL KYFEDFEKRI PREEMLQMQD IVLNEVKKLD PEYIATVCGS       
181 FRRGAESSGD MDVLLTHPNF TSESSKQPKL LHRVVEQLQK VRFITDTRSK GETKFMGVCQ       
241 LPSENDENEY PHRRIDIRLI PKDQYYCGVL YFTGSDIFNK NMRAHALEKG FTINEYTIRP       
301 LGVTGVAGEP LPVDSEQDIF DYIQWRYREP KDRSE 
 
 
224 
 
 
Figure 4.7. Series of Aminoacylated pdCpA Derivatives Synthesized for Site Directed 
Incorporation at Position 72 of Human DNA Polymerase Beta. 
 
4.2. Results 
In recent years, misacylated tRNAs have been used extensively to facilitate the 
introduction of unnatural amino acids into predetermined positions in proteins of 
interest.88,95,96,177-179 The same strategy was utilized for the incorporation of unnatural 
lysine analogues into position 72 of human DNA polymerase beta. In order to synthesize 
aminoacylated tRNA, the pdCpA derivatives of lysine and lysine analogues were 
generated from their respective amino acids. The key intermediate cyanomethyl ester of 
the N-protected amino acid was coupled with pdCpA to give a mixture of 2ʹ and 3ʹ 
dinucleotide esters. Pentenoyl protected lysine 4.18 was prepared from lysine (4.17) by 
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treatment with 4-pentenoic acid succinimide ester in the presence of Na2CO3 in 94% 
yield (Scheme 4.1).180 The pentenoyl protection was chosen as it can be readily 
deprotected by treatment with iodine without any undesirable side reaction at the tRNA 
level.181 Subsequently, dipentenoyl amide 4.18 was activated as cyanomethyl ester180 
4.19 by treatment with chloroacetonitrile in 63% yield. The treatment of cyanomethyl 
ester 4.19 by treatment with tris(tetrabutylammonium) salt of pdCpA97 in anh DMF 
afforded the lysine–pdCpA ester 4.13 in 79% yield (Scheme 4.1). 
 
Scheme 4.1. Synthesis of Lysyl–pdCpA 4.13. 
 
The syntheses of the pdCpA ester of pentenoyl protected N-methyllysine 4.14 and 
pentenoyl protected homoarginine 4.15 were also carried out in similar fashion from N-
methyllysine (4.20) and homoarginine (4.23), respectively (Schemes 4.2 and 4.3). The 
free amine of N-methyllysine (4.20) was protected using 4-pentenoic acid succinimide 
ester in the presence of Na2CO3 affording dipentenoyl amide 4.21 in 97% yield, the latter 
of which was activation as cyanomethyl ester180 4.22 by treatment with chloroacetonitrile 
in 41% yield (Scheme 4.2). Cyanomethyl ester 4.22 was then coupled with 
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tris(tetrabutylammonium) salt of pdCpA97 in anh DMF to afford the N-methyllysine–
pdCpA ester 4.14 in 95% yield. Similarly, homoarginine (4.23) was converted into N-
pentenoyl homoarginine (4.24) in 98% yield, followed by activation as the respective 
cyanomethyl ester 4.25 in 90% yield (Scheme 4.3). The pdCpA derivative of 
homoarginine 4.15 was prepared from cyanomethyl ester 4.25 in 70% yield.182 
 
Scheme 4.2. Synthesis of N-methyllysyl–pdCpA 4.14. 
 
Scheme 4.3. Synthesis of Homoargininyl–pdCpA 4.15. 
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The synthesis of pdCpA derivative of piperidylalanine commenced with the 
asymmetric synthesis of the amino acid precursor. To realize the asymmetric synthesis of 
piperidylalanine, a stereoselective strategy was employed using the Schöllkopf chiral 
reagent,183,184 which enabled the successful synthesis of a single unnatural S-isomer of 
the amino acid. The synthesis began with bromination of CBz protected 
hydroxymethylpiperidine (4.26) to give bromide 4.27 in 89% yield (Scheme 4.4).185 
Regioselective lithiation of Schöllkopf chiral auxiliary (4.28) with n-BuLi followed by 
treatment with bromide 4.27 at −78 °C afforded the adduct 4.29 as a single diastereomer 
in 52% yield. Mild hydrolysis with 2 M HCl184 afforded the α-substituted amino acid 
methyl ester 4.30 in quantitative yield. The CBz protecting group was removed from of 
the piperidyl side chain by hydrogenation over Pd/C to afford piperidylalanine 4.31 
quantitatively. The methyl ester of piperidylalanine (4.31) was protected as the 
dipentenoyl amide 4.32 in 54% yield over three steps. N-protected methyl ester 4.32 was 
subsequently hydrolyzed to afford the free acid, the latter of which was treated with 
chloroacetonitrile to afford the desired cyanomethyl ester180 4.33 in 38% yield over two 
steps. Treatment of cyanomethyl ester 4.33 with the tris(tetrabutylammonium) salt of 
pdCpA97 in anh DMF afforded pdCpA ester 4.16 in 90% yield. 
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Scheme 4.4. Synthesis of Piperidylalanyl–pdCpA 4.16. 
 
The strategy employed for incorporation of lysine analogues into human DNA 
polymerase beta is illustrated in Figure 4.8. The suppressor tRNA-COH, lacking the 
terminal cytidine and adenosine moieties at the 3ʹ end, was successfully transcribed from 
FokI-digested pYRNA8 plasmid DNA and was ligated with the pentenoyl protected 
aminoacylated pdCpA derivatives 4.13-4.16 via a T4 RNA ligase.97 The ligation 
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efficiencies were evaluated via denaturing acidic PAGE analysis as shown in Figure 
4.9.186 The N-pentenoyl protected misacylated tRNAs were deprotected by treatment with 
aqueous iodine to afford the activated tRNAs having lysine analogues with free α-amines 
as described previously.181,187 
 
Figure 4.8. Strategy Employed for Incorporation of Lysine Analogues Into Position 72 of 
Human DNA Polymerase Beta (EchDPB), the Gene for Which had Been Optimized for 
Expression in E. coli. 
 
 
Figure 4.9. Monitoring the Ligation Between the Suppressor tRNA-COH and 
Aminoacylated pdCpA Derivatives 4.13-4.16 After Pentenoyl Deprotection by Acidic 
Polyacrylamide Gel Electrophoresis and Methylene Blue Staining. (The experiment was 
performed by Dr. Sasha Daskalova). 
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optimized hDPB. The incorporation of the various lysine analogues was evaluated via 
denaturing PAGE analysis.185 In vitro translation of modified protein with homoarginine 
at position 72 from E. coli codon-optimized template gave 69.2% incorporation relative 
to in vitro translation of wild type protein from E. coli codon-optimized (EchDPB) 
template, summarized in Figure 4.10(I). Homoarginine (69.2%) and methyl lysine 
(21.3%) were incorporated in much better yields than lysine (16%), while 
piperidylalanine incorporation was only 5.8% compared to homoarginine incorporation, 
illustrated in Figure 4.10(II). This work was performed by Dr. Sasha Daskalova. 
 
 
Fig. 4.10. (I) In Vitro Translation of Wild Type Protein From E. coli Codon-optimized 
(EchDPB) and Non-optimized (hDPB) Template and In Vitro Translation of Modified 
Proteins With Incorporated pCN-Phe or Homoarginine at Position 72 From E. coli 
Codon-optimized Template or Non-optimized template Having an Amber Stop Codon at 
Position 72 (EchDPB72* and hDPB72*, respectively; monitored by SDS-PAGE and 
autoradiography); (II) In vitro Translation of Modified Proteins With Incorporated Lysine 
or Lysine Analogues at Position 72 From E. coli Codon-optimized Template Having an 
Amber Stop Codon at Position 72 (monitored by SDS-PAGE and autoradiography; 
relative incorporation compared to lysine incorporation (100%) is shown on the first row, 
relative yield compared to the yield of in vitro synthesized wild type hDPB from E. coli 
codon-optimized template is shown on the second row; experiment was performed by Dr. 
Sasha Daskalova). 
          Lys        homoArg   methyl Lys piperidylAla  no tRNA  tRNA only   pCN-Phe 
_______________ 
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    controls 
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4.3. Discussion 
In the pursuit of a better understanding of the mechanism involved in the excision 
of dRP by lyase domain of human DNA polymerase beta, a series of modified proteins 
were synthesized from their respective misacylated tRNAs.  Early studies demonstrated 
that the suppressor tRNA-COH, lacking the terminal cytidine and adenosine moieties at 
the 3ʹ-end, could be ligated with the pentenoyl protected amino acid to form the 
misacylated tRNA.94-97 A similar strategy was utilized in case of the protein of interest. 
The pdCpA derivatives 4.13–4.15 were prepared by first protecting the free amine as the 
4-pentenoyl derivative, followed by activation of the acid as the cyanomethyl ester and 
coupling with the tris(tetrabutylammonium) salt of dinucleotide pdCpA.97,180,181 
However, the synthesis of pdCpA derivative of piperidylalanine 4.16 was very 
challenging and started with the asymmetric synthesis of the piperidylalanine. Several 
attempts were made to alkylate the lithiated Schöllkopf chiral auxiliary with CBz 
protected chloromethylpiperidine but none of them resulted in successful asymmetric 
synthesis. Finally, CBz protected bromomethylpiperidine (4.27) was synthesized from 
CBz protected hydroxymethylpiperidine (4.26)184 and coupled with the lithiated 
Schöllkopf chiral auxiliary affording the adduct182,183 4.29 as a single enantiomer. Mild 
acid hydrolysis followed by hydrogenation with Pd/C afforded piperidylalanine 4.31, the 
latter of which was protected as the dipentenoyl methyl ester 4.32. Subsequently, the 
ester hydrolysis of the methyl ester 4.32 gave the free acid, the latter of which was treated 
with chloroacetonitrile to afford the activated cyanomethyl ester 4.33. The obtained 
cyanomethyl ester 4.33 was unstable, such that several purification attempts failed. 
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Finally, the partially purified cyanomethyl ester 4.33, obtained by extractive work-up, 
was used to ligate the dinucleotide pdCpA to afford the pdCpA derivatives 4.16 after 
HPLC purification. 
Misacylated tRNAs were generated by ligating abbreviated tRNA, lacking the 
terminal cytidine and adenosine moieties at the 3ʹ-end, with the pdCpA derivatives 4.13–
4.16 using T4 tRNA ligase.97 The ligase is an ATP dependent enzyme that catalyzes 
3ʹ→5ʹ phosphodiester bond formation in RNA. Treatment with aqueous iodine then 
afforded the tRNAs activated with unprotected amino acids, the latter of which were 
added to an in vitro transcription/translation system. The system contained the modified 
plasmid having an amber (TAG) stop codon at position 72 of the hDPB gene. The in vitro 
translation gave the modified proteins with unnatural amino acid residues at position 72 
of hDPB. 
 
4.4. Experimental Procedures 
 
Materials. The chemicals used were purchased from Aldrich Chemical Co., Sigma 
Chemical Co. or Combi-Blocks and were used without further purification. Anhydrous 
methanol, DMF and acetonitrile were used as purchased. Tetrahydrofuran and 
dichloromethane were distilled from sodium/benzophenone and calcium hydride, 
respectively. The tris-(tetrabutylammonium) salt of pdCpA was prepared by passing 
pdCpA through the activated TBA form of Dowex 50W×8 (200-400 mesh). 
General Experimental Procedures. Reactions were carried out under an argon 
atmosphere in flame-dried glassware.  Flash column chromatography was carried out 
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using silica gel (Silicycle R10030B, 60 particle size, 230-400 mesh), applying a low-
pressure stream of nitrogen or dry air.  Analytical thin layer chromatographic separations 
were carried out on glass plates coated with silica gel (60 particle size F254, Silicycle 
TLG-R10011B-323) and were developed by immersing the plates in a solution of 
potassium permanganate stain or ceric ammonium molybdate (CAM) stain followed by 
heating with a heat gun. 
Instrumentation. HPLC was performed using a Waters 600 pump coupled with a Varian 
ProStar 340 detector. 1H and 13C NMR spectra were recorded on Varian Inova 400 MHz 
and 100 MHz, respectively, using CDCl3 as solvent and internal standard.  1H NMR and 
13C NMR chemical shifts were reported relative to a residual CHCl3 at 7.26 ppm and 
77.16 ppm, respectively. Splitting patterns are designated as s, singlet; br s, broad singlet; 
d, doublet; dd, doublet of doublets; dt, doublet of triplets; m, multiplet; q, quartet and 
quint, quintet. High resolution mass spectrometric data were obtained at the Arizona State 
University CLAS High Resolution Mass Spectrometry Facility or the Michigan State 
Mass Spectrometry Facility.  
 
 
N,N-Dipentenoyl-L-lysine Cyanomethyl Ester (4.19). To 150 mg (1.03 mmol) of lysine 
4.17 were added 435 mg (4.10 mmol) of Na2CO3 in 5 mL water and 486 mg (2.46 mmol) 
of 4-pentenoic acid succinimidyl ester in 5 mL of 1,4-dioxane. The heterogeneous 
reaction mixture was stirred at room temperature overnight. The mixture was diluted with 
N
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N
H
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5 mL of water, acidified to pH 2-3 with 1 N NaHSO4 and extracted with three 30-mL 
portions of ethyl acetate. The organic layer was washed with 30 mL of brine, dried 
(MgSO4), filtered and concentrated under diminished pressure. The crude residue was 
quickly passed through a silica gel column (18 × 2 cm). Elution with 15:1→10:1 
chloroform–methanol afforded N,N-dipentenoyl-L-lysine (4.18) as a colorless oil: yield 
300 mg (94%); silica gel TLC Rf 0.13 (10:1 chloroform–methanol); mass spectrum 
(MALDI-TOF), m/z 311.37 (M + H)+, 333.38 (M + Na)+. This material was used directly 
in the next step without further purification. 
To 300 mg (0.32 mmol) of dipentenoyl lysine (4.18) in 15 mL of dry acetonitrile 
was added 0.67 mL (489 mg, 4.83 mmol) of dry triethylamine followed by 0.18 mL (219 
mg, 2.90 mmol) of chloroacetonitrile. The reaction mixture was stirred under nitrogen at 
room temperature for 18 h. The reaction mixture was diluted with 30 mL of ethyl acetate, 
washed successively with 10 mL of 1 N NaHSO4 and 10 mL of brine. The solution was 
dried (MgSO4), filtered and concentrated under diminished pressure. The residue was 
purified by flash chromatography on a silica gel column (18 × 2 cm). Elution with 
1:1→1:3 hexanes–ethyl acetate afforded cyanomethyl ester 4.19 as a colorless oil: yield 
212 mg (63%); silica gel TLC Rf 0.16 (1:3 hexanes–ethyl acetate); 1H NMR (CDCl3, 
400 MHz) δ 1.34 (m, 2H), 1.47 (m, 2H), 1.79 (m, 2H), 2.23 (m, 2H), 2.29-2.35 (m, 6H), 
3.20 (m, 2H), 4.46 (m, 1H), 4.74 (ABq, 2H, J = 16.0 Hz), 4.97 (d, 2H, J = 12.0 Hz), 5.00 
(m, 1H), 5.05 (m, 1H), 5.78 (m, 2H), 6.10 (t, 1H, J = 5.6 Hz) and 6.89 (d, 1H, J = 7.2 
Hz); 13C NMR (CDCl3, 100 MHz) δ 22.1, 29.1, 29.4, 29.6, 30.5, 35.1, 35.8, 38.2, 48.9, 
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51.9, 114.3, 115.57, 115.61, 136.9, 137.0, 171.1, 173.06 and 173.13; mass spectrum 
(MALDI-TOF), m/z 350.37 (M + H)+, 372.38 (M + Na)+. 
 
N,N-Dipentenoyl-L-lysine pdCpA Ester (4.13). To 7.40 mg (5.40 µmol) of the tris-
(tetrabutylammonium) salt of pdCpA was added a solution of 9.50 mg (27.2 µmol) of 
cyanomethyl ester 4.19 in 150 µL of anh DMF followed by 15.0 µL of triethylamine. The 
reaction mixture was sonicated at room temperature for 24 h and was purified on an 
Econosil C18 reversed phase semi-preparative (250 × 10 mm, 5 µm) using acetonitrile and 
50 mM aq NH4OAc (pH 4.5) mobile phases. A linear gradient was employed of (1:99 
acetonitrile–50 mM aq NH4OAc buffer→65:35 acetonitrile–50 mM aq NH4OAc buffer) 
over a period of 45 min at a flow rate of 3.5 mL/min. The fractions containing the desired 
product eluted at 15.6 min (monitoring at 260 nm) and were collected, frozen and 
lyophilized to give lysine–pdCpA ester 4.13 as a colorless solid: yield 4.00 mg (79%); 
mass spectrum (MALDI-TOF), m/z 929.35 (M + H)+; mass spectrum (ESI), m/z 927.2798 
(M − H)− (C35H49N10O16P2 requires m/z 927.2803).  
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N,N-Dipentenoyl-L-N-methyllysine Cyanomethyl Ester (4.22). To 130 mg (0.66 
mmol) of methyllysine (4.20) were added 420 mg (3.97 mmol) of Na2CO3 in 5 mL water 
and 365 mg (1.85 mmol) 4-pentenoic acid succinimidyl ester in 5 mL of 1,4-dioxane. The 
heterogeneous reaction mixture was stirred at room temperature overnight. The mixture 
was diluted with 5 mL of water, acidified to pH 2-3 with 1 N NaHSO4 and extracted with 
three 30-mL portions of ethyl acetate. The organic layer was washed with 30 mL of 
brine, dried (MgSO4), filtered and concentrated under diminished pressure. The crude 
residue was quickly passed through silica gel column (18 × 2 cm). Elution with 
15:1→10:1 chloroform–methanol afforded dipentenoyl methyllysine (4.21) as a colorless 
solid: yield 208 mg (94%); silica gel TLC Rf 0.4 (10:1 chloroform–methanol); mass 
spectrum (APCI), m/z 325.2130 (M + H)+ (C17H29N2O4 requires m/z 325.2127). This 
material was used directly in the next step without further purification.  
To 208 mg (0.64 mmol) of dipentenoyl methyllysine (4.21) in 15 mL of dry 
acetonitrile was added 0.45 mL (324 mg, 3.21 mmol) of dry triethylamine followed by 
0.18 mL (145 mg, 1.92 mmol) of chloroacetonitrile. The reaction mixture was stirred 
under nitrogen at room temperature for 18 h. The reaction mixture was diluted with 30 
mL of ethyl acetate, washed successively with 10 mL of 1 N NaHSO4 and 10 mL of 
brine. The solution was dried (MgSO4), filtered and concentrated under diminished 
pressure. The crude residue was purified by flash chromatography on a silica gel column 
N
H
O O
N
OO
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(18 × 2 cm). Elution with 1:1→1:3 hexanes–ethyl acetate afforded cyanomethyl ester 
4.22 as a colorless oil: yield 45.0 mg (41%); silica gel TLC Rf 0.16 (1:3 hexanes–ethyl 
acetate); 1H NMR (CDCl3, 400 MHz) δ 1.31 (m, 2H), 1.55 (m, 2H), 1.87 (m, 2H), 2.34-
2.45 (m, 8H), 2.99 (s, 3H), 3.36 (m, 1H), 3.44 (m, 1H), 4.44 (ABq, 1H, J = 5.6 Hz), 4.76 
(ABq, 2H, J = 15.6 Hz), 4.99-5.11 (m, 4H), 5.84 (m, 2H) and 6.98 (d, 1H, J = 6.0 Hz); 
13C NMR (CDCl3, 100 MHz) δ 21.7, 26.3, 28.6, 29.2, 29.5, 29.9, 33.0, 35.2, 35.4, 46.1, 
48.9, 52.3, 114.3, 115.5, 137.1, 137.3, 171.1, 173.3 and 173.4; mass spectrum (APCI), 
m/z 364.2233 (M + H)+ (C19H30N3O4 requires m/z 364.2236). 
 
N,N-Dipentenoyl-L-N-methyllysine pdCpA Ester (4.14). To 9.20 mg (6.76 µmol) of 
the tris-(tetrabutylammonium) salt of pdCpA was added a solution of 12.3 mg (33.8 
µmol) of cyanomethyl ester 4.22 in 150 µL of anh DMF followed by 15.0 µL of 
triethylamine. The reaction mixture was sonicated at room temperature for 18 h and was 
purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 5 µm) using 
acetonitrile and 50 mM aq NH4OAc (pH 4.5) mobile phases. A linear gradient was 
employed of (1:99 acetonitrile–50 mM aq NH4OAc buffer→65:35 acetonitrile–50 mM aq 
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NH4OAc buffer) over a period of 45 min at a flow rate of 3.5 mL/min. The fractions 
containing the desired product eluted at 16.5 min (monitoring at 260 nm) and were 
collected, frozen and lyophilized to give N-methyllysine–pdCpA ester 4.14 as a colorless 
solid: yield 6.00 mg (94%); mass spectrum (MALDI-TOF), m/z 943.50 (M + H)+; mass 
spectrum (ESI), m/z 941.2940 (M − H)− (C36H51N10O16P2 requires m/z 941.2960). 
 
N-(4-Pentenoyl)-L-homoarginine Cyanomethyl Ester (4.25).182 To 150 mg (0.80 
mmol) of homoarginine (4.23) were added 127 mg (1.20 mmol) of Na2CO3 in 5 mL 
water and 189 mg (0.96 mmol) 4-pentenoic acid succinimidyl ester in 5 mL of 1,4-
dioxane. The heterogeneous reaction mixture was stirred at room temperature overnight. 
The mixture was diluted with 5 mL of water, acidified to pH 4 with 1 N NaHSO4 and 
extracted with three 20-mL portions of ethyl acetate. The aqueous part was concentrated 
under diminished pressure, dissolved in methanol and the white precipitate was filtered 
off. The filtrate was concentrated to afford pentenoyl homoarginine (4.24) as a colorless 
oil: yield 211 mg (98%); silica gel TLC Rf 0.45 (3:1 ethyl acetate–MeOH); mass 
spectrum (MALDI-TOF), m/z 271.35 (M + H)+. This material was used directly in the 
next step without further purification. 
To 210 mg (0.78 mmol) of pentenoyl homoarginine (4.24) in 6 mL of dry DMF 
was added 0.54 mL (489 mg, 3.11 mmol) of dry N,N-diisopropylethylamine followed by 
0.18 mL (219 mg, 2.90 mmol) of chloroacetonitrile. The reaction mixture was heated at 
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45-50 °C under nitrogen for 48 h. The reaction mixture was concentrated under 
diminished pressure and purified by flash chromatography on a silica gel column (15 × 2 
cm). Elution with 3:1→1:1 ethyl acetate–methanol afforded cyanomethyl ester 4.25 as a 
colorless oil: yield 212 mg (88%); silica gel TLC Rf 0.58 (1:1 ethyl acetate–methanol); 
1H NMR (CDCl3, 400 MHz) δ 2.30-2.37 (m, 13H), 4.20 (m, 2H), 4.68 (m, 2H) and 5.74 
(s, 2H); 13C NMR (CDCl3, 100 MHz) δ 13.4, 19.5, 24.2, 29.5, 30.9, 31.7, 36.0, 44.0, 
50.3, 53.6, 56.0, 116.1 and 138.4.  
 
 
N-(4-Pentenoyl)-L-homoarginine pdCpA Ester (4.15).182 To 8.70 mg (5.4 µmol) of the 
tris-(tetrabutylammonium) salt of pdCpA was added a solution of 10.0 mg (27.2 µmol) of 
cyanomethyl ester 4.25 in 150 µL of anh DMF followed by 15.0 µL of dry triethylamine. 
The reaction mixture was sonicated at room temperature for 48 h and was purified on an 
Econosil C18 reversed phase semi-preparative (250 × 10 mm, 5 µm) using acetonitrile and 
50 mM aq NH4OAc (pH 4.5) mobile phases. A linear gradient was employed of (1:99 
acetonitrile–50 mM aq NH4OAc buffer→65:35 acetonitrile–50 mM aq NH4OAc buffer) 
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over a period of 45 min at a flow rate of 3.5 mL/min. The fractions containing the desired 
product eluted at 15.4 min (monitoring at 260 nm) and were collected, frozen and 
lyophilized to give homoarginine–pdCpA ester 4.15 as a colorless solid: yield 4.00 mg 
(70%); mass spectrum (MALDI-TOF), m/z 889.42 (M + H)+. 
 
Benzyl 4-(Bromomethyl)piperidine-1-carboxylate (4.27).185 To a stirred solution of 
600 mg (2.41 mmol) of alcohol 4.26 in 6.2 mL of anh dichloromethane were added 960 
mg (2.89 mmol) of carbontetrabromide and 758 mg (2.89 mmol) of triphenylphosphine. 
The reaction mixture was stirred at room temperature for 5 h. The reaction mixture was 
concentrated under diminished pressure and purified by flash chromatography on a silica 
gel column (18 × 3.5 cm). Elution with 6:1→4:1 hexanes–ethyl acetate afforded bromide 
4.27 as a colorless oil: yield 670 mg (89%); silica gel TLC Rf 0.4 (3:1 hexanes–ethyl 
acetate). 1H NMR (CDCl3, 400 MHz) δ 1.22 (m, 2H), 1.81 (m, 3H), 2.77 (m, 2H), 3.28 
(d, 2H, J  = 6.0 Hz), 4.22 (m, 2H), 5.13 (s, 2H) and 7.29-7.38 (m, 5H); 13C NMR (CDCl3, 
100 MHz) δ 30.8, 38.5, 38.7, 43.8, 67.1, 127.9, 128.0, 128.6, 136.9 and 155.2. 
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Benzyl 4-(((2S,5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-
yl)methyl)piperidine-1-carboxylate (4.29). To a stirred solution containing 90.0 µL  
(92.4 mg, 0.50 mmol) of Schöllkopf’s reagent (4.28) in 4.1 mL of anhydrous THF at −78 
°C was added 0.25 mL (0.63 mmol) of a 2.5 M solution of n-BuLi in hexane. The 
reaction mixture was stirred at −78 °C for 30 min under argon and then a solution 
containing 130 mg (0.42 mmol) of bromide 4.27 in 4.1 mL of anh THF was added. The 
reaction mixture was left to warm slowly to room temperature and stirred for 1 h under 
argon. The reaction mixture was diluted with 25 mL of saturated aq NH4Cl, extracted 
with two 30-mL portions of ethyl acetate, dried (MgSO4), filtered and concentrated under 
diminished pressure. The crude residue was purified by flash chromatography on a silica 
gel column (18 × 2 cm). Elution with 8:1→5:1→4:1 hexanes–ethyl acetate afforded 
adduct 4.29 as a colorless oil: yield 91.0 mg (52%); silica gel TLC Rf 0.4 (3:1 hexanes–
ethyl acetate); 1H NMR (CDCl3, 400 MHz) δ 0.69 (d, 3H, J  = 6.8 Hz), 1.05 (d, 3H, J  = 
6.8 Hz), 1.18 (m, 2H), 1.50 (t, 1H, J  = 8.4 Hz), 1.64 (d, 1H, J  = 13.2 Hz), 1.76 (m, 3H), 
2.27 (m, 1H), 2.78 (m, 2H), 3.67 (s, 3H), 3.68 (s, 3H), 3.93 (t, 1H, J  = 3.6 Hz), 4.01 (m, 
1H), 4.13 (br s, 2H), 5.12 (s, 2H) and 7.28-7.37 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ 
16.6, 19.0, 31.7, 32.2, 32.5, 40.9, 44.15, 44.21, 52.4, 53.3, 60.6, 66.9, 127.8, 127.9, 128.4, 
137.0, 155.3, 163.3 and 164.3; mass spectrum (MALDI-TOF), m/z 416.48 (M + H)+; 
mass spectrum (APCI), m/z 416.2542 (M + H)+ (C23H34N3O4 requires m/z 416.2549). 
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N,N-Dipentenoyl-L-piperidylalanine methyl Ester (4.32). To a stirred solution 
containing 231 mg (0.56 mmol) of adduct 4.29 in 12 mL of THF at 0 °C was added 8.4 
mL of 2 N aq HCl. The reaction mixture was stirred at room temperature for 2 h. The 
reaction mixture was then slowly poured into 50 mL of saturated aq NaHCO3, extracted 
with two 50-mL portions of ethyl acetate, dried (MgSO4) and filtered. The filtrate was 
concentrated under diminished pressure to afford protected amino acid 4.30 as a colorless 
oil: yield 180 mg (100%); silica gel TLC Rf 0.32 (1:1 ethyl acetate–methanol); mass 
spectrum (APCI), m/z 321.1809 (M + H)+ (C17H25N2O4 requires m/z 321.1814). This 
material was used directly in the next step without further purification. 
To the solution of 180 mg (0.56 mmol) of protected amino acid 4.30 in anh 
methanol was added catalytic amount of Pd/C and H2 gas was bubbled through for 45 
min. The reaction mixture was stirred at room temperature overnight. After the complete 
consumption of starting material, the reaction mixture was filtered through Celite 545® 
and concentrated under diminished pressure to afford L-piperidylalanine methyl ester 
(4.31) as a colorless oil: yield 105 mg (100%); silica gel TLC Rf 0.37 (1:4 ethyl acetate–
methanol); mass spectrum (APCI), m/z 187.1448 (M + H)+ (C9H19N2O2 requires m/z 
187.1447). This material was used directly in the next step without further purification. 
To 105 mg (0.56 mmol) of L-piperidylalanine methyl ester (4.31) were added 358 
mg (3.38 mmol) of Na2CO3 in 7.5 mL water and 311 mg (1.58 mmol) 4-pentenoic acid 
succinimidyl ester in 7.5 mL of 1,4-dioxane. The heterogeneous reaction mixture was 
stirred at room temperature overnight. The reaction mixture was diluted with 10 mL of 
brine and extracted with three 30-mL of portions of ethyl acetate. The organic layer was 
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dried (MgSO4), filtered and concentrated under diminished pressure. The crude residue 
was purified by flash chromatography on a silica gel column (18 × 2.5 cm). Elution with 
1:1→1:3 hexanes–ethyl acetate afforded methyl ester 4.32 as a colorless oil: yield 106 
mg (54% over three steps); silica gel TLC Rf 0.18 (1:3 hexanes–ethyl acetate); 1H NMR 
(CDCl3, 400 MHz) δ 1.10 (m, 2H), 1.55 (m, 2H), 1.71 (m, 2H), 1.88 (m, 1H), 2.30-2.44 
(m, 8H), 2.51 (m, 1H), 2.96 (m, 1H), 3.73 (s, 3H), 3.83 (d, 1H, J  = 12.8 Hz), 4.56 (d, 1H, 
J  = 12.0 Hz), 4.68 (m, 1H), 5.02 (m, 4H), 5.82 (m, 2H) and 6.12 (d, 1H, J  = 6.8 Hz); 13C 
NMR (CDCl3, 100 MHz) δ 25.5, 29.50, 29.54, 32.7, 32.8, 35.7, 39.6, 42.2, 46.0, 49.7, 
52.7, 77.4, 115.5, 116.0, 136.9, 137.4, 172.1 and 173.4; mass spectrum (MALDI-TOF), 
m/z 351.32 (M + H)+; mass spectrum (APCI), m/z 351.2292 (M + H)+ (C19H31N2O4 
requires m/z 351.2284). 
 
N,N-Dipentenoyl-L-piperidylalanine Cyanomethyl Ester (4.33). To a stirred 
solution containing 74.0 mg (0.21 mmol) of methyl ester 4.32 in 3.8 mL of 1:1:3 THF–
water–methanol was added 0.42 mL (0.42 mmol) of 1 N LiOH. The reaction mixture was 
stirred at room temperature for 2 h. The reaction mixture was diluted with acidified to pH 
2-3 with 1 N NaHSO4 and extracted with three 15-mL portions of ethyl acetate. The 
organic layer was washed with 10 mL of brine, dried (MgSO4) and concentrated under 
diminished pressure to gave dipentenoyl piperidylalanine as a colorless oil: yield 42.0 mg 
(59%); silica gel TLC Rf 0.4 (10:1 chloroform–methanol); mass spectrum (APCI), m/z 
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337.2124 (M + H)+ (C18H29N2O4 requires m/z 337.2127). This material was used directly 
in the next step without further purification. 
To 22.0 mg (0.06 mmol) of dipentenoyl piperidylalanine in 1.8 mL of dry 
acetonitrile was added 46.0 µL (33.3 mg, 0.33 mmol) of dry triethylamine followed by 
13.0 µL (15.1 mg, 0.20 mmol) of chloroacetonitrile. The reaction mixture was stirred 
under nitrogen at room temperature for 18 h. The reaction mixture was diluted with 10 
mL of ethyl acetate, washed with 10 mL of brine, dried (MgSO4) and filtered. The 
solution was concentrated under diminished pressure to afford cyanomethyl ester 4.33 as 
a colorless oil: yield 12.0 mg (49%); silica gel TLC Rf 0.21 (1:3 hexanes–ethyl acetate); 
mass spectrum (MALDI-TOF), m/z 376.38 (M + H)+; mass spectrum (APCI), m/z 
376.2240 (M + H)+ (C20H30N3O4 requires m/z 376.2236). The compound was used 
directly in the next step without further purification due to unstable nature. 
 
N,N-Dipentenoyl-L-piperidylalanine pdCpA Ester (4.16). To 7.90 mg (5.81 µmol) of 
the tris-(tetrabutylammonium) salt of pdCpA was added a solution of 11.0 mg (29.0 
µmol) of cyanomethyl ester 4.33 in 150 µL of anh DMF followed by 15.0 µL of 
N
NH2
ON
O
O
OPHO
OH
O
N
NN
N
NH2
O
OHO
OPO
OH
N
O
N
H
O
O
 
 
245 
triethylamine. The reaction mixture was sonicated at room temperature for 9 h and was 
purified on an Econosil C18 reversed phase semi-preparative (250 × 10 mm, 5 µm) using 
acetonitrile and 50 mM aq NH4OAc (pH 4.5) mobile phases. A linear gradient was 
employed of (1:99 acetonitrile–50 mM aq NH4OAc buffer→65:35 acetonitrile–50 mM aq 
NH4OAc buffer) over a period of 45 min at a flow rate of 3.5 mL/min. The fractions 
containing the desired product eluted at 17.7 min (monitoring at 260 nm) and were 
collected, frozen and lyophilized to give piperidylalanine–pdCpA ester 4.16 as a colorless 
solid: yield 5.00 mg (91%); mass spectrum (MALDI-TOF), m/z 955.65 (M + H)+; mass 
spectrum (ESI), m/z 953.2948 (M − H)− (C37H51N10O16P2 requires m/z 953.2960). 
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